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Abstract
The aim of this Ph.D. project was to investigate the effects of Colostrinin 
(CLN) on cells in culture, and its ability to prevent or alleviate cytotoxicity induced 
by reactive oxygen species (ROS) and beta-amyloid (AP). Two cell culture systems 
were used to analyse the effects of CLN; rat primary hippocampal cultures and the 
B50 rat neuronal cell line.
Bovine CLN was found to have no adverse effects on cell morphology or 
survival and to have a small, non-significant effect, on both menadione-induced, 
oxidative stress-mediated toxicity and A p i - 4 2 - i n d u c e d  toxicity of neurons in primary 
hippocampal cultures. This protective effect was found to potentially be related to the 
antioxidant effects of CLN. CLN was demonstrated to prevent a menadione-induced 
increase in ROS in the B50 cell line. Furthermore CLN was able to reverse a 
significant Api-42-mediated increase in the protein levels of the antioxidant enzyme 
Cu/Zu superoxide dismutase (SOD) in primary hippocampal cultures, although CLN 
alone caused an increase in SOD1 protein in the B50 cell line.
Bovine CLN was shown, in both B50 cells and primary hippocampal cells, 
not to significantly decrease the protein levels of cyclin dependent kinase 5 (Cdk5) 
which has previously been demonstrated to be involved in the mechanism of tumour 
necrosis factor (TNF) a-mediated protection against Ap-induced toxicity in primary 
hippocampal cultures. Furthermore CLN did not consistently alter the expression of 
activated caspase 3 in either B50 or primary hippocampal cells.
This study adds to the knowledge and understanding of the mechanism of 
action of CLN.
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Chapter 1
Introduction
16
In this introduction I will briefly summarise the cellular features exhibited in 
Alzheimer’s disease (AD) as well as some of the other main neurodegenerative 
diseases in order to illustrate some of the similarities and differences in the pathology 
and causative agents of these diseases. I will discuss the physiological processes of 
oxidative stress and apoptosis with a focus on how these are altered in pathology, 
most specifically in AD. Finally, I will review the literature on Colostrinin (CLN), 
focusing on its structure, its effects on the immune system and oxidative stress and 
evidence of its potential therapeutic effects in AD patients.
There are a number of neurodegenerative diseases of the central nervous 
system (CNS) including AD, Parkinson’s disease (PD), amyotrophic lateral sclerosis 
(ALS), multiple sclerosis (MS), and Huntington’s disease. These diseases have some 
common factors as they all involve cell loss within the CNS and protein aggregation 
in some form. Oxidative stress is also a common feature of these diseases and will be 
discussed in detail towards the end of this introduction. However there are also many 
differences in the proteins involved, cell types affected and underlying causes of the 
pathology of these different diseases. These differences lead to a spectrum of 
diseases which have similarities but may vary in age of onset and the rate of disease 
progression as well as the specific symptoms which may include cognitive 
impairment, or effects on motor control and movement.
17
1.1. Alzheimer’s disease
As detailed in the previous section a variety of neurodegenerative diseases 
exist. There are also several different types of dementia which manifest in various 
ways, including PD, Dementia with Lewy Bodies, AD, Creutzfeldt-Jakob disease, 
frontal lobe dementia, vascular dementia and alcohol-related dementia. For example 
Creutzfeldt-Jakob disease is characterised not only by rapidly progressive dementia 
but also commonly cerebellar or visual disturbance (Knight and Will 2004) and 
vascular dementia leads to deficits in executive function, however, the main decline 
seen in AD patients is in memory loss (Kalaria 2002). These diseases have different 
causes and may affect different types of cognitive functioning dependent on which 
areas of the brain are affected. Of these AD is the most common cause of dementia in 
the elderly, affecting around 18 million people worldwide (Farfara et al. 2008). At 
present there is no cure for AD and the only treatment is of the symptoms resulting 
from loss of transmitters, mainly acetylcholine (Palmer 2002).
According to the US Fisher Centre for Alzheimer’s Research Foundation, 
about 10 percent of people aged 65 and over, are affected by this disease and the 
prevalence doubles roughly every 10 years after age 65 (US Fisher Centre for 
Alzheimer’s Research Foundation). Half of the population aged above 85 years may 
have AD or exhibit symptoms to varying degrees of progression or severity.
Cognitive deficits arising from AD increase as the disease progresses and although 
AD does not in itself result in death, the decline in cognitive function and ability to 
look after oneself leads to malnutrition and general ill health with eventual death. 
Death typically occurs within 10 years of the diagnosis of the disease in the late onset 
form of AD which manifests after the age of 65.
The first descriptions of AD are reported to have come initially around 100 
years ago from Dr. Alois Alzheimer who had followed the disease progression of a
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lady referred to as Auguste D (Alzheimer et al. 1995). He made detailed drawings of 
his discoveries showing the now well- known pathological hallmarks of the disease. 
Despite Alzheimer being credited with discovery of the disease, pathology had been 
mentioned by others prior to this and since then these observations have been seen 
and confirmed in numerous cases of dementia.
Clinically AD manifests itself almost entirely as a cognitive disease with little 
in the way of physical disability. The cognitive decline begins as minor memory 
problems that may only be obvious to the patient themselves and progresses to full 
dementia. Various aspects of this dementia have been studied because an increase in 
the understanding of the exact causes of the deficit will allow more efficient 
treatment regimens and aid diagnosis. From one of these studies, using tests to 
specifically test structural and semantic knowledge of the same objects, it has been 
found that deficits in semantic and structural knowledge may not be connected 
(Hajilou and Done 2007). Furthermore aesthetic preferences have been shown to 
remain relatively intact despite the cognitive decline as evidenced by the fact that AD 
patients have shown the same stability in their art preference as normal controls 
(Halpem et al. 2008).
1.1.1. Pathology
Pathologically, AD is characterised by the presence, usually observed at post­
mortem, of extracellular senile plaques consisting mainly of aggregated beta-amyloid 
(AP) protein and intracellular neurofibrillary tangles (NFT) the main constituent of 
which is the cytoskeletal protein Tau (see Figure 1-1).
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Tau b ased  neurofibrillary tangle Amyloid b ased  Neuritic plaque
(C)
Figure 1-1: Detailed images ofNFT (a) and extracellular plaques (b) seen in AD (from Munoz and 
Feldman 2000). (c) clearly illustrates the cellular localisation of these pathological characteristics 
(Cole 2006).
The Ap present in plaques is produced from post-translational processing of 
the transmembrane protein amyloid precursor protein (APP). The normal 
physiological role of APP is unclear but it has been speculated to be neurotrophic 
and to have roles in development and memory as well as being involved in cell 
adhesion and cell signalling via intracellular protein interactions (Wolfe and 
Guenette 2007). Furthermore Ap, derived from APP, may have a function as a 
defence molecule in normal ageing although it initiates toxicity when it is allowed to 
accumulate in AD (Campbell 2001). During amyloidogenic processing APP is
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cleaved by (3 secretase to leave APPsp as well as a C99 fragment which after y 
secretase cleavage produces Ap along with the APP intracellular domain (AICD) 
fragment (see Figure 1-2). Alternatively APP can undergo non-amyloidogenic 
processing by a secretase cleavage to produce APPsa and C83 fragments, the C83 
fragment then undergoing y secretase cleavage to produce P3 and AICD fragments 
(see Figure 1-2). In non-amyloidogenic processing a  secretase cleaves APP in the 
centre of the Ap peptide sequence and therefore prevents the production of Ap (see 
Figure 1-2). The relative activity of a  secretase compared to p secretase therefore has 
a crucial effect on the amount of Ap that is produced.
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Figure 1-2: The amyloidogenic and non amyloidogenic processing of the transmembrane protein APP 
via a  or p and then y secretase activity. From LaFerla and Oddo (2005).
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The two main forms of Ap that are observed naturally are the 1-40 and 1-42 
fragments and the secretases involved in APP processing and fragment formation 
have been identified. The aspartic protease, BACE , has been identified as having p- 
secretase activity (Vassar et al. 1999) and a-secretase activity has been attributed to a 
protein named ADAM-10 while y secretase activity has been found to be due to a 
protein complex containing presenilins (PS) 1 and 2 and nicastrin (Pastorino and Lu
2006). The y secretase complex is associated with APP cleavage products in the early 
secretory pathway implying that this pathway may be the focal point of 
amyloidogenic processing (Selivanova et al. 2007).
NFT tangles are formed from aggregates of the cytoskeletal protein Tau. It 
has been shown that the aggregation of Tau protein is caused by 
p-hyperphosphorylation of the protein and that this aggregation may lead to the 
subsequent formation of NFT and increased toxicity (Grundke-Iqbal et al. 1986; 
Gomez-Ramos et al. 2006).
Severe neuronal damage occurs in AD leading to lesions containing 
dystrophic neurites and activated glia throughout the central nervous system (CNS) 
(Price et al. 1998). These lesions affect large areas of the brain, including the limbic 
system which leads to impaired memory formation, and therefore cognitive decline 
occurs as described in section 1.1 (Hajilou and Done 2007). Despite the general 
atrophy that occurs in the CNS during AD there are CNS areas that are particularly 
susceptible to degeneration including the medial temporal lobe where severe thinning 
i.e. cell loss, not seen in normal ageing has been found in AD patients (Dickerson et 
al. 2009). The cholinergic system has also been found to be particularly vulnerable in 
AD. Cholinergic markers including acetylcholine (ACh) and choline 
acetyltransferase, which catalyses the formation of ACh from choline and acetyl- 
CoA, decrease in the frontal and temporal lobes of patients with AD (Bartus et al.
1982) as well as in transgenic mouse models of AD (Bellucci et al. 2006). Some of 
these changes have been demonstrated to occur in the hippocampus from middle age 
in normal ageing although this age-related decrease has been found to be more severe 
in AD patients (Perry et al. 1992) and there are studies that show little change in 
these markers in the elderly compared to the young (Bartus et al. 1982). The 
cholinergic system has been demonstrated to have a crucial role in learning and 
memory by human studies using anticholinergics as well as animal lesion 
experiments (Schliebs and Arendt 2006) and therefore these changes in the 
cholinergic system could be largely responsible for the initial deficit seen in patients 
in relatively early stages of AD. This theory is supported by the fact that these 
cholinergic deficits have been found using work on transgenic mouse models of AD 
to correlate with cognitive impairments at 7 months as demonstrated using the step- 
down inhibitory avoidance test of memory and learning (Bellucci et al. 2006). As 
well as these presynaptic changes, alterations in the muscarinic ACh receptors 
(mAChR) in the limbic system have been demonstrated (Rinne et al. 1985; Pakrasi et 
al. 2007). Moreover the nicotinic ACh receptors (nAChR) containing the a-7 subunit 
appear to be particularly implicated in leading to neurodegeneration as Api-42 has 
been demonstrated in neuroblastoma cell cultures to co-localise with these nicotinic 
acetylcholine receptors and to selectively accumulate in neurons with higher 
densities of these receptors (Nagele et al. 2002). Furthermore it has been shown in 
hippocampal cell cultures that Ap can block the response of these nicotinic 
acetylcholine receptors in a non-competitive, voltage independent manor (Liu et al. 
2001).
Although the cholinergic deficit is very severe and occurs early in the disease 
process (Lowe et al. 1988; Bell and Cuello 2006) other neurotransmitter systems are 
also affected in AD. Gamma Aminobutyric Aacid (GABA)ergic neurons have been
23
found to be relatively unaffected in the early stages of the disease but a decrease in 
the number of these neurons has been demonstrated in later stages of the disease in 
several areas including the temporal cortex (Lowe et al. 1988; Bell et al. 2006). 
Furthermore Paula-Lima et al (2005). demonstrated that activation of the GABAa 
receptors could prevent the toxicity of A(3 implying a crucial role for GABA 
inhibition in the disease process (Paula-Lima et al. 2005). This GABAergic deficit 
has been associated with AD symptoms such as depression in the later stages of the 
disease (Lanctot et al. 2007).
There is also extensive evidence for the loss of glutamate signalling in AD, 
both post-synaptic with internalisation and reduction of glutamate receptors (Lau and 
Zukin 2007; Parameshwaran et al. 2007) and degeneration of glutamatergic neurons, 
in particular affecting the hippocampal pyramidal neurons and therefore affecting 
memory formation (Francis 2003). Examination of AD brain specimens antemortem 
demonstrated decreased glutamate in the cortex and CSF in early disease patients and 
a loss of glutmatergic neurons as the disease progressed (Procter et al. 1988). 
Furthermore, reduced glutamate transporter levels have been observed in the parietal 
and occipital lobes of AD patients that correlated with the number of tangles in the 
temporal cortex (Kirvell et al. 2006).
1.1.2. Neurotoxicity in Alzheimer’s disease
1.1.2.1. The primary cause of neurotoxicity
There is controversy over the primary cause of the neurodegeneration and 
lesions in AD. The current leading hypothesis is the amyloid hypothesis which states 
that it is the extracellular amyloid senile plaques that initiate neurodegeneration 
(Hardy and Higgins 1992) and that the NFT are a secondary effect caused by
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changes in kinase activity (Pastorino and Lu 2006). This hypothesis has received 
support from experimental evidence showing that Ap has a toxic effect leading to 
cell death in primary cell cultures including erythrocytes (Clementi et al. 2007), 
hippocampal cells (Alvarez et al. 2004) as well as numerous cell lines (Li et al. 1996; 
Costantini et al. 2005). Furthermore, Ap in culture has been shown to cause the 
phosphorylation of Tau protein which can lead to its aggregation and therefore 
induce the assembly of NFT, and Tau has been found to be toxic to cells in culture in 
an aggregation-dependent manner (Gomez-Ramos et al. 2006). Ap has also been 
found to directly influence Tau filament formation by inducing a caspase cascade 
which produces a toxic 17KDa fragment of Tau that may more easily aggregate 
(Gamblin et al. 2003). However, there is also a school of thought that says it is the 
Tau NFT formation that precedes the Ap aggregation and neurodegeneration which 
is supported by evidence showing that phosphorylated Tau levels are a better 
indicator of disease severity than Ap (Andersson et al. 2008) and that Tau has been 
found to be necessary for the toxicity of Ap as Tau depleted neurons were not 
susceptible to Ap-induced toxicity (Rapoport et al. 2002).
Inflammation occurs in AD and may be of considerable importance in 
contributing to the effects of AD (Munoz and Feldman 2000; Sastre et al. 2008). 
Speciale et al. (2007) found that AD patients had a decreasing number of circulating 
B lymphocyte cells depending on the severity of disease as well as increased levels 
of CD8+CD71+ cells and a significant decrease in interleukin 10 (IL-10) production 
after stimulation of peripheral blood mononuclear cells with Ap m o -
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1.1.2.2. Beta-amyloid-induced toxicity
Api-42 has been shown to aggregate more easily and therefore exhibit greater 
toxicity on cells in culture than Api-40 (Zou et al. 2003; Liu et al. 2005; Lim et al.
2007) and it has even been suggested that Api-40 may be protective against 
A p i - 4 2 - i n d u c e d  neurotoxicity (Zou et al. 2003). The shorter artificial AP25.35 fragment 
has been found to elicit increased toxicity compared to the two longer, naturally 
occurring fragments and investigation showed that the principal cause of the 
difference in toxicity was the exposure of a C terminal methionine in the AP25-35 
(Varadarajan et al. 2001).
The mechanism by which Ap leads to cellular toxicity is not yet clear despite 
extensive research. However it is known that there is a strong involvement of several 
cell signalling pathways (see Figure 1-3). These may lead to the increased 
phosphorylation of Tau which causes the accumulation of NFT and consequently 
more toxicity. For example the cell cycle regulating transcription factor, p53, has 
been found to be increased in AD patients and in vitro in HEK293 cells and causes 
Tau phosphorylation (Hooper et al. 2008). Moreover the phosphorylation at Tyr216 
and activation of the kinase, glycogen synthase kinase 3P (GSK3P) has been widely 
associated with the mechanism of the toxicity of Ap by extensive evidence (Kaytor 
and Orr 2002; Liu et al. 2005; Hooper et al. 2008; Hu et al. 2008) and GSK3P 
inactivation via phosphorylation at Ser 9 has been shown to prevent Ap-induced 
toxicity (Liu et al. 2005). GSK3P has been found to accumulate in NFT in the AD 
brain (Kaytor and Orr 2002) and in mice overexpression of GSK3P has been 
demonstrated to decrease long term potentiation (LTP) (Hooper et al. 2008). The 
effect of GSK3P on Ap-induced toxicity may be mediated in several ways. The effect 
could be via phosphorylation of GSK3Ps’ substrates P-catenin and heat shock factor- 
1 which would decrease their ability to regulate gene expression (Kaytor and Orr
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2002), directly via apoptosis, or via causing an increase in AP produced from APP by 
altering the activity of the p and y secretase (Hooper et al. 2008). GSK3p has also 
been found to be essential to the Ap-induced phosphorylation of Tau (Hu et al.
2008). Furthermore, the cyclin dependent kinase 5 (Cdk5) has been implicated in 
Ap-induced toxicity because activity and stability of the Cdk5-p35 complex has been 
observed to increase in hippocampal neurons that have been treated with APmo in 
vitro (Alvarez et al. 2001).
Another cell signalling pathway that has been associated with Ap-induced 
toxicity is the p75 neurotrophin receptor (NTR) cell death signal. Hippocampal 
injection of ApM2 has been shown to only decrease the number of basal forebrain 
ACh neurons in mice that were expressing the p75 NTR demonstrating the 
importance of this receptor, which is normally highly expressed by cholinergic 
neurons, in Ap-induced toxicity (Sotthibundhu et al. 2008). Moreover, Costantini et 
al. (2005) found that toxicity induced by AP1-42 fibrils was p75 NTR dependent 
although toxicity mediated by soluble oligomers was not and the p75 NTR appears to 
be protective against this latter type of toxicity in SH-SY5Y, human neuroblastoma, 
cells.
The APP protein itself may exacerbate the toxicity of Ap. APP has been 
found to make neurons more susceptible to Ap-induced toxicity (Sola Vigo et al.
2008) and APP reduces e protein kinase C (PKC) in cell lines (Liron et al. 2007). 
PKC can inactivate GSK3P so therefore the ability of APP to reduce PKC may cause 
an increase in GSK3P activity. APP has also been found to increase AP1-40 and AP1-42 
-induced toxicity in hippocampal cultures by binding to the APP protein binding 
sequence, Go (Sola Vigo et al. 2008).
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Figure 1-3: Some of the signalling pathways involved in the mechanism of Ap-induced toxicity and 
their inhibitors. Modified from Klementiev et al. (2007).
1.1.3. Prevention of beta-amyloid-induced toxicity
1.13.1. Prevention of the aggregation of beta-amyloid
The importance of the aggregation state on the level of toxicity induced has 
been emphasised in Section 1.1.2.2. Ap-induced toxicity may therefore be prevented 
by inhibiting the aggregation of Ap. Trehalose (Liu et al. 2005) and a peptide 
derived from activity-dependant neuroprotective protein (ADNP), NAP, which binds 
to microtubules, have both been shown to be protective against Ap-induced toxicity 
by preventing the aggregation of Ap (Ashur-Fabian et al. 2003). The polyphenol 
group, stilbenes, have also been demonstrated to prevent the aggregation of AP25.35 
(Riviere et al. 2007). However, not all compounds that prevent Ap aggregation are 
protective and a-antichymotrypsin was not found to be neuroprotective despite 
inhibiting the formation of fibrils (Aksenova et al. 1996).
I.I.3.2. Prevention of beta-amyloid-induced signalling
The detailed mechanism of Ap-induced toxicity is not definitively known but 
several pathways have been implicated as was discussed in detail in Section 1.1.2.2. 
The protective effects of a compound may therefore act via the inhibition of one of 
these signalling cascades. The protective effects of the antioxidant, Trolox, and 
17p oestradiol against Ap Mo-induced toxicity in hippocampal cultures have been 
attributed to preventing the Ap-induced increase in activation of GSK3p via 
activation of the Wnt pathway (Quintanilla et al. 2005). Activation of metabotropic 
glutamate receptor 5 also confers protection against APmo- induced toxicity in 
hippocampal slice cultures via activation of phosphoinositide-3 kinase (PI3K) and 
the serine/threonine kinase, Akt, which leads to inactivation of GSK3P (Liu 2005). a  
lipoic acid had also been demonstrated to exert protective effects against AP31-35 via 
activation of the PI3K/Akt pathway. Moreover lithium chloride is protective against 
behavioural deficits in APP transgenic mice by alteration of the GSK3P pathway 
(Rockenstein et al. 2007).
The cytokine TNFa has been found to be protective against Ap-induced 
toxicity in hippocampal cultures by decreasing Cdk5 protein levels and activity 
(Orellana et al. 2006) and by preventing Ap-induced increases in ROS (Barger et al.
1995). This effect on ROS has been attributed to kB dependent transcription (Barger 
et al. 1995). However Stepanichev et al. (2006), found that TNFa prevented 
Ap-induced cognitive impairment in rats in vivo but did not prevent Ap-induced 
toxicity in vitro.
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1.1.4. Risk factors for Alzheimer’s disease
Age is the biggest risk factor for AD as discussed above in Section 1.1, with 
50% of people over 85 developing the disease. The most common form of the 
disease has a sporadic onset without necessarily any family history although there are 
familial forms of AD (FAD) which have a genetic linkage and account for around 5- 
10% of AD cases (Maccioni et al. 2001). The age of symptomatic onset tends to be 
earlier in FAD than in sporadic AD and decreases through the generations that the 
disease is passed on. These FAD families have been widely studied in order to gain 
insight into the causes of AD. As may be expected given the role of APP processing 
and the aggregation of A(5 in AD initiation and progression, many of the genes that 
have been associated with AD are related to the processing of the APP protein. A 
link has been found between AD risk and several different mutations in the APP 
gene on chromosome 21 (Elbaz et al. 2007). Furthermore mutations in the genes 
encoding the y complex proteins, PS1 and 2 on chromosomes 14 and 1 respectively 
have also been implicated in FAD (Wragg et al. 1996; Raman et al. 2007; Wu et al.
2007). PS1 in particular has been demonstrated to have a highly significant impact 
on the risk of AD not only in the early onset disease but also for late onset patients 
(Wragg et al. 1996).
Down’s syndrome patients have an extremely high risk of developing AD due 
to the presence of an extra copy of chromosome 21 and therefore increased APP. 
Moreover as well as increased APP levels, low a  secretase and high p secretase 
levels have been seen in Down’s syndrome patients (Nistor et al. 2007).
Gender is also an important factor in disease progression with women being 
twice as likely as men to develop AD if factors such as age, level of education and 
physical activity are the same. This sex linkage may be due to increased average life 
span in women compared to men or may be related to hormonal changes in
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menopausal women especially given the reported connection between oestrogens and 
brain derived neurotrophic factor (Baum 2005; Sohrabji and Lewis 2006).
One of the well-documented risk factors for AD is the apolipoprotein E 
(ApoE) allele which is expressed. The presence of the ApoE4 allele has been 
demonstrated to increase risk of late onset AD (Corder et al. 1993). In contrast the 
presence of the ApoE2 allele has been found to decrease the risk of developing AD 
(Corder et al. 1994; Elbaz et al. 2007) (see Figure 1-4).
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Figure 1-4: The effects of ApoE phenotype on AD risk.
This figure illustrates the link between ApoE phenotype and comparative risk of being diagnosed with 
AD. This shows the relative age of onset of AD for individuals with 0,1 or 2 alleles o f ApoE4. (From 
Corder et al. 1993).
The cause of this link between ApoE and AD is unclear but it may be due to 
oxidative stress in the AD brain as Montine et a l (1997) have shown that the lipid 
peroxidation product 4 hydroxynonenol (4HNE) differentially modifies the ApoE
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protein (Montine et al. 1997). Alternatively as the ApoE receptor 2 has been 
demonstrated to be involved in neuronal survival in adults it has been suggested that 
the ApoE allele that is present may affect receptor activation and neuronal survival 
(Beffert et al. 2006).
As illustrated in Figure 1-5 as well as these genetic influences there are 
environmental factors that have been shown to affect the incidence of AD. Smoking 
has previously been reported to be beneficial in preventing the onset of AD (Hillier 
and Salib 1997) but this effect is unclear and recent studies have shown that smoking 
does not have any significant correlation with the development of AD (Doll et al. 
2000; Tyas et al. 2000) or indeed that it can increase the risk (Juan et al. 2004; Reitz 
et al. 2007). What is clear is that there is a strong link between increased AD risk and 
high LDL or total cholesterol which in turn links AD risk to cardiovascular disease 
risk (Michikawa 2003). Furthermore there is evidence that life style, in terms of 
mental and physical activity, can alter risk of dementia as it has been shown that a 
more mentally challenging job could decrease risk of AD (Potter et al. 2008) and that 
physical activity has a positive effect in maintaining cognitive health (Jedrziewski et 
al. 2007). This potential benefits of anaerobic exercise on cognitive health may be 
related to neurogenesis in the hippocampus since running has previous been 
demonstrated to improve cell proliferation and neurogenesis in the mouse dentate 
gyrus (van Praag et al. 1999) and to enhance learning and hippocampal neurogenesis 
in aged mice (van Praag et al. 2005). There is also evidence that anaerobic exercise 
may lead to a compensatory increase in oxidative defences in order to cope with the 
increased oxygen consumption and this may therefore prevent oxidative damage 
which could contribute to disease pathology (Radak et al. 2008).
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Figure 1-5: Schematic of the various influences on AD risk. Positive influences (leading to a decrease 
in risk of AD) are in yellow, negative influences (leading to an increase in risk of AD) are in red and 
those which have an uncertain effect are in blue.
There may be interactions between different risk factors, so for example the 
effect of the presence of the ApoE4 allele on hippocampal volume has been found to 
depend on gender (Fleisher et al. 2005) and ApoE phenotype is linked to cholesterol 
levels (Michikawa 2003). Moreover Down’s syndrome patients already have a high 
risk of developing dementia but this has been seen to be further increased in those 
with higher blood cholesterol levels (Zigman et al. 2007).
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1.1.5. Diagnosis
With any disease or illness early diagnosis is essential for the best possible 
outcome to the patient and in the case of AD it may mean being able to slow disease 
progression. The problem is that although diagnosis of AD is comparatively simple 
post-mortem when NFT and plaques mat be stained and observed in brain samples, it 
has been found to be difficult to conclusively diagnose AD as opposed to any other 
form of dementia as the definitive cause of dementia whilst the patient is alive. For 
example there is a remarkable symptomatic overlap between AD and vascular 
dementia, which is the second most common form of dementia, leading to loss of 
short term memory as well as sensory and motor disturbances and usually caused by 
ischaemic insult rather than any genetic influence (Yagami 2006). Nevertheless with 
the advent of improved technology alongside the traditional diagnostic cognitive 
tests including Alzheimers’ Disease Assessment Scale (ADAScog) and the Mini 
Mental State Evaluation (MMSE) diagnosis is gradually becoming more definitive 
and more research is going on to develop biochemical diagnostic tests. For instance 
techniques now allow the levels of factors such AP1-42 or Tau in the cerebrospinal 
fluid (CSF) to be used as markers of AD. However the procedure used to extract CSF 
is not straightforward and (Stefani et al. 2006) found that only Tau levels but not 
AP1-42 correlated with cognitive decline.
Reasonable reliability for diagnosis has, however, been seen with blood 
markers such as oxidatively-modified peroxiredoxin. Yoshida et al. (2009) and 
Gruden et al. (2007) found that the levels of autoantibodies to AP25-35, the astrocyte- 
specific protein SI00b as well as the neurotransmitter dopamine, reflecting the loss 
of the dopaminergic system in AD, were good markers of disease progression. The 
amounts of the ApMo and AP1-42 forms in plasma and in particular the ratio of the 
two forms has quite recently been found to correlate with severity of disease and the
34
risk of conversion from mild cognitive impairment (MCI) to AD (Shoji 2002; Graff- 
Radford et al. 2007; Wiltfang et al. 2007). Furthermore the use of the techniques of 
magnetic resonance imaging and positron emission tomography as diagnostic tools 
has increased and can be useful for diagnosis even in very early stages of disease 
(Mosconi et al. 2007).
1.1.6. Present Alzheimer’s disease treatments
The favoured treatment strategies for AD have varied over time and at 
present are not really satisfactory in the longer term. Currently the only effective 
treatment is to deal with the symptoms.
As the cholinergic system is especially vulnerable in AD some of the most 
common current treatments work on the acetylcholine system, in particular using 
cholinesterase inhibitors which prevent the breakdown of Ach and therefore help to 
maintain the cholinergic system and can afford symptomatic relief although mild side 
effects are common (Birks 2006). However, the gender of the patient has been found 
to alter the effectiveness of these drugs (Haywood and Mukaetova-Ladinska 2006) 
and their benefits may be related to preventing glutamate mediated toxicity (Takada- 
Takatori et al. 2006). Several cholinesterase inhibitors have been tested in clinical 
trials and reviews of these trials showed beneficial effects for rivastigmine (Birks 
2006), Galantamine which has shown improvement in patient ADAS-cog scores as 
well as improved or stabilised global ratings (Loy and Schneider 2006) and 
Donepezil which has demosntrated beneficial effects on AD AS-cog, MMSE and 
global clinical state of patients with mild to moderate AD over 24 weeks (Birks and 
Harvey 2006).
The discrepancy in gender risk for AD, especially in post-menopausal 
women, implies a link between AD and oestrogen level changes and therefore the
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potential of hormone replacement therapy (HRT) to reduce the incidence of AD has 
been investigated. The results of these studies have been variable. The use of HRT 
has been associated with a decreased AD risk in many studies (Zandi et al. 2002; 
Baum 2005) and oestradiol has been found to prevent memory deficits seen in rats 
treated with AP1-42 (Hruska and Dohanich 2007) as well as interfering with the 
formation of Ap fibrils (Morinaga et al. 2007). However the literature discussing the 
potential benefits of HRT as a preventative measure against AD is still rather 
unclear. Some studies have shown a positive correlation between HRT and AD with 
progesterone being considered detrimental (Honjo et al. 2005). Interestingly Honjo et 
al (2005) found that a non-feminising oestrogen form, J861, can have the same 
benefits as oestradiol in vitro in PC 12 cells as well as in the rat CNS (Honjo et al.
2005) and could potentially be a more practical long-term treatment for AD.
Antioxidant defence and the oxidative stress related damage that is found in 
AD patients is discussed in detail in Section 1.3.3. Another main area of research for 
AD therapies is that of compounds with antioxidant properties that will ameliorate 
this increase in oxidative stress related damage. For example vitamin E has been 
shown in vitro to prevent some of the effects of Ap including increasing the 
activation of inducible NOS, which is present in the CNS and the cardiovascular 
system and responds to stress signalling, and ROS production in vitro (Ayasolla et al. 
2004; Esposito et al. 2006). Furthermore the antioxidant effects of blueberry extract 
have been investigated and it was found to be neuroprotective in kainic acid treated 
rat hippocampi (Duffy et al. 2008). However, a review conducted by (Isaac et al. 
2008) found that there was no evidence of the efficacy of vitamin E to treat AD or 
MCI.
Drugs to reduce cholesterol have been tried as therapeutics, because high 
circulating levels of cholesterol has been associated with greater susceptibility to
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development of AD. These trials have shown positive results with ADScog scores 
significantly better in AD patients on the cholesterol lowering drug atorvastatin than 
controls (Sparks et al. 2006). This treatment has also been found to reduce the AD 
risk in Down’s syndrome patients with high cholesterol (Zigman et al. 2007). 
Moreover the effects of cholesterol-lowering drugs have been studied in rats and it 
was found that the drugs which could cross the blood brain barrier were acting as 
AChE inhibitors and therefore would be particularly beneficial as therapeutics 
(Cibickova et al. 2007). However, despite these promising reports a review of the 
clinical data suggests that statins do not give clinical benefits to preventing AD 
(Scott and Laake 2001).
Given the importance of A(3 and its aggregation state for the toxicity of the 
peptide and the development of AD, compounds which decrease Ap load and prevent 
aggregation or cause disaggregation are of interest from a therapeutic viewpoint. To 
this end Arendash et al. (2006) studied the effects of caffeine and found that it could 
decrease Ap production, and antioxidants such as polyphenols and vitamins E and C 
not only reduce the oxidative stress burden in the AD brain but also in some cases 
prevent Ap aggregation (Ono et al. 2006). There is also research into the use of 
secretase inhibitors to reduce the production of Ap (Lecanu and Papadopoulos 2007).
The idea of an AD vaccine has been explored in order to prevent excess Ap 
accumulation and aggregation and therefore prevent disease formation. There have 
been promising results from some studies. Antibodies against Ap have been shown 
to reduce intracellular Ap in vitro in neuroblastoma cells and primary neurons 
(Tampellini et al. 2007). Vaccination of APPswe/PSI transgenic mice with a AP1-42 
gene construct led to antibody production against AP1-42 and decreased Api-42 levels 
in the brain and reduced hippocampal plaques by 52% (Qu et al. 2007). Kim et al. 
(2007) found that they could elicit more reliable antibody responses in mice by using
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immunisation with a vector and DNA plasmid containing tandem repeats of APi-6. 
Passive immunisation of mice with single chain antibodies against Ap have been 
demonstrated to inhibit Ap aggregation and to decrease plaque burden in the brain 
when injected into the hippocampus or intramuscularly (Wang et al. 2009). 
Furthermore, it has been found that active vaccination of human patients with AN- 
1792 caused an antibody response and may reduce the plaque burden in the CNS in 
human patients (Nicoll et al. 2003). However, the active vaccination does not appear 
to alter the levels of NFT unless given very early (Nicoll et al. 2003) and may not 
have large effects on cognitive function (Gilman et al. 2005; Wisniewski and 
Konietzko 2008) and the safety of active vaccines was called into question when a 
clinical trial found that some patients, 6%, developed an inflammatory response and 
meningoencephalitis (Nicoll et al. 2003; Gilman et al. 2005). Passive immunisation 
has been shown to have potential efficacy on cognitive function in patients without 
the ApoE4 allele and will not cause the inflammatory response seen with active 
vaccines so there are several phase I and II clinical trials presently underway or being 
concluded (Wisniewski and Konietzko 2008). More novel approaches to vaccination 
are also being investigated and recently Cao et a l (2008) have investigated the 
possibility of vaccines using sensitized, bone marrow derived, dendritic cells. The 
authors found that in BALB/c mice there was a strong antibody response when 
dendritic cells were sensitized with mutated APm2 but not when sensitized with wild 
type APi-42 although an anti-inflammatory immune Th2 response was observed 
independent of the form of Ap 1-42 that had been used (Cao et al. 2008).
In addition to the potential benefits of physical and mental exercise, HRT and 
antioxidants, it has been shown that a diet rich in arachidonic and docosahexaenoic 
fatty acids may be preventative against the onset of AD symptoms (Kotani et al.
2006). However a review of studies on fatty acids and dementia concluded that there
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was a not a preventative benefit of using fatty acids against dementia (Lim et al.
2006).
1.1.7. Animal models of Alzheimer’s disease
Many mouse models of AD are available for use in research studies. These 
transgenic mice may have a mutation in the APP gene, the PS1 gene, the gene for 
Tau or a combination of these mutations and the specific characteristics of these 
models vary depending on the mutation used. The most commonly used APP 
mutation is the Swedish mutation, first found in a family with AD in Sweden at 
residues 670/671 which affects P secretase activity and mice with this mutation have 
been shown to have impaired reversal learning at 6 months with increasing preffontal 
cortex levels of AP1-42 (Zhuo et al. 2008) as well as altered novelty seeking prior to 
plaque formation (Senechal et al. 2008). Double transgenic animals are more 
commonly used as they employ APP mutations with PS1 or Tau mutation in order to 
display more of the phenotypic characteristics of AD. APP/Tau transgenic mice for 
example have been found to have increased Ap deposition and phosphorylated Tau 
accumulation in the brain leading to tangles as well as plaques and 
neurodegeneration with neuritis resembling those types seen in AD brains (Paulson 
et al. 2008; Perez et al. 2008). APP/PS1 transgenic mice have been demonstrated to 
have increased apoptosis in the cortex and hippocampus compared to wild type mice 
(Yang et al. 2008), decreased proliferation in the subgranular zone (Niidome et al. 
2008) and deficits in both passive avoidance and left-right discrimination learning 
(Filali et al. 2008). Some transgenic mice include mutations in all three proteins, 
APP, Tau and PS1 and these have been found to develop increased intracellular Ap, 
Tau accumulation then extracellular Ap which seems to correspond to cognitive 
deficits seen at around 6 months and decreased neurogenesis and finally NFT
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(Mastrangelo and Bowers 2008; Pietropaolo et al. 2008; Rodriguez et al. 2008). 
Triple transgenic mice have also been demonstrated to have synaptic deficits as well 
as impaired learning and memory (Cole 2006). Although these transgenic animals 
acquire plaque formation and Tau fibrils and show evidence of cognitive deficits 
they do not usually display the psychological effects of AD such as depression, 
although the APP/PS1 transgenic mice have been considered by Filali et al, (2008) to 
be demonstrating signs of apathy and depression by increased irritability, poor nest 
building and immobility in forced swimming tests.
1.2. Mechanisms of cellular death in vivo and in vitro
1.2.1. Apoptosis and necrosis
There are two main types of cell death that are observed in cells in vitro and 
these are referred to as apoptosis and necrosis. Apoptosis or programmed cell death 
is an ordered, caspase-dependent process and is characterised by the activation of 
apoptotic cascade molecules, DNA fragmentation, chromosome condensation and 
membrane potential changes (Yan and Shi 2005; Okouchi et al. 2007). Apoptosis 
occurs when cells are programmed to die during development, as a result of cellular 
stress and certain disease conditions such as Ap-induced cell death in AD (Forloni et 
al. 1993). Necrosis is considered a much less ordered form of cell death because it is 
caspase -independent and involves cell lysis with the release of cellular contents 
(Okouchi et al. 2007) but does not involve the complicated signalling cascades that 
are involved in the induction of apoptosis. The triggers for cell death via apoptosis 
differ from those for necrosis with necrosis being initiated via mitochondrial 
permeability defects and a consequent reduction in ATP production or excess
reactive oxygen species (ROS) (Bhatia 2004). However it has more recently become 
clear that necrotic cell death can be more regulated than was originally thought and 
there are pathways for the initiation of necrosis (Proskuryakov et al. 2002; Xu et al. 
2006; Okouchi et al. 2007). For example it has been demonstrated that death via poly 
(ADP-ribose) polymerase -1 is a form of regulated necrosis (Xu et al. 2006). The 
distinction between types of cell death is therefore not as clear as was initially 
thought.
1.2.2. Mechanisms of apoptosis
There are several mechanisms by which a cell may be assigned for apoptosis 
and once ordered the exact pathway by which apoptosis occurs may differ depending 
on cell type and the initiating factor. Some of the signalling pathways that are 
involved in this process are shown in outline form in Figure 1-6. Apoptosis can be 
initiated by molecules binding death signalling domain receptors on the cell surface 
or by toxic compounds or environmental effects such as radiation causing the release 
of cytochrome C from the mitochondria and either of these mechanisms will then 
cause a signalling cascade involving caspases (Yan and Shi 2005; Okouchi et al.
2007) (see Figure 1-6). Caspases are proteases that are activated when they are 
cleaved and then reform into active heterodimers. The caspase cascade is set in 
motion by the cleavage and activation of initiator caspases including caspase 8 and 9 
which can subsequently cleave and activate the activator caspases such as caspase 3 
and 7 (Yan and Shi 2005). The caspase cascade in turn sets in motion a chain of 
kinase activation that eventually leads to changes in gene expression switching on 
the expression of protease and DNA degrading enzymes leading to cell death. The 
intracellular pathways involved in apoptosis are complex; a large number of other
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molecules have pro or antiapoptotic actions. The details of these pathways will not 
be discussed in detail here.
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Figure 1-6: Mechanisms of the induction of apoptosis. This figure illustrates the mechanisms of the 
induction of apoptosis via death receptor-ligand interaction and mitochondrial disruption. From a 
review by Susan Elmore (Elmore 2007).
1.2.3. Apoptosis in beta-amyloid induced toxicity
There is evidence that apoptotic cell death and mitochondrial disruption are 
involved in the Ap induced toxicity in different cell types. AP25-35 has been shown to 
induce apoptosis in the SH-SY5Y cell line and both AP25-35 and AP1-40 have been 
found to induce apoptosis in hippocampal cultures (Forloni et al. 1993; Li et al.
1996). Furthermore in erythrocytes AP1-42 has been observed to cause an increase in 
activated caspase 3 and to alter oxygen metabolism (Clementi et a/.-2007). 
Hippocampal neurons have been demonstrated to be more susceptible to apoptosis in 
response to APmo or Ap25-35-induced increases in activated caspase 3 than cortical 
neurons and AP25.35 has been found to disrupt Ca2+ homeostasis in these hippocampal 
neurons (Resende et al. 2007). AP25-35 has also been seen to lead to decreased levels
42
of the anti-apoptotic molecule, Bcl-w, and increased levels of the pro-apoptotic, Bim, 
via JNK leading to exacerbated cytochrome C and Smac release from the 
mitochondria (Yao et al. 2007). However, despite the involvement of the initiation of 
apoptosis in Ap-induced toxicity increased expression of the anti-apoptotic molecule 
Bcl-2 did not protect against AP25-35 induced toxicity and cell death (Behl et al.
1993).
As well as increased caspase activation and evidence of apoptosis, 
mitochondrial dysfunction has been seen in relation to Ap induced toxicity. For 
example in rat astrocytes Ap has been found to cause an increase in phospholipase 
A2 via the activation of MAPK and NADPH leading to increased ROS and 
mitochondrial dysfunction (Zhu et al. 2006; Wang et al. 2007). Furthermore, Ap has
^  t
been demonstrated to cause Ca increase in astrocytes leading to mitochondrial 
dysfunction (Abramov and Duchen 2005).
1.2.4. Prevention of beta-amyloid-induced initiation of apoptosis
Ap leads to increased apoptosis (Forloni et al. 1993; Li et al. 1996; Awasthi 
et al. 2005) and mitochondrial dysfunction (Zhu et al. 2006; Wang et al. 2007) as 
detailed in Section 1.3.3 and compounds may protect against Ap-induced toxicity by 
preventing this Ap-mediated induction of apoptosis. For example oestrogen has been 
found to protect hippocampal cultures from Ap 1-40-induced toxicity by preventing 
Ap-induced activation of the apoptosis mediator caspase 3 (Park et al. 2007). 
Oestrogen has also been demonstrated to reverse the AP35_35-mediated down- 
regulation of the anti-apoptotic molecule, Bcl-2, and up-regulation of the pro- 
apoptotic molecule, Bcl-w, by preventing AP25.35 activation of JNK (Yao et al.
2007). Furthermore the natural flavenoid derivative, icaritin, which has been shown
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to have antioxidant and oestrogenic activity also protected rat cortical cultures 
against AP25-35-induced toxicity and corrected the AP25-35-mediated Bcl-2 imbalance 
via an oestrogen receptor-dependent pathway (Wang et al. 2007). The natural plant 
extract Lycium barbarum also protected rat cortical neurons by eliminating AP1-42 
and Ap25-35-induced increases in JNK and caspase 3 activation (Yu et al. 2005) and 
melatonin decreased AP1-42 and AP25-35-induced apoptosis in astroglioma cells (Feng 
and Zhang 2004).
1.2.5. Apoptotic markers
The study of apoptosis or the prevention of cell death as assessed by the level
of apoptosis are crucial in the study of neurodegenerative disease and therefore
reliable markers are needed for this process as a research tool. A commonly used
marker of cell death in vitro is propidium iodide which is taken into cells which have
compromised membranes and shows up as a fluorescent marker that may be seen
under the fluorescent microscope (Zhang et al. 2007). However, demonstrating
whether cell death is apoptotic or necrotic is not necessarily simple. In vitro several
markers are used as signs that apoptosis has been occurring for cell death or
protection experiments. These include demonstration of activation of the caspases, in
particular the executioner caspase, caspase 3 (see Figure 1-6). Activation of this
caspase may be seen using Western blotting and antibodies specific to the activated
form of the enzyme consisting of 12 and 17KDa units (Chiou et al. 2003; Ibuki et al.
2006) or using fluorescence activated cell sorting (FACS) analysis. The later
apoptotic marker annexin V is also used to confirm the occurrence of apoptosis
(Chiou et al. 2003; Zhang et al. 2007). DNA fragmentation is also used as a marker
of apoptosis using nuclear markers such as Hoechst that will allow one to see DNA
condensation by microscopy or by using electrophoresis (Ibuki et al. 2006). One of
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the most commonly used assays to measure apoptotic activity though is Terminal 
deoxynucleotidyl Transferase (TdT) mediated dUTP nick end (TUNEL) labelling 
which detects DNA fragmentation (Thakur et al. 2007).
1.3. Oxidative stress
Oxidative stress refers to the physiological stress due to the presence of ROS
• o_
such as the peroxide (OH ) and superoxide (O ) radicals or reactive nitrogen species.
These reactive species have an unpaired electron due to their involvement in 
reducing cellular reactions. The enzymes catalysing these reactions and the cycles of 
ROS production that may occur as a result of these reactions are shown in Figure 
1-7. The unpaired electron makes these species highly reactive and they can oxidise 
proteins, lipids or even DNA causing cellular damage and releasing products such as 
4-HNE, the aldehyde product of lipid peroxidation which is increased during 
oxidative stress, that can lead to more damage and eventually lead to cell death. This 
oxidative stress-related damage occurs when the balance between the cell’s 
antioxidant defences and ROS that cause damage is shifted in favour of the ROS due 
to ageing, disease or mitochondrial dysfunction.
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Figure 1-7: ROS production. The enzymatic reactions involved in ROS production. From (Chauhan 
and Chauhan 2006).
1.3.1. Antioxidant defence
The human body has extensive defence mechanisms in place to keep the 
redox balance in check and prevent oxidative stress-related damage. These defences 
include antioxidant enzymes to neutralise these ROS as well as non-enzymatic 
proteins and compounds that have antioxidant properties. The antioxidant enzymes 
include SOD which dismutates superoxide into oxygen and hydrogen peroxide 
(H2O2) and catalase which removes the resulting H2O2 . Three forms of SOD occur 
naturally and these vary according to the metal ions that they require and their 
cellular localisation; SOD1 is cytosolic and requires Cu/Zn, SOD2 is localised to the 
mitochondrial matrix and contains Mn and SOD3 is an extracellular Cu/Zn SOD; 
with SOD1 being by far the most prevalent (Noor et al. 2002). As well as the anti­
oxidant enzymes the compound glutathione produced by the enzyme glutathione 
synthetase has been shown to be crucial to antioxidant defence and this compound 
may be regulated in part by the anti-apoptotic Bcl-2 (Zimmermann et al. 2007). The 
vitamin E and C complexes have also been repeatedly demonstrated to have very 
strong antioxidant properties (Saeed et al. 2007; Traber and Atkinson 2007) and 
indeed Traber and Atkinson in 2007 argued in their review that the main function of
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vitamin E is as a peroxyl scavenger (Traber and Atkinson 2007). Moreover a 
bioluminescence substrate, coelenterazine, has been found to have anti-oxidant 
effects and to be able to protect rat hepatocytes from H2O2 induced damage although 
the dose chosen is critical as coelenterazine itself has also been found to be toxic at 
certain concentrations (Dubuisson et al. 2000). Aside from having a healthy diet rich 
in vitamin antioxidants it has been shown that anti-oxidant defences can be increased 
with regular exercise, which causes adaptation to the anaerobic conditions as 
discussed in a review by Radak et al. (2008).
1.3.2. Oxidative stress in pathology
Oxidative stress has been considered to be at the root of many pathologies. 
Oxidative stress damage naturally accumulates throughout life and is widely thought 
to contribute to normal ageing as well as neurodegenerative diseases which are 
considered to be diseases of old age. In ageing it been reported that there are 
reductions in antioxidants which may contribute to memory decline as well as an 
increase in lipid peroxidation (Droge and Schipper 2007). The brain has low anti­
oxidant defences and high oxygen consumption and as a consequence it is vulnerable 
to oxidative stress related damage. It is no surprise therefore that oxidative stress has 
been shown to have a role in almost all of the neurodegenerative diseases (reviewed 
in Reynolds 2007) with the presence of markers of oxidative stress damage in AD 
and PD and high ROS levels in MS (Noor et al. 2002; Bohr et al. 2007; Sayre et al. 
2008).
Glial cells are also vulnerable to oxidative stress although astrocytes appear 
to be less vulnerable than oligodendrocytes and microglia (Hollensworth et al. 2000). 
Oligodendrocytes are particularly susceptible to oxidative stress and in culture have 
been demonstrated to release the receptor for advanced glycation end products,
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which is involved in the activation of inflammatory genes at low levels of H2O2 and 
oligodendrocyte cell death is induced at higher H2O2 concentrations (Qin et al.
2008).
1.3.3. Oxidative stress in Alzheimer’s disease
In AD it has become clear that whatever the exact mechanism of disease 
initiation there is an important role for oxidative stress-related damage in AD 
pathology and disease progression in vivo as well as in Ap induced toxicity in vitro. 
The evidence for the involvement of oxidative stress in AD includes the observed 
increase in markers of oxidative stress including lipid and protein oxidation in 
patients with AD (Smith et al. 2000; Butterfield et al. 2001; Chauhan and Chauhan 
2006) . Specifically the lipid peroxidation marker 4-HNE has been demonstrated to 
be increased in the brains of AD patients compared to age-matched controls 
(Williams et al. 2006) and oxidative adducts have been found in forms of the 
oxidative marker 14-3-3 in AD patients (Santpere et al. 2007).
The levels of SOD1 have been found to be increased and oxidatively 
modified in AD patients and furthermore this excess SOD1 was seen to occur in 
aggregates associated with plaques (Choi et al. 2005). The activity of SOD1 has also 
been demonstrated to increase in AD patients in several studies (Noor et al. 2002) 
including one by Serra et al, 1994, which showed increased SOD1 activity in red 
blood cell homogenate from AD patients compared to controls (Serra et al. 1994). 
The mRNA levels of SOD1 has been found to be unchanged in the CSF in AD 
patients but SOD1 was higher in AD patient skin fibroblasts than controls (Urakami 
et al. 1995). This oxidative stress may be directly linked to AD pathology as it 
correlates with the activity of the P-secretase molecule BACE1 (Borghi et al. 2006).
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Changes in antioxidant enzymes have also been observed in animal models of 
AD. It has been observed that 4-HNE activity increases and SOD1 activity decreases 
in APP transgenic mice compared to controls (Schuessel et al. 2005). However,
SOD1 and haemoxygenase 1 proteins increase in an APP Swedish mutation 
transgenic mouse model of AD (described in Section 1.1.7) and, as in human 
patients, the increase occurs mainly around Ap deposits (Pappolla et al. 1998). The 
levels of Ap plaques have been found to be increased in the brains of mice with 
partial knock out of SOD2 (Li et al. 2004) and SOD2 has been shown to be nitrated 
although protein levels were unchanged in PS1/APP transgenic mice (Anantharaman 
et al. 2006).
There is evidence in vitro that Ap leads to oxidative stress and related 
damage. Harris et al. (1995), showed that A p^o caused an increase in ROS and 
carbonyl oxidation but decreased gluatamine synthetase activity in hippocampal 
cultures from embryonic rats (Harris et al. 1995). Furthermore AP25-35 has been 
found to cause lipid peroxidation in neuronal cultures from embryonic rats (Pike et 
al. 1997) and in synaptosomes from adult rats (Montiel et al. 2006). In hippocampal 
neurons in culture Api-40 has been demonstrated to increase SOD2 expression and 
temporally decrease SOD1 expression (Aksenov et al. 1998). However, Pappolla et 
al, (1998), saw an increase in SOD1 in PC12 cells derived from pheochromocytoma 
of the rat adrenal medulla that were treated with Ap (Pappolla et al. 2003).
1.3.4. Anti-oxidant effects against beta-amyloid-induced toxicity
Oxidative stress has been directly implicated in AD and in Ap-mediated 
cellular toxicity as detailed in Section 1.3.3 and several compounds that have been 
demonstrated to have antioxidant properties have been shown to protect against Ap- 
induced toxicity. In particular vitamin E has been found to protect against Ap-
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induced memory deficits in vivo (Yamada et al. 1999). In vitro vitamin E has been 
shown to protect neurons against Ap-induced damage (Montiel et al. 2006) and 
prevent the Ap-mediated increases in ROS and iNOS expression (Ayasolla et al.
2004) . 17p-oestradiol has also been demonstrated to prevent the Ap-induced 
oxidative stress mediated activation of p38 in MCF-7 cells in culture (Valles et al.
2008). The mechanism of this antioxidant effect of 17p-oestradiol has been 
suggested to be via activation of ERK1 and ERK2 which in turn causes translocation 
of NFkB, which up-regulates SOD2 expression (Borras et al. 2005). However, Pike 
et al. (1997) found that the antioxidant, probucol did not protect hippocampal cells 
from Api_42-induced toxicity (Pike et al. 1997).
1.4. The Limbic system and memory formation mechanisms
1.4.1. Limbic system structure and function
Because it is a key area affected in AD it is important to discuss the limbic 
system in some detail. The limbic system is a collection of brain areas situated 
primarily in the temporal lobe of the brain which together have been shown to be 
involved in memory consolidation, visceral motor activity and emotional responses 
to stimuli (Purves et al. 2001).
The limbic system is now generally accepted to include the cinglulate cortex, 
amygdala, hippocampus, thalamus, hypothalamus, cingulate gyrus and 
parahippocampal gyrus as well as some orbital and medial prefrontal cotical areas 
(Isaacson 1974; Purves et al. 2001). Whereas the hippocampus appears to only be 
important in contextual fear the amygdala has connections to and from the prefrontal 
cortex as well as the thalamus and has been shown to be critical for the emotional
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responses to stimuli, in particular being demonstrated to be involved in conditional 
fear responses and anxiety (Zigmond et al. 1999; Purves et al. 2001). Some of these 
responses, including the release of stress hormones, emotional behaviour and reflex 
actions, are mediated by connections to the hypothalamus, via the striata terminalis 
and the ventral amygdalofugal pathways, and the reticular formation in the brainstem 
(Isaacson 1974; Zigmond et al. 1999). Connections from the limbic system area to 
the midbrain may also be important for the control that the limbic system shows via 
the activity of the reticular formation (Isaacson 1974).
This system and it’s effects on motor responses is critical for shaping our 
behaviour in terms of recognising and remembering stimuli that we should be 
frightened of and therefore avoid. Furthermore this recognition also has clear 
advantages in that it allows us to recognise those who are unfamiliar and therefore 
may pose a threat.
1.4.2. The Hippocampus
I.4.2.I. Hippocampal structure and organisation
The hippocampus is part of the limbic system located in the temporal lobe of 
the brain and is known to have a major role in memory formation and the storage of 
long term memories via the processes of LTP and long term depression (LTD).
The cortex of the hippocampus is called archicortex as it contains only three 
or four cellular layers rather than the full six layers seen in the neocortex. The 
hippocampus consists of the CA1, CA2, CA3 regions and the dentate gyrus. The 
dentate gyrus receives inputs from the entorrhinal cortex and feeds connections via 
excitatory glutamatergic granule cells and mossy fibres onto the pyramidal cells of 
the CA3 region of the hippocampus. These pyramidal cells in the CA3 area extend
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projections via the Shaffer collaterals to hippocampal areas CA1 and CA2 (see 
Figure 1-8). The glutamatergic pyramidal cells of the CA1 are the main output of the 
hippocampus having connections to the subiculum which then has connections to 
other parts of the limbic system including the amygdala and also the entorrhinal 
cortex. The excitatory outputs of the pyramidal neurons of the hippocampus are 
regulated by the activity of inhibitory outputs from a diverse population of 
GABAergic intemeurons including the basket cells which surround the pyramidal 
axons and chandelier cells. As well as the excitatory and inhibitory neurons there are 
astrocytes, oligodendrocytes and microglia present in the hippocampus.
Dentate Gyrus
AC1/AC8 
SC - Schaffer collateral 
MF - Mossy Fibers
P P- Per for ant Path (lateral)
Figure 1-8: The circuitry of the hippocampus. Adapted from (Wang and Storm 2005).
1.4.2.2. The role of the hippocampus in long term potentiation and memory 
formation
LTP was first described by (Bliss and Lomo 1973). LTP refers to an increase 
in synaptic activity that leads to strengthening of synaptic connections between
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specific neurons and in this way ultimately gives the foundations for memory 
formation (Bliss and Lomo 1973). LTP initiation involves the activation of NMD A 
glutamate receptors by removal of the magnesium block which usually exists in these 
receptors and this allows increased Ca2+ influx. The resulting Ca2+ influx can then 
initiate kinase cascades which eventually lead to downstream changes in gene 
expression via the transcription regulator CREB in the early stages of LTP. There is 
also increased glutamate AMPA receptor translocation to the post-synaptic terminal 
as a result of this cascade and even eventually new synapses may form. In this 
manner further increases in synaptic transmission occur and the synaptic strength 
increases still more (Bliss and Lomo 1973).
I.4.2.3. The rat hippocampus
The position of the rat hippocampus differs from that of the human 
hippocampus which lies in the temporal lobe. In the rat the hippocampus is higher up 
in the forebrain. In vivo the structure, cell types, efferent connections and function of 
the hippocampus have been shown to be very similar as for the human hippocampus 
as described in Section 1.4.2.1 with exceptions in that humans have a much larger 
CA1 area and have connections onto the association cortices which the rat lacks but 
the rat has much stronger commissural connections onto the dentate gyrus than the 
human (Anderson et al. 2006).
In vitro dissociated rat hippocampal cultures contain a diverse neuronal 
population, most of which are microtubule associated protein (MAP)-2 positive 
(Domenici et al. 2002). Glial fibrillary acidic protein (GFAP) is a marker of mature 
astrocytes and the number of GFAP positive cells has been seen to increase through 
development (Gasser and Hatten 1990). It has been found that only around 5% of the 
cells at El 6-El 8 are GFAP positive and this proportion increases to around 15% by
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E20 (Gasser and Hatten 1990) but hippocampal cultures from both embryonic and 
early postnatal rats have also been demonstrated to contain GFAP positive astrocytes 
(Gasser and Hatten 1990; Domenici et al. 2002; Yamamoto et al. 2005; Hein et al.
2008). Moreover, 04  positive oligodendrocytes have been demonstrated to be 
present in hippocampal cultures (Xie et al. 2000; Hein et al. 2008). However Xie et 
al. (2000), did not find OX-42 positive microglia in hippocampal cultures from 
embryonic day 10 (El 8) rats (Xie et al. 2000).
I.4.2.4. Hippocampus and Alzheimer’s disease
As mentioned earlier the medial temporal lobe is highly vulnerable to the 
neurodegeneration seen in AD and the hippocampus in particular is one of the first 
areas to be affected. Hippocampal volume has been demonstrated to correlate with 
cognitive decline (Wolf et al. 2001) and MRI of people, with or without dementia 
symptoms, from families with a history of AD showed that hippocampal volume was 
reduced by as much as 25% in those with dementia compared to those without 
dementia symptoms (Wolf et al. 2008). Furthermore, the extent of hippocampal and 
entorrhinal atrophy have been found to be predictors of whether mild cognitive 
impairment will progress to AD (Devanand et al. 2007). The fact that these areas 
which are involved in memory formation and emotion are vulnerable and tend to be 
affected fairly early on in the disease process may explain some of the effects on 
memory.
The susceptibility of the hippocampus in AD related degeneration compared 
to other parts of the cortex has been attributed to differences in Ca2+ homeostasis due 
to the high levels of excitatory synapses present and the glutamate receptor subunits 
that they express (Brorson et al. 1995; Resende et al. 2007). Moreover some of the 
mutations associated with FAD have been demonstrated to affect the natural levels of
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neurogenesis within the hippocampus which would also increase vulnerability as lost 
neurons could be replaced less easily (Verret et al. 2007).
1.5. Colostrinin
1.5.1. Colostrinin isolation, structure and properties
CLN is a uniform mixture of low molecular weight polypeptides consisting of 
around 30 constituent peptides of varying size with the smallest of these being 6KDa 
(Janusz et al. 1974). The whole CLN complex is 18KDa and was first isolated from 
ovine colostrum in early milk. The levels of CLN are at their highest in the milk in 
the first few hours after birth. The complex was initially isolated from ovine 
colostrum by Janusz et a l in 1974 using electrophoresis methods to separate the 
components of the milk and the amino acid content was subsequently established 
using an automatic amino acid analyser (Janusz et al. 1974). The authors also found 
that CLN was highly proline rich with around 20% of the amino acids in the complex 
being proline but that it lacks both glycine and alanine and has a beta-sheet structure. 
Janusz et al (1974) also found that the constituent peptides had homology to the 
protein precursors annexin and (3-casein and that CLN is susceptible to protease 
digestion but resistant to collagenase.
Since the first isolation of the ovine form of CLN a more efficient mode of 
purification has been developed using methanol (Kruzel et al. 2004) and bovine CLN 
has also been isolated. Moreover several of the constituent peptides of the 
polypeptide including the active colostral-val nonapeptide, (CVNP: Val-Glu-Ser- 
Tyr-Val-Pro-Leu-Phe-Pro) have been investigated for their individual effects in vitro 
and in vivo to try and isolate the more critical active components of CLN. A table
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showing an amino acid analysis of CLN as percentages extracted from either ovine 
or bovine colostrum using two different methods (Janusz et al. 1974; Kruzel et al. 
2001; Kruzel et al. 2004), is shown in Table 1 below (Boldogh and Kruzel 2008). The 
two step methanol extraction is more efficient than the original method and gives 
consistently pure CLN (Kruzel et al. 2004) whether it is derived from ovine or 
bovine sources (see Table 1). Despite the fact that the bovine form has a slightly 
different amino acid composition to the ovine form of CLN (Boldogh and Kruzel
2008) it has been found to have the same molecular weight as the ovine form, to 
contain around the same number and size of proteins and, moreover, when tested has 
shown the same biological effects as the ovine form (Bacsi et al. 2005).
Amino Acid Colostrinin (CLN)
Ovine Original 
Method
Ovine MeOH 
Method
Bovine MeOH 
Method
Asp/Asn 3.42 2.80 5.13
Ser 5.66 5.05 6.94
Glu/Gln 15.48 15.77 17.99
Gly 3.15 3.03 2.95
His 2.54 2.14 3.28
Arg 2.32 3.34 1.62
Thr 5.73 5.30 4.32
Ala 2.78 2.13 3.06
Pro 21.07 22.50 20.79
Tyr 1.36 1.54 0.47
Val 9.27 11.10 8.15
Met 3.33 1.70 0.70
Lys 5.30 4.93 8.15
lie 3.17 3.42 3.21
Leu 11.04 10.47 10.33
Phe 4.38 4.77 5.41
Table 1: To show the detailed amino acid composition o f CLN with different modes of extraction. 
The numbers are percentages. From (Boldogh and Kruzel 2008).
The natural function of CLN in vivo and how it may become biologically 
active upon contact with the digestive tract is uncertain. However the effects of CLN 
on the immune system have been well documented (as detailed in Section 1.5.2 
below) and it has been suggested that it may be related to the uptake of
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immunoglobulins by the newborn or to ‘kickstart’ the immune system in the first few 
hours after birth. Other proline-rich polypeptides are known, in particular those 
isolated in hypothalamic neurosecretory granules, and these have been found to have 
effects on a range of processes including growth actor release and caspase 3 activity 
(Gladkevich et al. 2007) which implies that CLN could also have very diverse 
effects.
1.5.2. Colostrinin and effects on the immune system
As described in Section 1.5.1 CLN was initially of interest and investigated 
for its potential effects on the immune system. From these studies ovine CLN has 
been demonstrated to be able to stimulate the activation and growth of resting B 
lymphocytes, as well as affecting their differentiation, which can be assessed by 
plaque formation, with a similar same efficacy as LPS in vitro (Julius et al. 1988). 
CLN does appear though to stimulate a separate group of B lymphocytes to those 
induced by LPS as the effects are additive (Julius et al. 1988).
Moreover, ovine CLN alters the host-vs-graft response and has been seen to 
allow thymocytes that previously did not exhibit this response to be capable of 
producing the response in thymocyte cultures and in vivo in mice (Zimecki et al. 
1982). Ovine CLN has also been shown to alter the binding properties of peanut 
agglutinin (PNA) to thymocytes, changing the properties of the cells from helper 
cells to suppressor cells and vice versa (Lisowski et al. 1988). This CLN-mediated 
effect on PNA binding has been found to involve P-galactosidase activity (Sokal et 
al. 1998) and although the mechanism of these actions is not more clearly known it 
has been suggested that the effects of CLN on thymocyte differentiation and
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maturation may be mediated by CLN binding a receptor on the surface of thymocytes 
(Janusz and Lisowski 1993).
As well as regulating immune cell maturation CLN has been found to have 
other roles in regulating the immune system. In experiments utilising the injection of 
sheep red blood cells into mice in order to induce a humoral immune response it was 
found that ovine CLN given with the red blood cells was able to regulate the immune 
response differently depending on the current activation status of the immune system 
(Wieczorek et al. 1979). This regulatory effect means that if the immune response 
was high, CLN kept it under control by dampening it down and if the response was 
low then CLN caused a boost to ‘kick start’ the immune system. Furthermore, CLN 
was demonstrated to increase skin permability in guinea pigs and this appeared to be 
via effects on prostaglandins (Wieczorek et al. 1979).
Ovine CLN has further been demonstrated to be modest inducers of 
inflammatory cytokines, tumour necrosis factor (TNF)a and y interferon (IFN) , in 
murine resident peritoneal cells, human peripheral blood leukocytes (Inglot et a l 
1996; Kruzel et a l 2001) and in human whole blood cell cultures (Inglot et al. 1996) 
where CLN has been found to induce the release of interleukin-6 and interleukin-10 
as well as TNFa and ylFN (Zablocka et a l 2001). CVNP has also been observed to 
mediate the cytokine inducing effects of CLN in leukocytes and whole blood cell 
cultures but with less efficiency than the whole CLN complex (Inglot 1996;
Zablocka 2001) and the cytokine inducing activity of the nonapetide and hexapeptide 
of CLN appear to depend on whether they are monomers, dimmers or oligomers 
(Zablocka 2001).
Moreover, it has recently been reported by Boldogh et a l (2008), that CLN 
can help to decrease the severity of allergic responses such as mucin levels to
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ragweed pollen and house dust mites without itself causing an allergic reaction in a 
mouse model of allergic inflammation (Boldogh et al. 2008).
CLN has therefore been shown in vitro and in vivo to have several effects on 
immune system cells and function (Janusz and Lisowski 1993; Zimecki 2008). The 
bovine form of CLN has also been found by a recent study using microarray analysis 
on TR146, human buccal mucosal cells to regulate the expression of many genes 
involved in pathways for immune system function including mediating the 
downregulation of c-jun-terminal kinase (JNK) which is activated in response to 
stress signals (Szaniszlo et al. 2009).
As described above the CVNP of CLN has been demonstrated to have most 
of the biological effects that the whole CLN compound has on the immune system 
(Staroscik et al. 1983) and in particular the sequence Pro-Leu-Phe has been shown to 
be critical for these immunological effects (Janusz and Lisowski 1993).
In addition to the above effects, bovine CLN has also been shown in 
microarray analysis of buccal mucosal cells to regulate genes involved in cell 
proliferation (Szaniszlo et a l 2009) and to inhibit the proliferation of PC 12 cells via 
the activation of the cell-cycle regulator P53 and its downstream effecter, P21, (Bacsi 
et al. 2005). Moreover, both ovine and bovine forms of CLN bound to PC 12 cells 
and stimulated neurite outgrowth which was associated with the increased expression 
of the neuronal development marker, GAP-43, and required activation of P53 and 
P21 (Bacsi et al. 2005). The similarity of the extent of neurite outgrowth induced by 
CLN and the molecules involved in its induction led the authors to speculate that 
CLN may act at a receptor and mediate a similar pathway to nerve growth factor 
(Bacsi et al. 2005). Ovine CLN has also been found to affect the vitamin D-induced 
differentiation of HL-60 moncocyte cell line but only when given before or with
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vitamin D and therefore appears to affect an early stage in the process (Kubis et al. 
2005).
1.5.3. Colostrinin and oxidative stress
Research has accumulated to show that CLN can protect against oxidative 
stress related cellular damage in vitro (Boldogh and Kruzel 2008). Bacsi et al. (2006) 
found that CLN protects Chinese hamster V79 fibroblast cells from oxidative 
stress-induced mutations as well as spontaneous mutation and UV or chemically- 
induced mutation. Furthermore, the same authors demonstrated that CLN 
significantly increases the lifespan of both senescence sensitive and senescence 
resistant murine diploid cell cultures by around 30% via reducing ROS 
accumulation in the mitochondria and therefore preventing mitochondrial damage in 
these cells (Bacsi et al, 2007).
Ovine CLN has also been shown in the PC 12 cell line to prevent 4-HNE 
protein adduct formation, prevent 4-HNE -induced increases in JNK and P53 as well 
as decreasing 4-HNE-induced glutathione depletion and ROS production as seen 
using 2’7’-dichlorofluorescein (DCF) (Boldogh et al. 2003). Both the whole ovine 
CLN complex and CVNP have been found by Zablocka et a l (2000), to inhibit 
lipopolysaccaride (LPS)-induced nitric oxide (NO) release in whole blood cells 
(Zablocka et al. 2005). However, Mikulska and Lisowski (2003) found that in the 
human monocyte/macrophage cell line, THP-1, only the nonapeptide, but not whole 
ovine CLN could prevent LPS induced NO release. Furthermore CLN has been 
found to prevent increases in ROS levels in response to H2O2 or A(3 in SH-SY5Y 
cells (Boldogh and Kruzel 2008).
It is now thought that these antioxidant effects that are mediated by CLN 
appear not to be due to a direct antioxidant action of CLN in removing ROS but to be
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initiated via the inhibition of molecules which will lead to the production of ROS 
(Stewart 2008).
1.5.4. Colostrinin and Alzheimer’s disease
The research into the ability of CLN to affect the release of cytokines 
discussed in Section 1.5.2 involved the participation of AD patients that were given 
CLN orally (Inglot et al. 1996). CLN was later reported by a subset of the patients 
participating to also have a psycho-stimulatory effect (Inglot et al. 1996) and this led 
to interest into whether CLN may be beneficial for patients with dementia. Therefore 
two groups have conducted separate, placebo-controlled clinical studies which were 
set up to investigate whether CLN had a beneficial effect in AD patients at various 
stages of Alzheimer’s disease (Leszek et al. 1999; Leszek et al. 2002). Lezek et al 
(1999) carried out a trial with 46 AD patients separated into three receiving lOOpg 
ovine CLN, selenium or placebo tablets orally every other day for two weeks 
followed by three weeks off over 10 cycles. The authors found that 8 out of 15 
patients on CLN showed improvement in the MMSE test and the other 7 stabilised 
(Leszek et al. 1999). In comparison no improvement was observed in patients on 
selenium or placebo tablets although 13 of 15 patients on selenium and half of those 
on placebo stabilised (Leszek et al. 1999). These authors later carried out a longer 
trail in which 33 patients were given ovine CLN in the same treatment regimen as 
detailed for the first study for between 16 and 28 months and again found that CLN 
led to an improvement in MMSE test scores (Leszek et al. 2002). CLN was found to 
be particularly beneficial to patients in the early stages of the disease with relatively 
mild symptoms and slightly less beneficial to those at more advanced stages of 
disease. Furthermore the authors found that there were only mild and very short lived 
side effects such as anxiety and insomnia (Leszek et al. 1999; Leszek et al. 2002).
An independent study was then conducted by Bilikiewicz and Gaus (2004) to verify 
the results obtained by Leszek et al (1999). The authors had 105 AD patients and 
treated half of them with lOOpg ovine CLN and half with placebo tablets every other 
day for two weeks followed by three weeks off over 15 weeks before repeating this 
15 week treatment cycle giving all of the patients CLN (Bilikiewicz and Gaus 2004). 
Assessments were carried out on the patients at 15 weeks and 30 weeks using 
ADAS-cog, Clinical Global Impression of Change, MMSE, ADAS-non cog and 
Instrumental Activities of Daily Living and showed a stabilising effect with CLN 
according to ADAS-cog and Instrumental Activities of Daily Living (Bilikiewicz and 
Gaus 2004). As described in Section 1.1.10 more, larger clinical trials than these 
detailed for CLN have been carried out to investigate the efficacy of acetylcholine 
esterase inhibitors in AD and have shown efficacy even for more severe AD, where 
CLN has demonstrated far more of an effect for patients with mild AD (Birks 2006; 
Birks and Harvey 2006; Loy and Schneider 2006). Acetylcholine esterase inhibitors 
have been demonstrated to commonly lead to side effects which have resulted in 
people leaving studies (Birks 2006). CLN, which despite occasional more serious 
side effects such as psychosis and gastrointestinal disturbance appears to be very 
well tolerated with only mild, short lived side effects (Rattray 2005).
Further to the beneficial effects of CLN treatment seen in AD patients CLN 
has been shown to improve memory in rats. CLN has been demonstrated to improve 
spatial memory in aged rats as seen by the Morris water maze task (Popik et al. 1999; 
Popik 2001; Popik et al. 2001). CVNP has also been shown to affect spatial memory 
(Popik et al. 2001). However, the effect on spatial memory differs between CVNP 
and the whole peptide. CVNP appears to delay the extinction of memories (Popik et 
al. 2001) rather than improve the acquisition of these spatial memories as the whole 
polypeptide complex has been shown to be able to do. There is also evidence from
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the passive avoidance learning test in one-day old chicks showing that CLN can 
enhance long term memory (Stewart and Banks 2006) but only the whole 
polypeptide complex and not individual constituent peptides of CLN could mediate 
these effects on chick memory (Stewart and Banks 2006).
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Figure 1-9: Modes of action of CLN that may prevent pathology. From Boldogh and Kruzel (2008).
It is not known exactly how CLN exerts these positive effects in the CNS on
memory and in AD patients, or indeed how CLN may be processed when it’s given
orally. Some potential modes of action are illustrated in Figure 1-9. It may be that a
constituent peptide can cross into the CNS or possibly the effects are related to
cytokine release or cell signalling effects. Much work has been done to study its
effects and potential mechanisms including an antioxidant effect (Stewart 2008).
Oxidative stress is known to be very important in the development of AD and disease
progression as discussed in Section 1.3.2 and CLN has been demonstrated in several
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studies to exert antioxidant effects (as detailed in Section 1.5.3). Also as previously 
mentioned CLN has been observed to be a modest cytokine inducer, particularly of 
TNFa and INFy (Inglot et al. 1996; Blach-Olszewska and Janusz 1997; Zablocka et 
al. 2001). It is possible that CLN may be able to regulate release of anti­
inflammatory cytokines as well as the pro-inflammatory TNFa and INFy although 
this has not as yet been investigated. This ability to modulate the release of cytokines 
may therefore be another possible mechanism of action of CLN.
One potential mode of action for CLN that is directly linked to the pathology 
seen in AD patients is the discovery that CLN can hinder the aggregation of beta- 
amyloid (Schuster et al. 2005). This ability of CLN to affect aggregation could be 
central to CLN’s ability to benefit AD patients as the aggregation state of Ap has 
been demonstrated in vitro and in vivo to be crucial to the level of neurotoxicity that 
Ap causes. Furthermore Szaniszlo et al. (2009) demonstrated that bovine CLN can 
upregulate the Ap cleavage molecule bleomycin hydrolase and can downregulate the 
expression of the Ap precursor APP. Together these data suggest that CLN may 
prevent the accumulation of Ap plaques. Moreover, as discussed in Section 1.1.1., 
the phosphorylation and subsequent aggregation of Tau may exacerbate toxicity in 
AD and bovine CLN has been shown by microarray analysis on TR146, buccal 
mucosal cells to downregulate the gene expression of protein kinase A (PKA) which 
is involved in the phosphorylation of Tau (Szaniszlo et al. 2009).
This introduction has described the known effects of CLN and the potential 
benefits of the complex to patients with AD but it is also clear that there is a lot more 
to learn about the mechanism of action of CLN. The aim of this research was 
therefore to further investigate the mechanism of action of CLN using in vitro 
models.
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The toxicity of Ap and the vulnerability of the hippocampus as well as the 
relevance of oxidative stress in AD and other neurodegenerative diseases, has been 
discussed. Therefore the ability of bovine CLN to eleviate Ap-induced or ROS- 
induced toxicity in hippocampal cells in vitro was investigated. Furthermore, the 
effects of bovine CLN on ROS production, antioxidant defence and apoptosis in 
primary hippocampal cells and the B50 neuronal cell line were examined.
Chapter 2
Materials and methods
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2.1. Materials and antibodies
Full details of the materials and consumables used are in appendix 1, Section 
8.1 and the primary and secondary antibodies are in appendix 1, sections 8.2.1 and 
8.2.2 respectively.
2.2. Animals
Rats of the Sprague Dawley strain were used at Postnatal day 4 (P4) and E l 8. 
The litters usually contained about 12 pups. The mothers were kept in a 12 hour 
light/dark cycle, fed ad libitum with standard rat pellets and had free access to water. 
Animals were sacrificed by anaesthetic overdoes as approved as a Home Office 
approved Schedule 1 procedure.
2.3. Dissociated hippocampal culture
Primary hippocampal slice cultures (Bruce et al. 1996; Lezoualc'h et al.
1996) and dissociated cell cultures (Harris et al. 1995; Maiese et al. 1995; Kittur et 
al. 2002) from embryonic and early postnatal rat pups are extensively used as a 
model culture system for cell death and protection experiments.
A protocol for the culture of dissociated rat hippocampal cells was 
established, based on a method from a personal communication from Frances Colyer 
of The Life Sciences department, Open University. This method has been used 
previously by others in our laboratory and has been considered to be a reliable 
method for the culture of hippocampal cells. It is similar to the method used by
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Banker and Cowan (1977). Prenatal (El 8) or early postnatal (P4) rats were used for 
the hippocampal cultures because it has previously been found that cells from young 
animals produce cultures with improved viability. This last point is discussed in more 
detail in Chapter 3, Section 3.2.1.
2.3.1. Removal of the hippocampus
For cultures from P4 animals, 8-12 rat pups were used for each preparation. 
After decapitation the brain was accessed by an incision along the skin and skull and 
was removed using a spatula and then placed into dissection media (Dulbeccos 
Modified Medium (DMEM) medium with 1% penicillin/streptomycin).
For cultures from El 8 animals, tissue from an entire litter was used for each 
preparation. The mother was given an overdose of anaesthetic and an incision was 
made into the abdominal cavity and through the uterus wall to remove the pups. The 
brain was then removed from the pups by cutting through the skull beneath the brain. 
The hippocampi were located by separation of the cerebral hemispheres and the 
overlying cortex was pulled away with forceps. The hippocampi were then very 
gently excised using fine curved forceps, placed into fresh media (Banker and Cowan 
1977; Stoppini et al. 1991) and for P4 cultures the hippocampi were chopped into 3 
or 4 pieces.
2.3.2. Dispersion of cells
After removing the hippocampi the DMEM medium was removed and 
replaced with 1ml El solution (Earl’s balanced salt solution (EBSS) with 6mg/ml 
papain, lmg/ml cysteine, EDTA solution (1.64mM NaOH, 2mM EDTA) and ImM 
p-mercaptoethanol). The hippocampi were incubated in El at 37°C in a shaking
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water bath for 25 minutes. El solution was then removed and replaced with 1ml of 
E2 solution (DMEM with 1 mg/ml chicken egg white trypsin inhibitor and 1 mg/ml 
DNAase). The tissue was dispersed by trituration with a glass Pasteur pipette that 
had been flamed at the tip. The E2 solution was then made up to 10ml and the 
suspension spun at 800rpm for 5 minutes.
2.3.3. Cell counting and plating
Once the solution had been spun, the supernatant was removed and the pellet 
resuspended in 2ml medium containing horse serum (Basal Medium Eagles (BME), 
0.5% glucose, lmM sodium pyruvate, 1% penicillin streptomycin, N2 supplement 
and 10% horse serum (HS)). The solution was then made up to 10ml with more 
media and the cells were counted in a haemocytometer using trypan blue to stain any 
dead cells. The cells were then plated at an appropriate density for the experiment 
(20,000 -  80,000 cells/well) on poly-lysine coated 19mm coverslips in 12 well 
plates.
2.3.4. Maintenance of cultures
The media were changed 24 hours after the cultures were set up. On the third 
day in vitro (3 DIV) the media were replaced with media including the supplement 
B27, which contains antioxidants, vitamins, essential fatty acids and hormones 
(Brewer, 1997), but without horse serum.
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2.4. B50 cell line
The B50 cell line is a rat neuronal cell line produced from a chemically- 
induced neuroblastoma. The cell line has been well used in cellular toxicity and 
death experiments including investigation into the effects of hydrogen peroxide on 
cells in culture (Lai et al. 1993; Honma et al. 1997; Iwata et al. 1998). The line was 
purchased frozen from the European Collection of Cell Cultures (ECACC). The cells 
were maintained in DMEM with 2mM glutamine and 10% fetal calf serum (FCS) at 
37°C/ 5% CO2 and passaged at a 1:3 dilution twice weekly using trypsin-EDTA to 
release the cells. Cells were frozen in DMEM with 20% FCS and 10% DMSO in 1ml 
aliquots and kept at -80°C for 48 hours before being stored in liquid nitrogen.
2.5. Preparation of bovine CLN
Bovine CLN received in batches from Regen Therapeutics was dissolved in 
Phosphate Buffered Saline (PBS) at 2mg/ml and then diluted as appropriate for 
treatment. The natural concentration of CLN is unknown and therefore 
concentrations were based those used in previous experiments.
2.6. Preparation of menadione
Menadione from Sigma Aldrich (M5625) was dissolved in ethanol at lOOmM 
and then diluted in the culture media used on the cells in that specific experiment to
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between lpM  and 20pM for treatment of the cultures. This equates to between 
0.001% and 0.02% ethanol in the culture.
2.7. Preparation of beta-amyloid
APm2 was dissolved in saline and then diluted to lmg/ml in phosphate 
buffered saline (PBS) and incubated for 48hours at 37°C/5%C02 with or without 
bovine CLN. This pre-incubated stock was then diluted in culture media to the 
required concentration prior to treatment.
2.8. Immunohistochemistry
2.8.1. Cell preparation
The primary hippocampal cultures on glass coverslips were fixed in 4% 
paraformaldehyde/PBS pH 7.4 for 1 hour at room temperature (RT) and washed 
twice with PBS (Adamec et al. 2001; Alvarez et al. 2004).
2.8.2. Optimisation of immunolabelling
Several concentrations of the antibodies used were tested on the primary 
hippocampal cultures in order to optimise staining. Staining was considered 
optimised when there was clear staining of the cells being labelled without 
background fluorescence. Concentrations between 1:100 and 1:1000 were tested at 
RT overnight or for 48hours for the anti-MAP-2 antibody; 1:1000 for 48hours was
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found to be optimum. 1:100,1:1000 and 1:2000 at RT were tested for the anti-GFAP 
antibody and 1:1000 overnight was found to be optimum. Both anti-2, 3-cyclic 
nucleotide 3-phosphodiesterase (CNPase) and anti-CD 1 lb  were tested at 1:200,
1:250 and 1:400 at RT; the dilution of 1:250 overnight was chosen as optimum. 
Controls using only the secondary antibody without the primary antibody were also 
carried out for all antibodies and showed no background reactivity. Further controls 
that could have also been carried out are reagent only controls to check for 
background peroxidise activity and testing antibody specifity by blocking with a 
closely related antigen to the antigen that the antibody is against.
2.8.3. GFAP immunolabelling
GFAP is an astrocytic intermediate filament protein that has been well- 
characterised as a marker for astrocytes in the CNS (Eng et al. 2000) including those 
in embryonic (Assis-Nascimento et al. 2007) and adult rat hippocampal cultures 
(Brewer 1997). The antibody chosen (Dako-Cytomation 20334) for these 
experiments has been demonstrated to label rat and mouse astrocytes after fixation 
with paraformaldehyde (Castellano et al. 1991).
Non-specific binding was blocked with 10% donkey serum diluted in 
antibody diluting solution (ABDS) which contained PBS with 1 mg/ml lysine, 0.01% 
BSA, 0.05% azide to preserve cultures and 0.1% triton X I00 for permeabilisation. 
After removal of the blocking solution anti-GFAP antibody (1:1000 in ABDS) was 
applied overnight at RT with shaking. The biotin-strepavidin fluorescein secondary 
system was then used to visualise the immunolabelling. Following three 10 minute 
washes in PBS, anti-rabbit biotinylated antibody (1:250 in ABDS) was applied for 1 
hour at RT with shaking followed by a further three washes in PBS and incubation 
with strepavidin fluorescein (1:100 in ABDS) for 1 hour at RT with shaking. A foil
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cover was also used at this last stage to protect the fluorescence from light-induced 
fading.
2.8.4. MAP-2 immunolabelling
MAP is one of the most abundant microtubule associated proteins that is 
expressed in neurons of the both the CNS and PNS and it is expressed throughout 
development (Teng et al. 2001). MAP-1 and MAP-2 are both localised to nerve cells 
but MAP-2 has been more extensively studied and has, in particular, been used as a 
neuronal marker in hippocampal cultures (Adamec et al. 2001; Yu et al. 2007). The 
MAP-2 monoclonal antibody was therefore chosen as the neuronal marker because it 
is a pan neuronal marker that has been demonstrated to effectively label neurons in 
both embryonic and neonatal rat neuronal cultures and it is compatible with 
paraformaldehyde fixation (Adamec et al. 2001; Yu et al. 2007).
Non-specific binding was blocked using 10% goat serum and then anti- 
MAP-2 (1:1000) antibody was applied for 48 hours at RT with shaking followed by 
three 10 minute washes in PBS and goat-anti-mouse amino-methyl-coumarin-acetate 
(AMCA) conjugated secondary antibody (1:100) for 1 hour with shaking and a foil 
cover.
2.8.5. CNPase and CDllb immunolabelling
CNPase is an oligodendrocyte marker and CD1 lb  is commonly used as a 
microglial marker.
Non-specific binding was blocked using 10% goat serum and then anti- 
CNPase (1:250) antibody or anti-CDl lb  antibody (1:250) was applied for 48 hours 
at RT with shaking followed by three 10 minute washes in PBS and goat-anti-mouse
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rhodamine conjugated secondary antibody (1:100) for 1 hour with shaking and a foil 
cover.
2.8.6. Cell counting
Double labelling with GFAP (1:1000) and MAP-2 (1:1000) or GFAP 
(1:1000) and CNPase (1:250)/CD1 lb (1:250) antisera was carried out and coverslips 
were mounted onto microscope slides with Citifluor (glycerol/PBS) mountant. The 
immunofluorescence was then visualised using an Olympus BX61 fluorescence 
digital photomicroscope. The FITC filter (excitation 494, emission 518) was used to 
visualise the fluorescein (excitation 494, emission 521) conjugated GFAP labelling 
while AMCA (excitation 349, emission 448) conjugated, MAP-2 labelling was 
observed under the DAPI filter (excitation 345, emission 445) and rhodamine 
(excitation 550, emission 570) conjugated CNPase and CD1 lb  labels were visualised 
using the texas red filter (excitation 595, emission 615).
After some preliminary tests using several counting methods with fewer or 
more frames and in different forms, circular grids or cross shaped grids, a square grid 
of 100 frames was chosen as the optimum. Positive cells were counted manually for 
each cell type individually using the grid system on the stage manager function on 
the microscope at x400 magnification. One hundred grid squares (347.64pm by 
260.73 pm) covering 9mm of the coverslip in total were counted for each coverslip 
and there were at least three replicates for each condition per experiment. Only 
healthy/viable looking cells; smooth, round neurons and flat, filamentous astrocytes 
with a clearly visable nucleus, that were clearly positively stained were counted and 
the cells on the lines at the left hand side and bottom of the square were not counted 
in order to avoid recounting (see Figure 2-1). Digital images were taken at x200 or 
x400 magnification using AnalySiS software.
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Figure 2-1: Illustration of the counting procedure followed using one frame out of the 100 frames 
used for each coverslip as an example. The cells in red on the left and bottom lines o f the frame would 
not have been counted. Any cells in the positions of the blue cells would have been counted if they 
were positively stained and met morphological criteria.
2.9. Electron microscopy (EM)
Dissociated hippocampal cultures from P4 rats were prepared as described in 
2.3 and treated at DIV  6 with media alone or with lOOng/ml CLN for 24 hours. 
Cultures were then fixed in 2% paraformaldehyde/2% glutaraldehyde in 0.1 M 
sodium cacodylate buffer pH 7.4 for lhr and post fixed in 1% osmium tetroxide in 
0.1M sodium cacodylate for lhr before washing in sodium cacodylate buffer.
Cultures were then dehydrated in graded ethanol with 10 minutes in 50, 70,
80, 95% ethanol and then 2 x 1 0  minutes in 100% ethanol before being put in 100% 
ethanol containing molecular sieve beads for 10 minutes to absorb moisture. The 
coverslips were then placed in 50:50 100% ethanol:resin (Epon 812/Araldite M 
epoxy resins) for 20 min.
Each coverslip was removed from the culture plate using forceps and the 
resin/ethanol was drain off onto filter paper. The ethanol was then allowed to 
evaporate and each coverslip was placed culture side down onto the surface of a 
mould filled with resin. The resin was polymerised by heating for 48hrs in an oven at 
60°C and the mould was removed. The glass coverslip was then removed by 2 hrs 
immersion in hydrofluoric acid before being rinsed with water and allowed to dry.
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Preparations were then viewed under a light microscope through the resin block to 
locate cells and the resin blocks were then trimmed with a glass knife and 1pm thick 
sections cut, collected on a glass slide and stained with 1% toluidine blue before 
viewing in a light microscope to definitively confirm the presence of cells. For 
electron microscopy serial sections of grey/white colour (60-70 nm) were cut with a 
Diatome diamond knife and collected using Pioloform-coated slot copper grids. 
Sections were counterstained with saturated ethanolic uranyl acetate, followed by 
lead citrate, and were then placed in a rotating grid holder to allow uniform 
orientation of Sections on adjacent grids in the JEOL 1010 electron microscope, 
sections were viewed at a magnification of 6000 on the microscope screen and 
captured digitally with a GATAN Bioscan camera. Images were printed at a final 
magnification of x20K.
2.10. MTS cytotoxicity assay
The MTS cytotoxicity assay uses the reduction of the tetrazolium salt, 3-(4,5- 
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- 
tetrazolium (MTS), to soluble formazan as a measure of the mitochondrial activity 
within cell cultures. To carry out this assay B50 cells were plated at 5,000 cells/well 
in 96 well culture dishes, treated with CLN immediately after plating or on DIV1. 
Menadione treatment was carried out on DIV1. On DIV2 the MTS solution was 
added to the culture medium in a 1:5 dilution for 1 hour at 37°C before the assay 
being read at 490nm in a plate reader.
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2.11. Dichlorofluorescein diacetate and reactive oxygen species
2.11.1. Dichlorofluorescein diacetate (DCFH-DA)
DCFH-DA is a compound that can freely enter cells where it is converted to 
insoluble DCFH by esterases. DCFH can then react with peroxides to produce the 
fluorescent compound DCF which can be viewed under the microscope. The 
fluorescence can be quantified as a measure of relative ROS production (Harris et al. 
1995; Xie et al. 1996; Sultana et al. 2005).
2.11.2. Cell preparation and treatment
B50 cells were plated at 200K cells/well on coverslips in 6 well culture plates 
and the experiment was begun on DIV2. The cells were treated with lOpM 
menadione with or without lpg/ml CLN for 24 hours before addition of 25pM 
DCFH-DA for i  hour.
2.11.3. Confocal microscopy and analysis
Images were taken of 3 separate fields in the centre of each coverslip on the 
Leica DMIRBE confocal microscope. The FITC channel was used to excite the 
fluorescence (excitation 494, emission 518) and the x60 oil immersion objective was 
used to view the samples and take images. A scanning distance of 10pm was chosen 
in order to pass through the entire monolayer and twenty scans were taken over this 
distance and then combined to obtain high quality images. Quantification was then 
carried using mean and maximum intensity values of the images which were 
obtained for each field of view using Volocity software.
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2.12. Western blot
2.12.1. Cell preparation
In order to ensure sufficient protein yield for the Western blot, cells were 
plated in large 6 well culture plates at high densities of 400,000 cells/well for 
primary hippocampal cells and 100,000 cells/well for B50 cells and treated as 
described for the individual experiment. After treatment cells were lysed with radio- 
immunoprecipitation assay (RIPA) lysis buffer containing protease inhibitors to 
prevent destruction of the protein, sonicated and then spun to remove debris. Protein 
content of the samples was then assayed using a detergent compatable (DC) 
colorimetric protein assay protein assay. Primary hippocampal cell lysate gave low 
protein yields and 20pg of protein onto the gels was considered sufficient. However, 
much higher yield was obtained from the B50 cell lyaste and therefore 50pg of 
protein was used as more protein will allow clearer bands.
2.12.2. SDS PAGE
Cell lysate was diluted in ddH20 to the appropriate protein concentration, 4x 
Laemmli sample buffer (SDS, Tris, glycerol, P-mercaptoethanol and bromophenol 
blue) was added to the samples and samples were boiled for 10 minutes. After being 
spun down the samples were loaded onto a 15% SDS polyacryamide gel. The gel 
was run in Tris/glycine/SDS running buffer at 100V for 2 hours at RT and 
transferred in transfer buffer containing Tris/glycine and 20% ethanol onto 
nitrocellulose membrane overnight at 4°C.
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2.12.3. Western blotting
Western blots for SOD1 or Cdk5 were then performed. After blocking non­
specific binding on the nitrocellulose membrane by 1 hour incubation in 5% dried 
skimmed milk (Marvel) in PBS/Tween at RT anti-SODl (Abeam ab51254) or anti 
Cdk5 (Santa Cruz SC-173) antibodies were then applied to the membrane at 1:25,000 
in 50ml 5% milk/PBS/Tween, or 1:200 in 2ml 5% milk/PBS/Tween, respectively for 
1 hour at RT with shaking. The membrane was then washed in 5% milk in 
PBS/Tween for 1 hour with shaking and several changes of the solution before being 
incubated in anti-rabbit horseradish peroxidise conjugated secondary for 1 hour at 
RT with shaking. A further two washes in 5% milk in PBS/Tween, one wash in 
PBS/Tween and finally a PBS only wash were then carried out following the 
secondary antibody incubation.
ECL chemiluminescent reagent was used to detect horseradish peroxidase on 
the secondary antibody. The ECL reagents A and B were mixed in a 1:1 dilution and 
the membrane was shaken in the solution for 2 minutes then placed in clear plastic in 
a film case. Developing film was then exposed to the blot for an appropriate time and 
an EXOMAT developing machine in a darkroom was used to develop the film.
A second blocking step in 5% marvel/PBS Tween was then carried out and 
rabbit anti-actin antibody applied overnight at 4°C with shaking before washing in 
5% milk in PBS/Tween as above and incubating in anti-rabbit secondary antibody 
for lhr at RT with shaking. The final washing procedure and ECL developing was 
then carried out as above.
2.12.4. Quantification
The developed Western blot films were scanned as greyscale images and the 
software program ImageJ was used to carry out densitometry analysis on these
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images. This analysis was carried out by selecting the same area over each separate 
band and using the analyse gels function on the ImageJ software to obtain a plot. The 
area under this curve gave desnity values for each band. The density value for the 
observed protein band was then divded by the value for the corresponding actin band 
to give an actin normalised band density.
2.13. Fluorescence Activated Cell Sorting analysis
FACS allows the separation and counting of cells in a given sample 
according to size and fluorescence.
Primary hippocampal cells from El 8 rats and B50 cells were prepared for 
FACS analysis. Cells were plated in 6 well plates at 400,000 cells/well for primary 
cells and 100,000 cells/well for B50 cells. The cultures were treated as described for 
the specific experiment and then released with trypsin. This cell suspension was spun 
at 4,000rpm for 5mins, washed in PBS and then resuspended in 0.4% 
paraformaldehyde for 30mins.
For the intracellular protein active caspase 3 the procedure was carried out as 
follows. After fixation the cells were spun and then washed twice with spinning 
(4,000rpm for 5mins) in 0.01% triton X/PBS solution to permeabilise the cells before 
incubation in an anti-activated caspase 3 antibody which binds to both subunits of the 
enzyme (Abeam, abl3847.1:500 in 0.01% triton-X/PBS) for 60mins. The cells were 
then washed in 0.01% triton X/PBS solution twice again and the secondary donkey- 
anti rabbit biotinylated antibody was applied for 40mins (1:250 in 0.01% Triton- 
X/PBS). Following two more washes the streptavidin fluorescein antibody was added
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for 40mins at RT (1:100 in 0.01% Triton-X/PBS). The cells then had two final 
washes and were resuspended in PBS for the analysis on the FACS analyser.
2.14. Analysis and statistics
Quantitative data were obtained for all experiments in the form of cell counts, 
absorbance values for MTS, intensity values for DCF, semi-quantitative 
densitometry values expressed as percentage of control for Western blots and 
percentages of stained cells in 10,000 for FACS analysis. Densitometry values were 
expressed as percentage of control because this was considered the clearest way to 
illustrate this data due to variations in the control band density between experiments. 
Where relevant the mean of the replicates for each condition within experiments was 
then calculated. The overall mean and standard errors were then calculated by 
pooling the results of repeat experiments and histograms were produced.
Advice regarding appropriate statistical tests was obtained from Dr. Faria in 
the statistics department at The Open University. Normality of the data was 
established using plots of the data and variance within groups was tested using 
homogeneity of variance in the SPSS statistics package version 16 to check if the 
data met the criteria for parametric testing. For data that was considered to meet the 
criteria for parametric tests a one-way ANOVA was used in order to analyse the 
variance in the means between groups with a Bonferroni post-hoc test as this is a 
simple, commonly used post-hoc test which is flexible and therefore suitable for a 
range of data sets. Where the data did not meet the criteria for a parametric test the 
non-parametric Kruskal-Wallis test for difference between more than two groups was 
carried out and if this showed a significant difference the Mann-Whitney, non-
parametric test for comparisons between two groups was used as a post-hoc test. 
These tests were carried out using the SPSS statistics package version 16.
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Chapter 3
Characterisation of dissociated 
hippocampal cultures and trophic effects of
CLN
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3.1. Aims
The aim of these experiments was two-fold;
a) to establish the cell types present, with relative proportions, in the primary 
hippocampal cultures that were to be used as a model culture system and
b) to investigate whether bovine CLN alone has any adverse or trophic effect on 
these cells in culture.
In order to achieve these aims primary dissociated hippocampal cultures were 
set up from both P4 and E l8 Sprague Dawley rats and cultures were treated with 
bovine CLN at a range of concentrations for 24 hours.
Immunostaining was carried out using antibodies against the neuronal marker 
MAP-2 and the astrocytic marker GFAP as well as microglial (CD1 lb) and 
oligodendrocyte (CNPase) markers.
Analysis by EM was also carried out on dissociated cultures from P4 rat 
hippocampus.
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3.2. Introduction
3.2.1. Dissociated rat hippocampal culture as a model system
Dissociated hippocampal cultures were chosen as a model system for the 
investigation of the effects of CLN on cells in culture and analysis of the mechanism 
of action of CLN in its beneficial effects for AD patients. This culture system was 
chosen for several reasons.
Firstly, the limbic system and in particular the hippocampus have been shown 
to be areas that are among the first and most severely affected areas in the AD brain. 
Furthermore, as discussed in Chapter 1, Section 1.5.4, CLN has been demonstrated to 
improve the hippocampal dependent, spatial memory in aged rats (Popik et al. 1999) 
and associative learning in day old chicks (Stewart and Banks 2006) which is 
mediated by the chick brain area that is equivalent to the hippocampus. The 
hippocampus is therefore an area of great importance in protection against AD 
progression and in particular for the protective effects of CLN.
Secondly, dissociated rat hippocampal cultures have been extensively used as 
a model system for a wide variety of studies including the investigation of synaptic 
formation (Yamamoto et al. 2005) the toxicity of viruses (Brunner et al. 2007) and 
neurotrophic effects (Heaton et al. 1994; Okuda et al. 1994). In particular these 
cultures have been a major model used in vitro to analyse Ap induced toxicity 
(Whitson and Appel 1995; Puttfarcken et al. 1996; Paula-Lima et al. 2005). These 
cultures have also been used to study oxidative stress mediated toxicity (Zhang et al. 
2001) although organotypic hippocampal cultures have more frequently been used 
for these studies (Lezoualc'h et al. 1996; Masino et al. 1999; Avshalumov and Rice 
2002; Niiyama et al. 2005).
These dissociated cells have also been demonstrated to maintain properties of 
in vivo hippocampal cells when in vitro. Banker and Cowen (1979) showed that
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approximately 45% of hippocampal cells in culture closely resembled normal 
pyramidal cells and synapses in culture have been shown to be similar to those at a 
corresponding developmental time in vivo (Boyer et a l 1998). Increases observed in 
Ca2+ channels of cells in culture have been found to correspond to patterns seen in 
neurons in vivo (Porter et al. 1997). Furthermore, the developmental pattern of 
GABAa receptor expression has been found to be similar in vitro and in vivo 
(Brooks-Kayal et al. 1998).
Embryonic and postnatal rat hippocampi were chosen as the source of cells 
rather than those from adult rats because the cells from younger animals have been 
more commonly used and have been found to have improved survival rates in 
culture. Cells isolated from older animals have proven much more difficult to culture 
although there are methods that have been found to work for the culture of 
hippocampal cells from aged animals (Brewer 1997; Evans et al. 1998). In 
hippocampal cultures it has been demonstrated that these cells from older animals 
have similar properties to cells from embryonic rats although the embryonic cells 
fired more action potentials in response to a depolarising current (Evans et al. 1998).
3.2.2. The effects of CLN on cell survival in culture
As discussed in Chapter 1, Section 1.5.2, CLN has been found to have some 
regulatory effects on the immune system, affecting the activation and differentiation 
of cells in the immune system as well as stimulating neurite outgrowth in PC 12 cells 
(Bacsi et al. 2005) and regulating genes involved in cell proliferation (Szaniszlo et 
al. 2009). CLN may therefore be hypothesised to mediate a trophic effect on primary 
hippocampal cells in culture leading to neurite outgrowth and/or increased cell 
proliferation. These experiments were designed to investigate that hypothesis.
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This work focussed on both neurons and astrocytes. The main interest here 
was neuronal survival with reference to neurodegeneration in AD and astrocytes 
have been demonstrated to directly affect neuronal survival via trophic support and 
removal of toxins (Gasser and Hatten 1990; Ye and Sontheimer 1998 and reviewed 
in Markiewicz and Lukomska 2006). Furthermore a role for astrocytes has been 
established in the development of amyloid plaques and AD (Nagele et al. 2004; 
Farfara et al. 2008), as well as in affecting the severity of Ap-induced toxicity in 
vitro (Domenici et al. 2002; Abramov and Duchen 2005; Ramirez et al. 2005).
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3.3. Methods
3.3.1. Characterisation of cultures and the effect of CLN on cell numbers
Dissociated hippocampal cultures from El 8  and P4 rats were set up using the 
methods described in Chapter 2, Section 2.3. Cells were plated at 40,000 cells/well in 
1 2 -well plates.
Bovine CLN was prepared as described in Chapter 2, Section 2.5 and diluted 
in culture media to concentrations of CLN between lng/ml and lOOng/ml. Control 
cultures were treated with culture media alone. Cultures were treated on DIV3 with at 
least 3 replicate coverslips, per condition, per culture.
Twenty four hours after treatment, immunolabelling, cell counting and 
analysis were carried out as described in Chapter 2, Section 2.8.
3.3.2. Electron microscopy
Dissociated hippocampal cultures were set up as described in Chapter 2 
Section 2.3 and plated at 80,000 cells/well.
In order to allow a dense monolayer of cells to form with and allow for the 
maturation of synapses the cells were maintained in culture until DIV6. The cultures 
were then treated with culture medium alone or lOOng/ml bovine CLN diluted in 
culture medium. Twenty four hours after treatment, cultures were fixed and 
processed for EM as described in Chapter 2 Section 2.9.
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3.4. Results
3.4.1. Characterisation of primary hippocampal cultures
Immunolabelling was optimised on cultures at DIVA as detailed in Chapter 2, 
Section 2.8.2 and showed that cultures from El 8  hippocampus contained mainly 
MAP-2 positive neurons with small numbers of GFAP positive astrocytes (see Figure 
3-1A and C) but no CD1 lb  positive microglia were present. In cultures from El 8  
hippocampi there appeared to be some positive CNPase staining for 
oligodendrocytes, however, this was faint and from inspection of cell morphology 
and phase contrast images it was decided that this staining was not specific (see 
Figures 3-1E).
Cultures from P4 hippocampi consisted largely of MAP-2 positive neurons 
and GFAP positive astrocytes (see Figure 3-2 A and C). There appeared to also be 
small numbers of microglia. In cultures from P4 hippocampi there appeared to be 
some positive CNPase staining, however, this was again feint and it was decided that 
this staining was not specific (see Figures 3-2E).
In cultures from both P4 and El 8  rat hippocampus there were large numbers 
of MAP-2 positive neurons present along with strongly GFAP positive astrocytes 
(see Figures 3-3 and 3-4) and by DIVA the cultures were well established, neurons 
were rounded and had extended long, sometimes multiple, processes (see Figures 3- 
3 A and B). GFAP positive astrocytes were present in both flattened and stellate 
forms (as described in Gasser and Hatten, 1990. see Figures 3-4C). The proportion of 
GFAP positive astrocytes and MAP-2 positive neurons differed between cultures 
originating from El 8  hippocampus and those from P4 hippocampus (see Figures 3-3 
and 3-4). In cultures from P4 rat hippocampus the astrocytes appeared to cover the 
neurons and some cells were also observed which were of ‘astrocytic’ type 
morphology but which were not strongly GFAP positive (see Figure 3-4).
89
Immunolabelling
1 0 0  p m
A: MAP-2
1 0 0  p m
C: GFAP
1 0 0  p m
E: CNPase
Secondary only controls
B: MAP-2 secondary only
D: GFAP secondary only
1 0 0  p m
1 0 0  p m
1 0 0  p m
F: CNPase secondary only
Figure 3-1: Representative images of MAP-2 (A), GFAP (C) and CNPase (E) immunolabelling in 
cultures from E l8 rat hippocampus. Cultures were paraformaldehyde fixed at DIVA and processed for 
immunocytochemistry. Secondary only controls are also shown for anti-mouse AMCA conjugated 
(B), anti-rabbit FITC conjugated (D) and anti-mouse Rhodamine conjugated (F) secondary antibodies.
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Secondary only controlsImmunolabelling
B: MAP-2 secondary onlyA: MAP-2
D: GFAP secondary onlyC: GFAP
1 0 0  p m
1 0 0  p m
1 0 0  p m
1 0 0  p m 1 0 0  p m
E: CNPase F: CNPase secondary only
Figure 3-2: Representative images of MAP-2 (A), GFAP (C) and CNPase (E) immunolabelling in 
cultures from P4 rat hippocampus. Cultures were paraformaldehyde fixed at D IV4 and processed for 
immunocytochemistry. Secondary only controls are also shown for anti-mouse AMCA conjugated 
(B), anti-rabbit FITC conjugated (D) and anti-mouse Rhodamine conjugated (F) secondary antibodies.
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A: Phase contrast
100 |jm
B: MAP-2
100 pm
C: GFAP
Figure 3-3: Representative phase contrast (A) and the corresponding MAP-2 (B), GFAP (C) 
immunocytochemistry images of cultures from E18 (A-C) rat hippocampus that were seeded at 40,000 
cells/well and paraformaldehyde fixed at D IV4 to be processed for immunocytochemistry.
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P4
A: Phase contrast
100 (jm
B: MAP-2
100 |jm
C: GFAP
Figure 3-4: Representative phase contrast (A) and the corresponding MAP-2 (B), GFAP (C) 
immunocytochemistry images of cultures from P4 (A-C) rat hippocampus that were seeded at 40,000 
cells/well and paraformaldehyde fixed at DTV4 to be processed for immunocytochemistry.
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Quantification, carried out using a counting grid on 9mm of each coverslip, 
as described in Chapter 2, Section 2.8.6, showed that in cultures from El 8  rat 
hippocampus MAP-2 positive neurons outnumbered the GFAP positive astrocytes by 
approximately 4:1 (P < 0.001). The converse was true in cultures from P4 
hippocampus and approximately four times as many GFAP positive astrocytes as 
MAP-2 positive neurons were present in these cultures (P < 0.001) (see Figure 3-5). 
There was also a significant difference between the number of MAP-2 positive 
neurons at El 8  compared to P4 and the number of GFAP positive astrocytes at El 8  
compared to P4 (see Figure 3-5).
* P< 0.001
E18 P4
Figure 3-5: Quantification of the relative numbers of MAP-2 and GFAP positive cells in dissociated 
hippocampal cultures from E l8 and P4 rats. There was a significant difference between the number of 
MAP-2 positive neurons and GFAP positive astrocytes in cultures from both El 8 and P4 hippocampi 
(from one-way ANOVA P < 0.001). The number of MAP-2 positive neurons and GFAP astrocytes in 
cultures from El 8 hippocampi were also significantly different to the number of corresponding cells 
in cultures from P4 hippocampi (from one-way ANOVA P < 0.001). n=8 cultures with at least 3 
replicates per experiment. Error bars represent standard errors. * represents P < 0.001.
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3.4.2. The effect of CLN on hippocampal cells in culture
3.4.2.I. The effect of CLN on cell numbers in cultures from E18 
hippocampus
In cultures from El 8 hippocampi 24 hours of treatment with bovine CLN 
alone at concentrations ranging between lng/ml and lOOng/ml did not have any 
notable effect on the morphology of cells compared to control cultures and did not 
cause any notable changes in neurite extension (see Figure 3-6). Quantification 
showed that 24 hour treatment with CLN at these concentrations had no effect on the 
number of MAP-2 positive neurons (see Figure 3-7) or GFAP astrocytes (see Figure 
3-8).
E18
A: Control
C: lOng/ml CLN D: lOOng/ml CLN
Figure 3-6: Phase contrast images of cultures from E l8 hippocampi at D IV4 showing that CLN at 1 
(B), 10 (C) and lOOng/ml (D) had no effect on cell morphology and neurite outgrowth compared to 
controls (A).
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Control 1ng/mlCLN 10ng/mlCLN 100ng/mlCLN
Figure 3-7: Quantification of the numbers of MAP-2 positive neurons in dissociated hippocampal 
cultures from El 8 rats seeded at 40,000 cells/well and treated with CLN showing that there was no 
effect with CLN (P > 0.9 from one-way ANOVA). n>3 with at least three replicates per condition. 
Bars represent standard errors.
250 i
Te
5  200
Control Ing/mlCLN 10ng/mlCLN 100ng/mlCLN
Figure 3-8: Quantification of the numbers of GFAP positive astroytes in dissociated hippocampal 
cultures from El 8 rats seeded at 40,000 cells/well and treated with CLN showing that there was no 
effect with CLN. (P > 0.9 from one-way ANOVA). n>3 with at least three replicates per condition. 
Error bars represent standard errors.
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3.4.2.2. The effect of CLN on cell numbers in cultures from P4 
hippocampus
P4
B:lng/ml CLNA: Control
C: lOng/ml CLN D: lOOng/ml CLN
Figure 3-9: Phase contrast images of cultures from P4 hippocampi at D IV4 showing that CLN at 1 
(B), 10 (C) and lOOng/ml (D) had no effect on cell morphology and neurite outgrowth compared to 
controls (A).
In cultures from P4 hippocampi, CLN alone at concentrations ranging 
between lng/ml and lOOng/ml also did not have any effect on the morphology of 
cells compared to control cultures and no notable effect on neurite extension (see 
Figure 3-9). Quantification of cell numbers confirmed that CLN had no effect on the 
number of MAP-2 positive neurons (see Figure 3-10) or GFAP positive astrocytes 
(see Figure 3-11) compared to control cultures.
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Control 1ng/mlCLN 10ng/mlCLN 100ng/mlCLN
Figure 3-10: Quantification of the numbers of MAP-2 positive neurons in dissociated hippocampal 
cultures from P4 rats seeded at 40,000 cells/well and treated with CLN showing that there was no 
effect with CLN on the numbers of these cells present in cultures (P > 0.9 from one-way ANOVA). 
n>3 with at least three replicates per condition. Error bars represent standard errors.
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Figure 3-11: Quantification of the numbers of GFAP positive neurons in dissociated hippocampal 
cultures from P4 rats seeded at 40,000 cells/well and treated with CLN showing that there was no 
effect with CLN on the numbers of these cells present in cultures (p > 0.9 from one-way ANOVA). 
n>3 with at least three replicates per condition. Error bars represent standard errors.
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3.4.3. The effect of CLN on hippocampal cell ultrastructure
Investigation of the effects of bovine CLN at the ultrastractural level using 
EM showed no obvious qualitative changes in any cellular structures, mitochondria, 
nuclei or cell processes in the cultures with CLN treatment in these conditions, 
compared to untreated control cultures (see Figures 3-12). There were no necrotic or 
unusual structures present and none of the cells present appeared to be affected by 
the CLN treatment over 24 hours. Figure 3-12D shows what may be a synapse 
although this is not confirmed.
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Figure 3-12: EM micrographs of control (A-D) and lOOng/ml bovine CLN treated (E-H) 
hippocampal cultures from P4 hippocampus fixed at D/V7 showing the dendrites (D), axons (A), 
nuclei (N), nucleoli (Nu) and mitochondria (M).
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3.5. Discussion
In any investigation using a culture system as a model for study it is 
important to fully understand the system being used and the cell types that are 
present within the cultures in order to be able to completely comprehend the 
ramifications of any treatment on the cultures and to give the most informed analysis 
possible of results.
To this end the presence and proportion of neurons, astrocytes, microglia and 
oligodendroytes in untreated hippocampal cultures was first examined. These 
experiments showed that the model culture system is a mixed culture containing 
mainly neurons with astrocytes. The proportions of neurons to astrocytes differed 
between cultures from E l 8  hippocampus and those from P4 hippocampus. The 
greatly increased number of GFAP positive astrocytes relative to MAP-2 positive 
neurons in cultures from postnatal hippocampus compared to cultures from 
embryonic hippocampus was expected. This difference in numbers is due to higher 
numbers of mature astrocytes in postnatal rats (Gasser and Hatten 1990; Eng et al. 
2000) leading to much higher numbers of GFAP-expressing cells and higher levels 
of GFAP expression in these cultures and also to the natural death of some neurons 
during development (Sendtner et al. 2000). Inspection of some fields of cultures 
from embryonic rats under phase contrast and fluorescence confirmed that under 
phase contrast there were no cells of astrocytic morphology that did not stain 
positively for GFAP showing that the difference in cell numbers was not due to 
staining artefacts.
The proportions of cell types that were to be expected in these cultures was 
detailed in Chapter 1, Section 1.5.2.3. Although microglial proliferation has been 
observed in organotypic hippocampal cultures from early postnatal rats when the 
hippocampus has undergone traumatic injury (Laskowski et al. 2007) the lack of
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microglia in the cultures from E l8  hippocampus is in keeping with the observations 
of Xie et al. (2000) showing that in hippocampal cells from El 8  rats cultured in basal 
medium contain very few microglia. These authors also found very similar 
proportions of MAP-2 and GFAP positive cells to those observed in this study in 
cultures from E l 8  rats cultured in basal medium with B27 as they were here (Xie et 
a l  2 0 0 0 ).
In cultures from both El 8  and P4 hippocampus CLN ranging between lng/ml 
and lOOng/ml had no trophic effect. EM data indicated that there were no 
ultrastructural changes in cultures from P4 hippocampus treated with bovine CLN at 
lOOng/ml for 24 hours.
This work demonstrated that the hippocampal cultures as used in these 
experiments contain neurons and astrocytes and that the proportions of these cell 
types changes at different stages of development. Moreover it indicates that bovine 
CLN has no adverse effects on primary hippocampal cells in these conditions.
The higher proportion of neurons to glia and greater proportion of neurons in 
the cultures from E l8  rats seen in these initial experiments compared to those from 
P4 rats led to the decision to continue using cultures from El 8  hippocampus for the 
subsequent work.
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Chapter 4
The effects of bovine CLN on beta-amyloid 
and menadione-induced toxicity in cells in
culture
103
4.1. Aims
The aim of these experiments was to investigate the possible protective effect 
of bovine CLN against menadione-induced, oxidative stress-mediated, toxicity, and 
APi-42-induced toxicity on primary hippocampal cells, cultured as described in 
Chapter 3, and the B50 cell line in culture. The rationale for using B50 cells as a 
model system is that it is a rat neuronal cell line and therefore is a good cell line 
comparison to the primary rat hippocampal cells and it has previously been used for 
toxicity studies as discussed in Chapter 2, Section 2.4.
In order to observe any changes in the morphology or number of cells in 
these cultures in the presence of AP1-42 or menadione and bovine CLN, MAP-2 
positive neurons and GFAP positive astrocytes were studied. Dissociated 
hippocampal cultures were treated with Api-42, menadione and bovine CLN and 
double immunolabelled for MAP-2 and GFAP. The ability of bovine CLN to protect 
these cells against the toxicity of menadione and Api-42 was investigated.
An MTS assay was carried out to assess changes in cell survival in the B50 
cell line upon treatment with menadione and bovine CLN.
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4.2. Introduction
4.2.1. Models of oxidative stress in vitro
H2O2 treatment has commonly been used as a method of inducing oxidative 
stress in vitro. Treatment with H2O2 leads directly to increased ROS production and 
oxidative stress-induced damage in many cell types in culture, including rat neuronal 
cell lines (Iwata et al. 1998; Miyazaki et al. 1999) and rat hippocampal slice cultures 
(Avshalumov and Rice 2002). Moreover, H2O2 has been extensively used on primary 
hippocampal neurons in culture as a model of cell death in response to oxidative 
stress (Zhang et al. 2001; Avshalumov and Rice 2002). However, H2O2 can be quite 
unstable over time and is sensitive to exposure to light leading to reduction in its 
activity.
A regularly used alternative method for creating a model of oxidative stress 
in cell culture is to treat cells with the compound menadione. Menadione is a semi- 
quinone (see Figure 4-1) and leads to the production of ROS including H2O2 and 
superoxide as it is reduced from the semi-quinone to the quinone. Menadione may 
then be re-oxidised and in this manner a redox cycle can be continued leading to the 
accumulation of ROS which can cause significant cellular damage and cell death.
O
O
Figure 4-1: The structure of menadione (from www.sigmaaldrich.com).
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4.2.2. CLN and protection against oxidative stress-induced toxicity
As described in detail in Chapter 1, Section 1.5.3 the antioxidant effects of 
CLN have been extensively studied and there has been evidence for such anti­
oxidant effects in several cell types (Boldogh et al. 2003; Bacsi et al. 2005; Bacsi et 
al. 2006; Bacsi et al. 2007). However, no research has yet been done to analyse the 
effects of CLN on the survival of cells in culture subjected to oxidative stress- 
induced toxicity.
The first part of this work therefore aimed to assess the protective effects of 
CLN against oxidative stress using menadione-induced neurotoxicity in primary 
hippocampal cultures and the B50 cell line. Menadione was chosen as the oxidative 
stress inducer in these experiments because it has been widely used in a variety of 
cell types such as hepatocytes (Thor et al. 1982) and myenteric plexus neurons 
(Thrasivoulou et al. 2006) and is not as sensitive to temperature and time as H2O2 . 
Moreover, it has previously been found by Adamec et al. (2000) that treatment with 
lOpM menadione for 24 hours will lead to significant levels of cell death in primary 
hippocampal cultures.
4.2.3. Beta-amyloid-induced toxicity in hippocampal cells in culture
As discussed in Chapter 1, Section 1.1.2 the current leading theory of AD 
pathology is the amyloid hypothesis. Prevention of Ap-induced toxicity is therefore 
seen as the key to preventing AD progression.
The hippocampus is known to be highly vulnerable to AD-induced cell death 
and this damage is a major cause of the disease symptoms of memory loss and 
cognitive decline (Rodriguez et al. 2008). Therefore the effects of Ap on 
hippocampal cells in culture have been extensively studied (Pike et al. 1991; Liu et 
al. 2001; Kelly and Ferreira 2007; Resende et al. 2007). The importance of the
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aggregation state of A(3 on the toxicity has been discussed in Chapter 1, Section
1.1.2. Several authors have demonstrated the aggregation-dependent toxicity of 
APi-40 (Harris et al. 1995; Liu et al. 2005; Resende et al. 2007), Api-42 (Pike et al. 
1991; Lorenzo and Yankner 1994; Puttfarcken et al. 1996; Zou et al. 2003; Liu et al. 
2005) and AP25-35 (Forloni et al. 1993; Takadera et al. 1993; Resende et al. 2007) on 
hippocampal cultures from embryonic rats.
As well as the aggregation state and form of Ap used, the age of the culture 
when treated may also be important to the level of toxicity achieved. Ap 1-42 has been 
found to be toxic when hippocampal cells were treated on DIV1 for 48 hours but it 
has been shown that Api-40 has a higher level of toxicity on hippocampal cells that 
have been in culture for 3 days or more than on 1 or 2 day old cultures (Whitson and 
Appel 1995). Furthermore, Yankner et al. (1990) showed that A p^o may even be 
neurotrophic to new hippocampal cultures and only become toxic on mature cultures 
of DIV3 or more.
4.2.4. CLN and protection against beta-amyloid induced toxicity
CLN has been demonstrated to be beneficial to AD patients and halt disease 
progression but there has been very little work to directly analyse the effects of CLN 
on Ap-induced cell death in cultured cells. The focus has been on the effects of CLN 
in patients (Leszek et al. 1999; Leszek et al. 2002), on spatial memory in rats (Popik 
et al. 1999; Popik 2001; Popik et al. 2001) and on the prevention of oxidative stress 
induction (Boldogh et al. 2003; Bacsi et al. 2006; Bacsi et al. 2007). There has only 
been one study investigating the effects of CLN on cell survival after Ap-induced 
toxicity. Schuster et al (2005) showed that pre-incubation and co-administration of
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CLN, at low concentrations, with Ap^o could protect SH-SY5Y human 
neuroblastoma cells against AP1-40 induced toxicity.
The second part of this work replicated the study by Shuster et a l (2005), that 
was described above using primary hippocampal cells in order to investigate whether 
the protective effect of CLN seen in the cell line also occurs in primary hippocampal 
cells in culture. Api-42 was used instead of Api-40 for two reasons; firstly because of 
the reported increased toxicity of AP1-42 and secondly because AP1-42 can be 
dissolved in distilled water and PBS whereas AP1-40 has to be dissolved in acid 
(Biosource product data sheets for 03-136 and 03-112) which may interfere with 
other effects on the cultures.
In addition to the effects of astrocytes on neuronal survival as discussed in 
Chapter 3, Section 3.2.2 astrocytic plaques have been found to be involved in the 
development of the toxicity in AD (Nagele et al. 2004). It is entirely feasible that that 
any effects of CLN on neurons may be due to changes in the astrocytes within the 
cultures. It was therefore also considered of great importance as part of these 
experiments to look at the effects of AP1-42, bovine CLN and menadione on GFAP 
positive astrocytes as well as effects on neurotoxicity.
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4.3. Methods
4.3.1. Immunocytochemistry
4.3.1.1. Preparation of cell cultures
The method for the culture of dissociated hippocampal cells was as described 
in Chapter 2; Section 2.3. For immunocytochemistry the cells were plated in 12 well 
plates with at least three replicates per condition at 80,000 cells/well to allow cell­
cell interactions or 20,000 cells/well to allow clearer visualisation of any changes in 
neurite extension.
4.3.1.2. Menadione treatment
Bovine CLN and menadione were prepared as described in Chapter 2,
Section 2.5 and 2.6 respectively. On DIV3 cultures were treated with lOpM 
menadione alone in 0.01% ethanol, lOOng/ml or lpg/ml bovine CLN alone or 
menadione with bovine CLN for 24 hours. Control cultures were treated with 0.01% 
ethanol in the culture media and bovine CLN was diluted in 0.01% ethanol in culture 
media to ensure that any changes observed were not due to the presence or absence 
of ethanol used to dissolve the menadione.
4.3.1.3. Beta-amyloid treatment
Bovine CLN was prepared as described in Chapter 2, Section 2.5 and Api-42 
was prepared as described in Chapter 2, Section 2.7. On DIV3 cultures were treated 
with 25pM AP1-42 alone, 5pg/ml bovine CLN alone or Ap^ 2  with bovine CLN for 
48 hours. Control cultures were treated with an equal amount of PBS to that in which 
the AP1-42 is diluted and bovine CLN given alone was diluted in PBS. 25 pM Api-42
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was chosen for this experiment because this is a concentration that has previously 
been shown to cause toxicity in these cells (Woods et al. 1995) and the work carried 
out by Schuster et al (2005) used 25 pM ApMo.
4.3.I.4. Immunocytochemistry and quantification
Cells were fixed at DIV5 in 4% paraformaldehyde and immunocytochemistry 
for GFAP and MAP-2 was carried out as described in Chapter 2, Section 2.8. 
Positively stained cells were then counted as described in Chapter 2, Section 2.8.6.
4.3.2. MTS cytotoxicity assay in the B50 cell line
B50 cells were plated as described in Chapter 2, Section 2.10. Cells were 
treated on DIV1 with lOng/ml, 500ng/ml, 2pg/ml or lOpg/ml bovine CLN 24 hours 
prior to the addition of 10 or 20 pM menadione or at the time of menadione treatment 
for a further 24 hours. Control cultures and CLN treated cultures were treated with 
0 .0 1  or 0 .0 2 % ethanol to ensure that any changes observed were not due to the 
ethanol used to dissolve the menadione. The MTS assay was then carried out as 
detailed in Chapter 2, Section 2.10.
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4.4. Results
4.4.1. The effect of CLN against menadione-induced toxicity
4.4.1.1. The effect of menadione and CLN on cell morphology and numbers in 
primary hippocampal cultures
For this experiment cultures were plated at a higher density (80,000 
cells/well) than the cultures described in Chapter 3 to allow for more cell-cell 
interaction because this interaction may affect cell survival.
Bovine CLN alone at lOOng/ml had no marked effect on the morphology of 
MAP-2 positive neurons in primary hippocampal cultures at a density of 80,000 
cells/well (see Figure 4-3 A and B).
lOpM menadione alone caused a reduction in the number of MAP-2 positive 
neurons compared to control cultures (see Figure 4-3A and C) and quantification 
showed this to be a significant reduction of 52±12% (P < 0.001 see Figure 4-5). 
Administration of lOOng/ml bovine CLN with lOpM menadione caused a small 
increase in the number of MAP-2 positive neurons compared to menadione treatment 
alone (see Figure 4-3C and D) which upon quantification was found to be non­
significant (P = 0.274 see Figure 4-5).
However, neither lOOng/ml CLN nor lOpM menadione given independently 
or together caused a visible change in the number of GFAP positive astrocytes 
present in the cultures (see Figure 4-4) and this was confirmed by quantification data 
(see Figure 4-6). Menadione treatment therefore caused a 50% decrease in the 
neuron/astrocyte ratio but bovine CLN alone at lOOng/ml did not affect the 
neuron/astrocyte ratio.
I l l
Phase contrast: cultures at 80,000 cells/well
AiControl B:100ng/ml CLN
C:10fiM Menadione D: lOfiM Menadione and lOOng/ml CLN
Figure 4-2: Phase contrast images of 80,000 cells/well cultures from E18 hippocampi treated with 
0.01% alcohol in culture media (control. A), lOOng/ml CLN (B), lOpM menadione (C) or CLN with 
menadione (D) for 24 hours. Control cultures (A) contained rounded cells with processes along with 
some flat cells. CLN treatment (B) did not appear to affect the total cell number compared to controls. 
However, menadione treatment (C) led to a reduction in the total number of cells present in the culture 
compared to control.
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MAP-2 positive neurons: cultures at 80,000 cells/well
AiControl B:100ng/ml CLN
100 pi
100 mi 100 Mm
100 Mm
C:10^iM Menadione D: 10[iM Menadione and lOOng/ml CLN
Figure 4-3: Images of MAP-2 immunolabelling on 80,000 cells/well cultures from El 8 hippocampi 
treated with 0.01% alcohol in culture media (control. A), lOOng/ml CLN (B), lOpM menadione (C) or 
CLN with menadione (D) for 24 hours. Control cultures (A) had rounded MAP-2 positive neurons 
with processes. The morphology of MAP-2 positive neurons in cultures treated with lOOg/ml CLN (B) 
did not differ from control cultures. However, treatment with menadione (C) led to a change in 
morphology and a reduction in the number of MAP-2 positive neurons compared to control cultures. 
This effect was only slightly reversed when CLN was given along with menadione (D).
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GFAP positive astrocytes: cultures at 80,000 cells/well
( S> ---------
100 (jm
A:Control B:100ng/ml CLN
100 pm
C:10(iM Menadione D: 10|aM Menadione and lOOng/ml CLN
Figure 4-4: Images of GFAP immunolabelling on 80,000 cells/well cultures from El 8 hippocampi 
treated with 0.01% alcohol in culture media (control. A), lOOng/ml CLN (B), 10pM menadione (C) or 
CLN with menadione (D) for 24 hours. Control cultures (A) contained reasonably small numbers of 
GFAP positive astrocytes. The number and morphology of GFAP positive astrocytes was not affected by 
CLN treatment (B) and these cells were relatively unaffected by menadione treatment (C) compared to 
MAP-2 positive neurons (Figure 4-3C).
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*  P <  0.001
Control 100ng/ml CLN 10pM men 10|jM m en + 100ng/ml
CLN
Figure 4-5: Quantification of the number of MAP-2 positive neurons present in primary El 8 rat 
hippocampal cultures at 80,000 cells/well under treatment conditions with lOOng/ml CLN, lOpM 
menadione or both together. This shows that CLN had no effect on the number of MAP-2 positive 
cells present in the cultures but menadione treatment caused a 52±12% reduction in the number of 
MAP-2 positive cells present (from one-way ANOVA P < 0.001). n=3 with at least 3 replicates per 
condition per experiment. Bars represent standard errors. * represents P < 0.001.
Control lOOng/mlCLN 10pM m en 10pM m en +100ng/m l
CLN
Figure 4-6: Quantification of the number of GFAP positive astrocytes present in primary El 8 rat 
hippocampal cultures at 80,000 cells/well under treatment conditions with lOOng/ml CLN, lOpM 
menadione or both together. None of the treatment conditions had any notable effect on the number of 
GFAP positive astrocytes present in the cultures. n=3 with at least 3 replicates per condition per 
experiment. Bars represent standard errors.
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For subsequent experiments cultures were set up at 20,000 cells/well rather 
than 80,000 cells/well in order to allow better visualisation of any changes in neurite 
extension and length.
lOOng/ml bovine CLN had no visible effect on the morphology of MAP-2 
positive or GFAP positive cells in these lower density cultures compared to controls 
(see Figures 4-8 and 4-9) but caused an increase in MAP-2 positive neurons which 
upon quantification was found not to be significant (P = 0.207. see Figure 4-10). 
Closer inspection showed that this increase in the number of MAP-2 positive neurons 
did not appear to be accompanied by an increase in neurite extension (see Figure 4- 
12).
The toxic effect of menadione was more pronounced in these lower density 
cultures and lOpM menadione caused a large reduction in the number of MAP-2 
positive neurons compared to control cultures (see Figure 4-8A and C) with a small 
decrease in GFAP positive astrocyte numbers (see Figure 4-9A and C).
Quantification showed that the menadione-induced reduction in the number of MAP- 
2 positive neurons was 90±22% compared to controls and that lOOng/ml bovine CLN 
given with menadione led to a doubling of the number of MAP-2 positive neurons 
compared to menadione treatment alone, however this did not quite reach 
significance (P = 0.073 see Figures 4-10). The small menadione-induced decrease in 
the number of GFAP positive astrocytes was not significant (P = 0.329. see Figure 4- 
11).
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Phase contrast: cultures at 20,000 cells/well
ArControl B:100ng/ml CLN
i
C:10ftM Menadione D: lOfiM Menadione and lOOng/ml CLN
Figure 4-7: Phase contrast images of 20,000 cells/well cultures from E18 hippocampi treated with 
0.01% alcohol in culture media (control. A), 100ng/ml CLN (B), lOpM menadione (C) or CLN with 
menadione (D) for 24 hours. Control cultures (A) contained rounded cells with processes along with 
some flat cells. CLN treatment (B) did not appear to affect the total cell number compared to controls. 
However, menadione treatment (C) led to a reduction in the total number of cells present in the culture 
compared to control.
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MAP-2 positive neurons: cultures at 20,000 cells/well
A: Control B:100ng/ml CLN
100 (jn
100 pi 100 pm
100 Mm
C:10|xM Menadione D: lOpM Menadione and lOOng/ml CLN
Figure 4-8: Images of MAP-2 immunolabelling on 20,000 cells/well cultures from El 8 hippocampi 
treated with 0.01% alcohol in culture media (control. A), lOOng/ml CLN (B), lOpM menadione (C) or 
CLN with menadione (D) for 24 hours. Control cultures (A) had rounded MAP-2 positive neurons 
with processes. The morphology of MAP-2 positive neurons in cultures treated with lOOg/ml CLN (B) 
did not differ from control cultures. However, treatment with menadione (C) led to a change in 
morphology and a reduction in the number of MAP-2 positive neurons compared to control cultures. 
This effect was only slightly reversed when CLN was given along with menadione (D).
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GFAP positive astrocytes: cultures at 20,000 cells/well
100 |jm
A: Control B:100ng/ml CLN
C:10pM Menadione D: 10(iM Menadione and lOOng/ml CLN
Figure 4-9: Images of GFAP immunolabelling on 20,000 cells/well cultures from El 8 hippocampi 
treated with 0.01% alcohol in culture media (control. A), lOOng/ml CLN (B), lOpM menadione (C) or 
CLN with menadione (D) for 24 hours. Control cultures (A) contained reasonably small numbers of 
GFAP positive astrocytes. The number and morphology of GFAP positive astrocytes was not affected 
by CLN treatment (B) and these cells were only slightly affected by menadione treatment (C) 
compared to control cultures.
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*  P <  0.001
Control 10Ong/ml CLN 10|jM m en 10jjM m en + 1 0Ong/ml
CLN
Figure 4-10: Quantification of the number of MAP-2 positive cells present in primary El 8 rat 
hippocampal cultures at 20,000 cells/well under treatment conditions with lOOng/ml CLN, 10pM 
menadione or both together. 1 OOng/ml CLN alone had a small trophic effect on the MAP-2 positive 
neurons in these cultures. Menadione treatment caused 90±22% reduction in the number of MAP-2 
positive neurons present in the cultures (from one-way ANOVA P < 0.001). a n=3 with at least 3 
replicates per condition per experiment. Errors bars represent standard errors. * represents P < 0.001.
25 -
©>
20 -
Control 100ng/ml CLN 10pM men 10|j M m en + 1 0Ong/ml
CLN
Figure 4-11: Quantification of the number of GFAP positive cells present in primary El 8 rat 
hippocampal cultures at 20,000 cells/well under treatment conditions with 1 OOng/ml CLN, 10pM 
menadione or both together. 1 OOng/ml CLN alone had no effect on the number of GFAP positive 
astrocytes in these cultures. In cultures treated with CLN and menadione the number of GFAP 
positive astrocytes was slightly reduced compared to control cultures and menadione treated cultures. 
n=3 with at least 3 replicates per condition per experiment. Errors bars represent standard errors.
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IS
A: Control B: 1 OOng/ml CLN
Figure 4-12: Phase contrast images of control (A) cultures and cultures treated with 1 OOng/ml CLN 
(B) from E l8 hippocampi, plated at 20,000 cells/well and fixed at D IV 4. This shows that CLN had no 
notable effect on neuritres.
Higher concentrations of CLN (lpg/ml) alone also showed no effect on the 
morphology of MAP-2 or GFAP positive cells compared to control cultures (see 
Figures 4-8A, 4-9A, 4-14A and 4-15A). Quantification confirmed that treatment with 
lpg/ml CLN did not affect the number of MAP-2 positive neurons (see Figure 4-16) 
or GFAP positive astrocytes (see Figure 4-17).
This higher concentration of bovine CLN offered a small effect on the 
menadione-induced reduction in MAP-2 positive neurons but this was not 
significant. Menadione casued a 60±30% decrease in MAP-2 positive neurons and 
the increase in MAP-2 positive neuron numbers when 1 pg/ml CLN was given with 
menadione compared to menadione treatment alone was not significant (P =
0.517.see Figures 4-16).
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Phase contrast: cultures at 20,000 cells/well
A: 1 [ig/ml CLN B:10fiM Menadione and 1 p,g/ml CLN
Figure 4-13: Phase contrast images 20,000 cells/well cultures from E l8 hippocampi treated with 
l^ig/ml CLN (A) or lOpM menadione with lp.g/ml CLN (B) for 24 hours. The total number of cells 
present in the culture was not different compared to control (Figure 4-7A) in cultures treated with 
lpg/ml CLN (A).
MAP-2 positive neurons: cultures at 20,000 cells/well
%
10 0  |jn 1 0 0  |jm
A: lp,g/ml CLN B: 10[xM Menadione and l(tg/ml CLN
Figure 4-14: MAP-2 immunolabelling images of 20,000 cells/well cultures from E l8 hippocampi 
treated with lp,g/ml CLN (A) or lOpM menadione with lpg/ml CLN (B) for 24 hours. TTie 
morphology and number of MAP-2 positive neurons in cultures treated with 1 [Ag/ml CLN (A) did not 
differ from control cultures (Figure 4-8A). The menadione-induced reduction in the number of MAP-2 
positive cells (Figure 4-8C) was only slightly affected when 1 pg/ml CLN was given with menadione 
(B).
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GFAP positive astrocytes: cultures at 20,000 cells/well
1 0 0 |j r r l  100 pm
A: l|j,g/ml CLN B: IOjiM Menadione
and lpg/ml CLN
Figure 4-15: GFAP immunolabelling images o f20,000 cells/well cultures from E l8 hippocampi 
treated with lpg/ml CLN (A) or lOpM menadione with lpg/ml CLN (B) for 24 hours. Treatment with 
lpg/ml CLN (A) had no effect on GFAP positive astrocytes. Upon treatment with lOpM menadione 
and lpg/ml CLN (B) GFAP positive astrocytes were unaffected compared to control cultures (Figure 
4-9A) and slightly increased compared to menadione treated cultures (Figure 4-9C).
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*  P= 0.001
Control 1|jg/mlCLN 10|jM m en 10|jM m en + 1pg/ml
CLN
Figure 4-16: Quantification of the number of MAP-2 positive cells present in primary El 8 rat 
hippocampal cultures at 20,000 cells/well treated with lpg/ml CLN, 10pM menadione or both 
together. CLN alone had a no effect on the number of MAP-2 positive neurons in these cultures. 
Menadione treatment caused a 90±22% reduction in the number of MAP-2 positive neurons present in 
the cultures (from one-way ANOVA P = 0.001) and CLN partially protected against this reduction 
(from one-way ANOVA P = 0.517). n=3 with at least 3 replicates per condition per experiment. Errors 
bars represent standard errors. * represents P < 0.01.
Control 1pg/ml CLN 10pM men 10pM m en + ipg/m l
CLN
Figure 4-17: Quantification of the number of GFAP positive cells present in primary El 8 rat 
hippocampal cultures at 20,000 cells/well treated with 1 pg/ml CLN, lOpM menadione or both 
together. Neither lpg/ml CLN nor lOpM menadione had any notable effect on the number of GFAP 
positive astrocytes present in these cultures. n=3 with at least 3 replicates per condition per 
experiment. Errors bars represent standard errors.
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4.4.1.2. The effect of CLN on menadione-induced cytotoxicity in the B50 cell 
line
In order to assess the effects of bovine CLN alone and against menadione- 
induced toxicity in the B50 cell line an MTS cytotoxicity assay was carried using 
five different concentrations of CLN ranging between lOng/ml and lOpg/ml. These 
CLN treatments were given alone or with menadione at 10 or 20pM.
The results showed that bovine CLN at concentrations ranging between 
lOng/ml and lOpg/ml has no trophic effect in terms of cell number on B50 cells in 
culture (see Figures 4-18 to 4-22).
Menadione for 24 hours consistently induced toxicity, by 50-60% upon 
treatment with lOpM menadione and 71-75% upon treatment with 20 pM menadione 
when compared to controls. Bovine CLN did not prevent this menadione-induced 
cell loss at any of the concentrations of CLN used whether given prior to or along 
with menadione treatment (see Figures 4-18 to 4-22) although CLN at lOng/ml had a 
very small effect against toxicity induced by 20pM menadione treatment (see Figure 
4-18).
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Figure 4-18: MTS assay absorbance values at 490nm on B50 cells treated with menadione and 
lOng/ml bovine CLN. This shows that 10 or 20pM menadione caused a reduction in absorbance at 
490nm compared to control and CLN treated cultures (from one-way ANOVA P < 0.001). lOng/ml 
CLN did not protect against menadione-induced cytotoxicity despite a very small improvement when 
CLN was given with menadione compared to 20pM menadione alone (from one-way ANOVA P > 
0.9). * is represents P < 0.001.
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Figure 4-19: MTS assay absorbance values at 490nm on B50 cells treated with menadione and 
lOOng/ml bovine CLN. This shows that lOpM menadione caused a reduction in absorbance at 490nm 
compared to control and CLN treated cultures (from one-way ANOVA P < 0.001). lOOng/ml CLN did 
not protect against menadione-induced cytotoxicity (from one-way ANOVA P > 0.9). * represents P < 
0 .0 0 1 .
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Figure 4-20: MTS assay absorbance values at 490nm on B50 cells treated with menadione and 
500ng/ml bovine CLN. This shows that lOpM menadione caused a reduction in absorbance at 490nm 
compared to control and CLN treated cultures (from one-way ANOVA P < 0.001). lOOng/ml CLN did 
not protect against menadione-induced cytotoxicity (from one-way ANOVA P > 0.9). * represents P < 
0.001.
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Figure 4-21: MTS assay absorbance values at 490nm on B50 cells treated with menadione and 
2|ig/ml bovine CLN. This shows that 10 and 20pM menadione caused a reduction in absorbance at 
490nm compared to control and CLN treated cultures (from one-way ANOVA P < 0.001). 2pg/ml 
CLN did not protect against menadione-induced cytotoxicity (from one-way ANOVA P > 0.9). * 
represents P < 0.001.
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Figure 4-22: MTS assay absorbance values at 490nm on B50 cells treated with menadione and 
lOpg/ml bovine CLN. This shows that 10 and 20pM menadione caused a reduction in absorbance at 
490nm compared to control and CLN treated cultures (from one-way ANOVA P < 0.001). 10jig/ml 
CLN did not protect against menadione-induced cytotoxicity (from one-way ANOVA P > 0.9). * 
represents P < 0.001.
4.4.2. The effect of CLN against beta-amyloid-induced toxicity
4.4.2.I. Changes in neuronal morphology upon treatment with bovine 
CLN and/or beta-amyloidi-42
On visual inspection of the cultures, 48 hour 25 pM AP1-42 treatment had a 
marked effect on the morphology of the MAP-2 positive neurons that were present 
(see Figure 4-24A and C). Neurons in control cultures treated with PBS and in 
cultures treated with 5pg/ml bovine CLN for 48 hours had rounded morphology and 
extended several processes (see Figure 4-24A and B). However neurons in cultures 
treated with Api-42 lacked processes and appeared shrunken (see Figures 4-23C and 
4-24C). These changes in morphology were still present when 5pg/ml bovine CLN 
was pre-incubated and co-administered with Api-42 (see Figure 4-24D).
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The morphology of GFAP positive astrocytes was not altered upon treatment 
with A(31 -4 2  compared to controls (see Figure 4-25A and C). APi. 4 2  caused a 
reduction in the total number of cells present in cultures compared to controls (see 
Figure 4-23A and C).
Phase contrast: cultures at 20,000 cells/well
A: Control
h k  & mm w  * m m  g
C: 25pM AP D: 25pM Ap and 5pg/ml CLN
Figure 4-23: Phase contrast images of 20,000 cells/well cultures from E18 hippocampi treated with 
PBS (A), 5pg/ml CLN (B), 25pM ApM2 (C) or 5pg/ml CLN and 25pM Afr_42 (D) for 48 hours. 
Control cultures had rounded cells with processes as well as a few flat cells (A). Treament with 
5pg/ml CLN (B) didn’t affect the total number of cells present in the cultures compared to controls. 
However, treatment with AJ3i_42 (C) caused a reduction in the total number of cells present in the 
culture compared to control (A). Pre-incubation and co-administration of CLN with ApW2 only had a 
small effect against the APi^-induced reduction in the number of cells (D).
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MAP-2 positive neurons: cultures at 20,000 cells/well
A'.Control
100 |jm  I  100 pm
C: 25|xM A(B D: 25\aU A0 and 5ng/ml CLN
Figure 4-24: MAP-2 immunolabelling images of 20,000 cells/well cultures from E l8 hippocampi 
treated with PBS (A), 5fig/ml CLN (B), 25pM ApM2 (C) or 5pg/ml CLN and 25(xM APm2 (D) for 48 
hours. The morphology and number of MAP-2 positive neurons in cultures treated with 5pg/ml CLN 
(B) did not differ from control cultures. However, treatment with A p^2 (C) led to a change in 
morphology compared to controls (A). Pre-incubation and co-administration of CLN with APi_42 only 
had little effect against the ApM2-induced change in cell morphology (D).
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GFAP positive astrocytes: cultures at 20,000 cells/well
A:Control B: 5pg/ml CLN
C: 25 pM A|3 D: 25 pM AP and 5pg/ml CLN
Figure 4-25: GFAP immunolabelling images o f20,000 cells/well cultures from E l8 hippocampi 
treated with PBS (A), 5pg/ml CLN (B), 25 pM ApM2 (C) or 5pg/ml CLN and 25 pM ApM2 (D) for 48 
hours. The morphology GFAP positive astrocytes in cultures treated with 5pg/ml CLN (B) or 5pg/ml
CLN and 25 pM ApW2 (C) did not differ from control cultures.
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4.4.2.2. Changes in cell survival in culture upon treatment with beta- 
amyloid with or without CLN
Quantification revealed a significant level of cell loss upon treatment of 
dissociated hippocampal cultures with Ap 1-42- Treatment with 5pg/ml CLN alone 
had no significant effect on the number of MAP-2 cells present in the cultures but 
treatment with 25pM AP1-42 for 48 hours resulted in a significant 44 ±13% (SE)
(P = 0.003) reduction of MAP-2 positive cells compared to control cultures (see 
Figure 4-26). A small non-significant increase in MAP-2 positive cells when CLN at 
5pg/ml was pre-incubated and administered along with APi_42 compared to Api-42 
alone was also observed (see Figure 4-26).
* P=0.003
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Figure 4-26: Quantification of the number of MAP-2 positive neurons in dissociated hippocampal 
cultures at 20,000 cells/well treated with Ap M2 and CLN. The number of MAP-2 positive cells was 
relatively unchanged after 48 hours treatment with 5pg/ml CLN alone compared to PBS treated 
controls (from one-way ANOVA P= 0.804). However the number of neurons decreased when cultures 
were treated with 25 pM AP M2 alone (from one-way ANOVA P = 0.03). n=4 with at least 3 replicates 
per condition in each experiment. Error bars represent standard errors. * indicates P= 0.003.
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Treatment of cultures with 25 pM Ap 1-42 for 48 hours also led to a reduction
in the number of GFAP positive cells present in the cultures (see Figure 4-27). This
decrease in the number of GFAP positive cells was less when CLN at 5pg/ml was
given along with 25 pM ApM2 compared to 25 pM Ap 1-42 alone (see Figure 4-27).
60 1
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Control 5|jg/ml CLN 25jjM Ap1-42 25pM Ap1-42 + 5pg/ml
CLN
Figure 4-27: Quantification of the number of GFAP positive astrocytes in dissociated hippocampal 
cultures at 20,000 cells/well treated with ApM2 and CLN. The number of GFAP positive cells was 
relatively unchanged after 48 hours treatment with 5pg/ml CLN alone compared to PBS treated 
controls. However the number of astrocytes decreased when cultures are treated with 25 pM Ap M2 
alone (from one-way ANOVA P = 0.088) and CLN gave only a minimal protective effect against this 
ApM2 induced toxicity. n=4 with at least 3 replicates per condition in each experiment. Error bars 
represent standard errors.
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4.5. Discussion
4.5.1. The effect of CLN against menadione-induced toxicity in primary 
hippcoampal cells
The first experiments described in this chapter were designed to study the 
effect of the oxidative stress inducer, menadione, on primary hippocampal cells and 
the B50 cell line in culture. This oxidative stress-mediated model of cell death 
allowed investigation into the potential of bovine CLN to alleviate oxidative stress- 
induced cell death.
The results showed that, in low density cultures treated with lOOng/ml bovine 
CLN alone there was a 27±13% increase in MAP-2 positive neurons in these cultures 
compared to controls. This small effect may be due to CLN causing the release of 
trophic factors into the culture media. This hypothesis receives support from 
previous work showing that CLN can upregulate the expression of the platelet 
derived growth factor (PDGF) in TR146 mucosal cells (Szaniszlo et al. 2009). 
However, in the work described here, 1 pg/ml CLN had no trophic effect on cell 
numbers and from the results presented in this Chapter, Section 4.1.1.1 and in 
Chapter 3, CLN at lOOng/ml did not have any effect on cell morphology or numbers 
in cultures from El 8 hippocampi plated at higher densities. The specificity of the 
conditions needed in order to see the small effect on cell numbers might be due to 
lOOng/ml being an optimal concentration of CLN for causing a trophic effect and 
improved background cell survival in higher density cultures compared to those 
seeded at low density because of cell-cell interaction. Improved background cell 
survival would make a trophic effect less apparent. Alternatively the effect may be 
due to the release of a trophic factor and this may then be less concentrated on the 
individual cells in higher density cultures compared to low density cultures.
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As expected from previous results, menadione at lOpM caused a significant 
reduction in the number of MAP-2 positive neurons present in primary hippocampal 
cultures. This cell loss was particularly severe in the lower density, (20,000 
cells/well), cultures. The cell loss is likely to be mainly due to cell death by necrosis 
as it has also been found by Adamec et al. (2000) that a lOpM concentration of 
menadione, which is considered a high dose, cell death is largely necrotic rather than 
apoptotic (these forms of cell death and their differences were discussed in detail in 
Chapter 1, Section 1.3.1 and 1.3.2) which is the case with lower doses of menadione 
(lpM ) (Adamec et al. 2000). However, it has also been found in previous studies 
that over shorter time periods of up to 60 minutes much higher doses of menadione, 
in the range of 40-100pM, have led to the increased expression of the apoptotic 
marker annexinV (Chiou et al. 2003). This implies that some apoptosis is likely to be 
occurring at the mid-range concentration (lOpM) of menadione used in these 
experiments. lOpM menadione was used for the cell death model described in this 
Chapter because it has been found to cause more marked cell death in a shorter time 
period than lower concentrations of menadione (Adamec et al. 2000).
Although there was a small reduction in the number of GFAP positive 
astrocytes in low density cultures in response to menadione treatment, this was not as 
marked as the reduction in MAP-2 positive neurons that was observed and only led 
to a small, non-significant reduction in the number of GFAP positive astrocytes 
present in these cultures. This result implies that the toxicity of menadione is neuron- 
specific. Although this lack of glial cell loss upon treatment with menadione could 
potentially be a glial scar-like effect, whereby cell stress leads to proliferation of 
astrocytes (Faijerson et al. 2006), this would lead to an increase in the number of 
GFAP positive cells rather than no change. It is therefore most likely due to 
increased resistance of astrocytes to oxidative stress induced damage. This latter
135
hypothesis is in agreement with previous work by Hollensworth et a l (2000) 
showing that GFAP positive astrocytes were less susceptible to menadione-induced 
injury and had more efficient repair systems than oligodendrocytes or microglia 
(Hollensworth et al. 2000).
This work examining the effects of bovine CLN against menadione-induced 
oxidative stress on primary hippocampal cells has shown that at the concentrations 
used (lOOng/ml and lpg/ml) CLN has only a small effect which is non-significant on 
the oxidative stress-related damage caused by treatment with menadione. The 
protective effect was most apparent in low-density (2 0 , 0 0 0  cells/well) cultures where 
lOOng/ml CLN given along with lOpM menadione increased the number of MAP-2 
positive cells to 20±3% of controls compared with 10±0.2% in cultures treated with 
menadione alone.
4.5.2. The effect of CLN against menadione-induced toxicity in the B50 cell line
The B50 cell line has previously been used for oxidative stress experiments 
using H2O2 and it was found that a dose of lOOpM for 24 hours caused a 40-50% 
decrease in cell viability (Iwata et al. 1998; Miyazaki et al. 1999). These cells have 
therefore been shown to be susceptible to the damage by oxidative stress in culture 
and were a good choice for further study of the possible protective effects of CLN as 
described in Section 4.1. The results showed a 50-60% decrease in cell viability with 
10pM menadione and 71-75% decrease in viability with 20pM menadione over 24 
hours. CLN treatment along with menadione was not able to prevent the menadione- 
induced cell death at any of the concentrations used.
The results from the experiments on the B50 cell line demonstrated that at the 
concentrations tested (1 Ong/ml-1 Opg/ml) bovine CLN alone is not trophic to these 
cells in culture. This observation appears to be contrary to the study by Bacsi et al.
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(2005) showing CLN to have some trophic effects and increase neurite length in the 
PC 12 cell line by activating P53 and P21. However, the study by Bacsi et al, (2005) 
involved study of cell culture over considerably longer time scales than the work 
described here. Furthermore, different cell lines may react differently to treatment 
even though they are both neuronal lines derived from rat tissue, because the PC 12 
cell line is derived from rat adrenal medulla and the B50 cell line is derived from rat 
hippocampus.
4.5.3. The effect of CLN against Api-4 2 -induced toxicity in primary
hippocampal cells
The experiments described here are the first to examine the effects of CLN on 
primary hippocampal cells that have been treated with Ap. As CLN has been shown 
to prevent the toxicity of AP1-40 on SHSY-5Y cells in culture when pre-incubated and 
co-administered with APi^o (Schuster et al. 2005) it was considered important to 
know whether this protection by CLN also occurs in primary cell cultures treated 
with Ap. Therefore this experiment was designed to replicate this previous work on 
cell lines using primary hippocampal cells. As described in Section 4.2.4 APm2 was 
chosen because of its preparation procedure and faster induction of toxicity over 
AP1-40. AP1.42 was pre-incubated with or without bovine CLN for 48 hours prior to 
cell treatment. The cells were then treated for 48 hours before being fixed and stained 
for the neuronal marker MAP-2 and the astrocytic marker GFAP.
CLN was prepared slightly differently for the experiments with AP1-42 
compared to those with menadione (see Section 4.3.1) and was used at a higher 
concentration (5pg/ml compared to lOOng/ml and lpg/ml). The results presented
137
here show that CLN diluted in PBS and media at 5 jig/ml and given alone had no 
trophic effect on these cells.
Forty eight hour treatment with 25pM APm2 caused a significant 44±13% 
decrease in the number of MAP-2 positive neurons present in these primary cell 
cultures compared to controls. This is in keeping with many previous studies 
showing the toxicity of APm2 on primary hippocampal cells in culture as discussed 
in Section 4.2.3.
When bovine CLN was pre-incubated with Ap 1-42 there was a non-significant 
trend against the APi-42-induced decrease in MAP-2 positive neurons, implying that 
CLN at this concentration may have a small effect against APi-42-induced 
neurotoxicity. The effect seen here is not as dramatic as the significant protective 
effect of CLN seen previously by Schuster et al (2005) and there may be several 
reasons for this difference; firstly, the effect that was shown by Schuster et al. used a 
cell line and here the effect of CLN on primary hippocampal cells was being 
investigated for the first time. Furthermore the authors in the preceding work had 
used APmo treatment whereas AP1-42 was used here. As explained in the introduction 
AP1-42 was chosen for these experiments because APm2 has been shown to be more 
toxic to primary hippocampal cells in culture than APmo and APm2 can be dissolved 
in water and PBS rather than acid.
Bovine CLN alone was seen to have no significant effect on the number of 
GFAP positive cells present in the hippocampal cultures although there was small 
but non-significant increase in cell numbers. This result supports data in Chapter 3, 
Section 3.6 showing that lower concentrations of bovine CLN had no notable effect 
on the number of GFAP positive astrocytes. However APm2 treatment led to a 50% 
reduction in the number of GFAP positive cells present in cultures. This is in keeping 
with work done by Assis-Nascimento et al. in 2007 showing that embryonic rat
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astrocytes in culture are vulnerable to the toxicity of Ap (Assis-Nascimento et al. 
2007). This AP1.42 induced reduction in GFAP positive cell numbers was not reversed 
by the presence of CLN pre-incubated with AP1-42 showing that CLN was not able to 
protect astrocytes from the effects of AP1-42 at these concentrations and in these 
treatment conditions. It is entirely possible though that although CLN cannot protect 
the astrocytes, per se, the small effect of CLN seen on neurons may occur via the 
astrocytes. Evidence in support of this theory comes from work showing that other 
protective compounds such as LPS and IFN-y have been found to help prevent Ap- 
mediated neurotoxicity via changes in the activity of astrocytes and the release of 
protective factors (Ramirez et al. 2005). Therefore the small increase in the number 
of GFAP positive astrocytes with CLN alone may be interesting regarding the 
prevention of neurotoxicity because an increase in the number of astrocytes might 
have an indirect effect on neuronal survival. However, there is work by Domenici et 
al (2 0 0 2 ), which would argue against this hypothesis as these authors showed that 
the presence of astrocytes in cultures may actually increase neuronal vulnerability to 
Ap-induced neurotoxicity, and pure neuronal cultures where astrocytic growth was 
prevented by treatment with arabinosylcytosine were far less vulnerable than mixed 
cultures (Domenici et al. 2002).
4.5.4. Summary
These experiments have demonstrated that bovine CLN may have a small 
effect against menadione-induced toxicity and Api-42-induced toxicity on MAP-2 
positive neurons in primary hippocampal cultures but has less of a protective effect 
against the APi-42-induced toxicity on GFAP positive astrocytes. Bovine CLN did 
not protect B50 cell cultures from menadione-induced toxicity.
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Chapter 5
Investigation of the mechanism of action of
CLN
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5.1. Aims
The aim of these experiments was to elucidate the mechanism of the 
protective effects of CLN that have been observed against both menadione and Af>- 
induced toxicity on neuronal cells. There were three aspects involved in this analysis 
and these are illustrated in Figure 5-1.
Firstly, the effect of CLN on oxidative stress and antioxidant defence was 
investigated by analysing the ability of CLN to prevent the production of ROS and to 
affect the protein levels of the antioxidant enzyme SOD1.
Secondly, the effect of bovine CLN on the protein kinase Cdk5 was studied. 
Cdk5 has been demonstrated to be involved in Ap-induced toxicity and to be 
inhibited by TNFa.
Thirdly, the effect of bovine CLN on apoptosis was investigated by FACS 
analysis of the levels of activated caspase 3 in cultures upon treatment with bovine 
CLN and lpM  menadione.
The primary hippocampal cultures described in Chapter 3 and B50 cells were 
used as the model systems.
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5.2. Introduction
5.2.1. Oxidative stress markers in vitro
An increase in the levels of activity or protein expression of anti-oxidant 
enzymes such as SOD in cultures would indicate that the cells are responding to 
some form of oxidative stress. Measurement of these parameters can be carried out 
using Western blotting to investigate changes in protein levels or assays to examine 
changes in enzyme activity. Furthermore changes in the levels of ROS being 
produced may be directly measured using DCFH-DA (Hempel et al. 1999; Halliwell 
and Whiteman 2004). DCFH-DA can freely enter cells where it reacts with esterases 
to produce an insoluble form of the molecule which can then react with peroxides to 
leave a fluorescent compound DCF, the intensity of which may be measured using a 
confocal microscope (Jakubowski and Bartosz 2000).
5.2.2. Protection against beta-amyloid-induced toxicity
There are several aspects of the mechanisms of Ap-induced toxicity upon 
which a compound may act in order to prevent the toxicity. This effect may be 
directly on Ap and its production or aggregation or it may be more indirect.
The importance of the aggregation state on the level of toxicity induced has 
been emphasised both in Chapter 1, Section 1.1.2.2 and in Chapter 4, Section 4.2.3. 
As detailed in Chapter 1, Section 1.1.5.1 compounds such as trehalose (Liu et al. 
2005), NAP (Ashur-Fabian et al. 2003) and the polyphenol group (Riviere et al.
2007) are protective against Ap-induced toxicity by preventing this aggregation.
The protective effects of a compound may also act upon one of the pathways 
which has been implicated in Ap-induced toxicity as was discussed in detail in 
Chapter 1, Section 1.1.5.2. Furthermore anti-oxidants have been shown to be
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protective against Ap-induced toxicity as detailed in Chapter 1, Section 1.3.4 and 
compounds may protect against Ap-induced toxicity by preventing this Ap-mediated 
induction of apoptosis as discussed in detail in Chapter 1, Section 1.2.4.
Some compounds may be protective against Ap-induced toxicity by 
combinations of these effects. Components of green and black teas have been found 
to be protective against Ap-induced toxicity in hippocampal cultures by decreasing 
ROS accumulation as well as preventing apoptosis and AP25-35 fibril formation 
(Bastianetto et al. 2006) and the red wine associated antioxidant, resveratrol, has 
been shown to prevent both ROS accumulation and apoptosis initiation by AP25-35 in 
PC12 cells (Jang and Surh 2003).
5.2.3. Mechanisms of protection by CLN
There are numerous potential mechanisms by which CLN may mediate its 
protective effects against menadione and APi^-induced toxicity and some of these 
are outlined in Figure 5-1.
As discussed in Chapter 1, Section 1.5.4 CLN has been shown to prevent the 
toxicity of APmo in SHSY-5Y cells by inhibiting and even reversing the aggregation 
of AP1-40 (Schuster et al. 2005). This ability of CLN to prevent A p^o fibril 
formation was confirmed by (Bourhim et al. 2007) and this known action of CLN is 
shown in a green box in Figure 5.1.
There is also considerable evidence that CLN may reduce oxidative stress as 
described in detail in Chapter 1, Section 1.6.3. Not only would prevention of 
oxidative stress-induced damage explain the protective effects of CLN against 
menadione-induced toxicity but as described detailed in Chapter 1, Section 1.4.3, 
Ap-induced toxicity has been linked to oxidative stress and in particular SOD1 has
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been found to be increased in cultures treated with Ap (Pappolla et al. 1998). It was 
therefore hypothesised that the protective effects of CLN may be due to its 
antioxidant action. This hypothesis was examined by analysing the ability to CLN to 
prevent a menadione-induced increase in ROS production in B50 cells and the 
effects of bovine CLN, menadione and Api-42 on SOD1 protein levels in the primary 
hippocampal cultures described in Chapter 3 as well as B50 cells.
A further mechanism by which CLN may have a protective effect against 
Ap-induced toxicity is via the release of cytokines. CLN has been demonstrated to be 
a modest inducer of cytokines, particularly of TNFa and gamma interferon (ylFN) 
(Inglot et al. 1996; Blach-Olszewska and Janusz 1997). As discussed in Chapter 1, 
Section 1.1.5.2 TNFa treatment has been found to reduce the toxicity of Api-42 by 
causing reduction in both protein levels and activity of Cdk5. Therefore a second 
hypothesis to be investigated was that CLN may reduce Cdk5 activation via the 
release of TNFa and thus prevent Api-42-induced toxicity.
As discussed in Chapter 1, Section 1.3.3 Ap toxicity has been shown to 
involve the initiation of apoptosis, specifically caspase 3 activation, and menadione 
has also been demonstrated to induce caspase 3 activation (Adamec et al. 2000). 
Although CLN has been demonstrated to affect the cell cycle (Bacsi et al. 2005;
Bacsi et al. 2007) and to down regulate gene expression of caspase 3 in the TR146 
buccal mucosal cell line (Szaniszlo et al. 2009) no work has been done to investigate 
the effects of CLN on apoptosis in primary cells or to establish whether the change in 
caspase 3 gene expression correlates with changes in protein levels. The third 
hypothesis to examine was whether CLN may prevent caspase 3 activation.
The potential points for the mechanism of action of CLN against ROS 
production, alterations in anti-oxidant defence via changes in the levels of SOD1, 
prevention of Cdk5 activation via TNFa or prevention of the activation of caspase 3
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and therefore apoptosis induction were investigated in this study and are shown in 
purple with question marks in Figure 5-1.
Menadione
CLN?
tR O S
A(3 oligomers
TNFa
CLN?
CLN?
Figure 5-1: To show the known points of action for protection against AP-induced toxicity and 
potential mechanisms of action of CLN. Previously known points of action for CLN are in green and 
those investigated here are in purple with question marks. Toxic compounds are in black and 
compounds affected by these are in orange. Arrows represent an activation or increase, flat lines 
represent an inhibition.
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5.3. Materials and methods
5.3.1. ROS production analysis
B50 cell cultures were plated at 100,000 cells/well in 6  well culture plates 
and treated DIVl with lOpM menadione and 1 pg/ml bovine CLN. On D IVl ROS 
production analysis was carried out using the fluorescent ROS marker DCF and the 
images were analysed as described in Chapter 2, Section 2.11.
5.3.2. Western blotting
For these Western Blot experiments much higher cell densities were used 
than those used for experiments described in previous chapters. The rationale for this 
change was that whereas in previous experiments the key element had been to clearly 
observe changes in the cells morphology and number within the culures for these 
Western Blot experiments dense cultures were necessary to obtain the large amounts 
of protein that were needed from the cell lysate.
5.3.2.1. B50 cell lysate
B50 cells were plated at 100,000 cells/well in 6  well cultures plates and the 
media was changed DIVl.
5.3.2.2. Primary hippocampal cell lysate
Hippocampal cells were plated at 400,000 cells/well in 6  well culture plates 
and maintained as described in Chapter 2, Section 2.3.4.
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5.3.2.3. Treatment
Bovine CLN, menadione and AP1-42 were prepared as detailed in Chapter 2, 
Sections 2.5, 2.6 and 2.7 respectively. The cultures were treated on DIV3. For the 
menadione experiments cultures were treated with 5ng/ml or 50ng/ml bovine CLN 
and lpM  menadione in 0.001% ethanol and control cultures were treated with 
0.001% ethanol in the culture media and bovine CLN was diluted in 0.001% ethanol 
in culture media to ensure that any changes observed were not due to the presence or 
absence of ethanol used to dissolve the menadione. For AP1-42 experiments cultures 
were treated with i) PBS for control, ii) lOpM Api_42» iii) 5ng/ml or 5pg/ml bovine 
CLN and iv) AP1-42 pre-incubated and co-administered with bovine CLN. The 
concentrations of CLN that have been chosen for this experiment, as for the 
experiment described in Chapter 4, Section 4.4.1.3 were based on the those used by 
Shuster et al, (2005) when investigating the effects of CLN against Ap -induced 
toxicity. The concentration of Api_42 chosen here is lower than that used in the 
experiment described in Chapter 4, Section 4.4.1.3 because it was not desirable to 
cause severe cell loss for these experiments, only to initiate toxicity.
5.3.2.4. Western blotting
On DIV4 Western blot sample preparation, gels and Western blot analysis 
were carried out as described in Chapter 2, Section 2.12.
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5.3.3. FACS analysis
Cells were plated in 6  well cultures plates as detailed in Chapter 2, Section 
2.13 and the media was changed at DIVl. The cultures were treated on DIV3 with 
5ng/ml bovine CLN and lpM  menadione.
On DIV4 FACS analysis of activated caspase 3 levels in the cultures was 
carried out as detailed in Chapter 2, Section 2.13.
148
5.4. Results
5.4.1. The effects of bovine CLN on the prevention of oxidative stress
5.4.1.1. The effect of CLN on menadione-induced ROS production in the B50 
cell line
Twenty four hours of treatment of B50 cells with lOpM menadione was used 
to induce ROS production in order to produce a model in which to test the ability of 
CLN to reduce ROS production. The results from confocal microscopy of DCF 
stained cultures showed that 1 jig/ml bovine CLN alone caused no change in ROS 
production compared to control cultures. However, IOjiM menadione caused a large 
20 fold increase (1,900±42% of controls. P= 0.037) in the level of fluorescence of the 
ROS marker DCF compared to control cultures (see Figure 5-2). Bovine CLN at 
1 pg/ml reversed this menadione-induced increase in ROS-induced fluorescence back 
to control levels (P = 0.046 see Figure 5-2).
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Figure 5-2: Quantification of DCF fluorescence on B50 cell line cultures from confocal images 
showing that CLN alone had no effect on ROS production compared to controls (p = 0.480) but ROS 
levels were increased upon treatment with IOjiM menadione (P = 0.037). This menadione-induced 
increase was reversed when CLN is given along with menadione (P = 0.046). The ROS production 
was not changed in cultures treated with menadione and CLN compared to controls (P = 0.114) or 
CLN treated cultures (P = 0.116). n=3 and error bars represent standard errors. * represents p< 0.05.
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5.4.1.2. The effect of treatment with bovine CLN and beta-amyloid on the
protein levels of the antioxidant enzyme SOD1 in primary hippocampal 
cultures.
Treatment of the primary hippocampal cultures with bovine CLN alone at 
5ng/ml or 5pg/ml did not lead to changes in the protein levels of SOD1 compared to 
controls. However 24 hour treatment of these cultures with lOpM Ap i . 4 2  did cause an 
increase in the SOD1 protein levels of 29±8% compared to the control (P = 0.037, 
see Figure 5-3 and 5-4). Pre-incubation and co-administration of 5ng/ml or 5pg/ml 
bovine CLN with Afh- 4 2  reduced the A(3i.42-induced increase in SOD1 protein levels 
to control levels and densitometry showed this reduction to just reach significance (P 
= 0.05, see Figures 5-3 and 5-4).
SOD1
12KDa
Actin
45KDa
Control 5ng/ml 5pg/ml 10uM lOpM
CLN CLN a B ,-  Apl-42 APl-42
+ 5ng/ml +5pg/ml 
CLN CLN
Figure 5-3: A representative Western blot for SOD1 on primary hippocampal cell lysate after 
treatment with bovine CLN and AP]_42 showing that lOpM ApM2 caused an increase in SOD1 protein 
levels but this Ap ^-induced  increase was reversed when CLN at 5ng/ml or 5pg/ml was pre­
incubated and co-administered with ApM2; actin is shown for normalization.
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Figure 5-4: Densitometric quantification of Western blots for SOD1 from primary hippocampal cell 
line lysate after treatment with 5ng/ml or 5pg/ml bovine CLN, lOpM ApM2 or CLN pre-incubated 
and co-administered with APi_42 . SOD1 levels in cultures treated with CLN at 5ng/ml or 5pg/ml did 
not differ from controls (P = 0.487 and 0.121 respectively). 10fiM ApM2 increased SOD1 protein 
levels in these cells (P = 0.037) and pre-incubation and co-administration of bovine CLN prevented 
this increase (P = 0.05). n=3. * represents P < 0.05. Error bars represent standard errors.
5.4.I.3. The effect of treatment with bovine CLN and beta-amyloid on the 
protein levels of the antioxidant enzyme SOD1 in B50 cells.
Treatment of B50 cell cultures with 5ng/ml bovine CLN caused an 80±7% 
increase in the protein levels of SOD1 compared to control (P = 0.037, see Figures 5- 
5 and 5-6). Treatment with lOpM AP1.42 led to a small decrease in the levels of 
SOD1 protein in these cultures (P = 0.037) and the CLN mediated increase in protein 
levels was absent when CLN was pre-incubated and co-administered with lOpM 
Api-42 (see Figures 5-5 and 5-6).
151
SOD1 12KDa
Actin 45KDa
Control 5ng/ml 10|iM ApM2 10pMApM2
CLN + 5ng/ml
CLN
Figure 5-5: A representative Western blot for SOD1 on B50 cell lysate after treatment with 5ng/ml 
bovine CLN and lOpM APi_42 showing an increase in SOD1 protein levels upon treatment with 
5ng/ml CLN compared to control and a small decrease with A[3M2 compared to control. Actin is 
shown for normalization.
Control 5ng/ml CLN 10pM AJ51-42 10pM A|51-42 + 5ng/ml
CLN
Figure 5-6: Densitometric quantification of Western blots for SOD1 on B50 cell line lysate after 
treatment with 5ng/ml bovine CLN, lOpM ApM2 or CLN pre-incubated and co-administered with 
ApM2 showing that bovine CLN increased SOD1 protein levels in these cells (P = 0.037) but lOpM 
ApM2 caused only a small decrease (P = 0.037) in the enzyme protein levels. When CLN was pre- 
incubated and co-administered with APi_42 the protein levels were reduced form those observed with 
CLN alone (P = 0.05). n=3. * represents P < 0.05. Error bars represent standard errors.
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5.4.1.4. The effect of treatment with bovine CLN and menadione on the protein 
levels of the antioxidant enzyme SOD1 in B50 cells.
Both bovine CLN and menadione at the concentrations given were found to 
cause a small increase in the SOD1 protein levels in cultures and this increase was 
slightly more pronounced when CLN and menadione were given together (see Figure 
5-7). Densitometric analysis showed that none of these changes reached significance 
(see Figure 5-8).
SOD1
12KDa
Actin 45KDa
Control 5ng/ml lpM lpM
CLN Menadione Mendione +
5ng/ml CLN
Figure 5-7: A representative Western blot for SOD1 on B50 cell line lysate after treatment with 
5ng/ml bovine CLN, lpM  menadione or both showing that both treatments increased SOD1 protein 
levels in these cells but SOD1 protein levels were highest when CLN and menadione were given 
together. Actin is shown for normalisation.
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Figure 5-8: Densitometric quantification of Western blots for SOD1 on B50 cell line lysate after 
treatment with 5ng/ml bovine CLN, lpM menadione or both showing that both treatments increased 
SOD1 protein levels in these cells but SOD1 protein levels were highest when CLN and menadione 
were given together. n=4. Error bars represent standard errors. From a Kruskal-Wallis test this 
experiment did not reach significance (P = 0.270).
5.4.2. The effect of bovine CLN on Cdk5 levels
5.4.2.I. The effect of treatment with CLN and beta-amyloid on the protein 
levels of Cdk5 in primary hippocampal cultures.
A small increase in Cdk5 protein levels was observed upon treatment with 
CLN or lOpM Api_42 alone. This increase in Cdk5 protein levels over control levels 
was significant for CLN at 5ng/ml and 5 jig/ml as well as for lOpM AP1-42 
(P= 0.037.see Figures 5-9 and 5-10). Pre-incubation and co-administration of 5ng/ml 
CLN with AP1-42 led to significantly higher Cdk5 levels compared to controls 
(P= 0.037) although the effects did not appear to be cumulative. However, pre­
incubation and co-administration of 5pg/ml CLN with A p  1-42 r e s u l t e d  in Cdk5 
protein levels that were similar to control levels and levels that were significantly 
lower than those observed with AP142  treatment alone (P = 0.046) but not CLN 
treatment alone (see Figures 5-9 and 5-10).
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Cdk5 36KDa
Actin 45KDa
Control 5ng/ml 5ug/ml 10uM lOftM 10pM
CLN CLN AR ApM2 ApM2
+ 5ng/ml +5pg/ml 
CLN CLN
Figure 5-9: A representative Western blot for Cdk5 on primary hippocampal cell lyase after treatment 
with bovine CLN and 1 OpM ApM2 showing that CLN and ApM2 both led to an increase in Cdk5 
protein levels but when 5pg/ml CLN was pre-incubated and co-administered with Ap1.42 Cdk5 protein 
levels were at control levels. Actin is shown for normalisation.
* * P = 0.046
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Figure 5-10: Densitometric quantification of Western blots for Cdk5 on primary hippocampal cell 
lysate after treatment with CLN and Af3 showing that CLN and A(3M2 both led to an increase in Cdk5 
protein levels compared to controls (P = 0.037) and this increase remained when 5ng/ml CLN was 
pre-incubated and co-administered with Afh.^ ( P = 0.037). However when 5pg/ml CLN was pre- 
incubated and co-administered with ApM2 Cdk5 protein levels were reduced compared to ApM2 alone 
(P = 0.046). n=3. * represents P < 0.05. Error bars represent standard errors.
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5.4.2.2. The effect of treatment with CLN and beta-amyloid on the protein 
levels of Cdk5 in B50 cell cultures.
Some variability in the Cdk5 protein levels was observed when B50 cultures 
were treated with lOpM Api.4 2 , 5ng/ml bovine CLN or 10pM Ap 1 .4 2  pre-incubated 
and co-administered with CLN. However, overall there was no notable change in the 
protein levels of Cdk5 in B50 cultures with any of these treatments when compared 
to controls although there was a small decrease with Api-4 2  treatment alone (see 
Figures 5-11 and 5-12).
Cdk5 36KDa
Actin 45KDa
Control 5n§/ml lO gM A p,^ lO g M A p ^  
CLN + 5ng/ml
CLN
Figure 5-11: A representative Western blot for Cdk5 on B50 cell line lysate after treatment with 
bovine CLN and 10pM A p ^  showing little change from controls with any treatment. Actin is shown 
for normalisation.
156
Control 5ng/ml CLN 10pMA|J1-42 1 0 |jM Ap1«42 + 5ng/ml
CLN
Figure 5-12: Densitometric quantification of Western blots for Cdk5 on B50 cell lysate after 
treatment with 5ng/ml bovine CLN and 10pM ApM2 showing little change in Cdk5 protein levels 
with CLN or APi_42 treatment. n=3. Error bars represent standard errors. From a Kruskal-Wallis test 
this experiment did not reach significance (P = 0.501).
5.4.3. The effect of bovine CLN on the number of cells expressing activated 
caspase 3
FACS analysis showed that there was variation in background number of 
cells expressing active caspase 3 in control cultures. However, no consistent increase 
or decrease in the percentage of cells expresing active caspase 3 compared to 
controls in response to CLN was seen in either primary hippocampal cells (see 
Figures 5-13 and 5-14) or B50 cells (see Figures 5-15 and 5-16). In B50 cells lpM  
menadione caused a reduction in the percentage of cells expressing active caspase 3 
compared to controls although upon quantification (see Figures 5-15 and 5-16) this 
reduction in expression did not reach significance.
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Figure 5-13: FACS analysis contour plots for active caspase 3 in primary hippocampal cells after 
treatment with 50ng/ml bovine CLN. The upper right quadrant represents cells in the cell population 
of interest and are positively stained for activated caspase 3.The bottom right quadrant represents cells 
in the cell population of interest but that are unstained for caspase 3 and the left quandrants represent 
cells not in the population of interest or cell debris. CLN did not consistently cause a change in the 
number of cells expressing activated caspase 3.
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Figure 5-14: Quantification of FACS analysis for active caspase 3 in primary hippocampal cells after 
treatment with 50ng/ml bovine CLN. CLN did not consistently cause a change in the number of cells 
expressing activated caspase 3 compared to control cultures (from one-way ANOVA P = 0.878). n=6 
Error bars represent standard errors.
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Figure 5-15: FACS analysis contour plots for active caspase 3 in B50 cells after treatment with 
5ng/ml bovine CLN and 1 pM menadione. The upper right quadrant represents cells that in the cell 
population of interest and are positively stained for activated caspase 3.The bottom right quadrant 
represents cells in the cell population of interest but that are unstained for caspase 3 and the left 
quandrants represent cells not in the population of interest or cell debris. There was no consistent 
change in the number of cells expressing activated caspase 3 upon treatment with CLN but menadione 
treatment caused a small reduction in the number of cells expressing activated caspase 3.
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Figure 5-16: Quantification of FACS analysis for active caspase 3 in B50 cells after treatment with 
5ng/ml bovine CLN and 1 pM menadione showing that there was no consistent change in activated 
caspase 3 expression levels upon treatment with CLN. Menadione treatment caused a small reduction 
in the number of cells expressing activated caspase 3 although a one-way ANOVA showed that these 
did not reach significance (P = 0.494). n=3. Error bars represent standard errors.
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5.5. Discussion
Having investigated potential protective effects of bovine CLN against 
menadione and Ap ^ -m ediated toxicity in primary hippocampal cells the next stage 
of the project was to investigate, using the same cell culture systems, how CLN may 
affect anti-oxidant defence, protein kinase protein levels and apoptosis.
5.5.1. The effect of bovine CLN, menadione and beta-amyloid on oxidative 
stress
In accordance with previous studies demonstrating the ability of CLN to 
reduce H2O2 or Ap-induced increases in ROS (Boldogh and Kruzel 2008) CLN was 
found to prevent a menadione-induced increase in ROS in B50 cells.
The results of the Western blot experiment which examined changes in SOD1 
protein levels in primary hippocampal cultures treated with bovine CLN at 5ng/ml or 
5pg/ml and IOjiM AP1-42 showed that the protein levels were unchanged with CLN 
treatment alone but increased by 29±8% compared to controls with AP1-42 treatment 
alone. This APi-42-mediated increase in the Cu/Zn form of the SOD protein levels is 
in agreement with previous experiments by Pappolla et al. (1998) studying SOD1 
levels, which showed that SOD1 is increased in a transgenic mouse model of AD as 
well as in PC 1 2  cell cultures that had been treated with AP25-35. Furthermore it was 
found that when bovine CLN at both 5ng/ml and the high concentration of 5pg/ml 
was pre-incubated and co-administered with Api-42 the APi-42-induced increase in 
SOD1 protein levels were reduced to control level. This result implies that in primary 
hippocampal cells bovine CLN at the concentrations tested is able to prevent a 
APi-42-induced increase in oxidative stress which leads to increased expression of 
antioxidant defences.
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However, the same experimental conditions in the B50 cell line produced 
different results to those in the primary hippocampal cells. In the B50 cell line 
5ng/ml bovine CLN caused an 80±7% increase in SOD1 protein levels compared to 
controls with a small decrease in protein levels in response to AP1-42 treatment and no 
change compared to controls when CLN was pre-incubated and co-administered with 
APi-42- The mechanism of action of CLN and AP1-42 must therefore differ between 
primary hippocampal cells and B50 cells. Abromov and Duchen (2005) showed that 
the Api-42-mediated increase in oxidative stress in primary cortical and hippocampal 
cultures was mediated via depolarization in astrocytes present in the cultures 
(Abramov et al. 2005) so the lack of SOD1 response to AP1-42 in B50 cells could be 
due to the absence of astrocytes in these cultures. Furthermore, as discussed in 
Chapter 4, Section 4.5, the culture media used may affect the survival of cells in 
culture (Xie et al. 2000) and this may therefore have an effect on the cell type 
specific response to ApM2-
As in the Western blot experiments described above investigating the effect 
of bovine CLN with Api-42 on B50 cells CLN alone was found to increase in SOD1 
protein levels in B50 cells in Western blot experiments analysing the effects of CLN 
and menadione on SOD1 protein levels. In these experiments bovine CLN or 
menadione alone induced a small increase in SOD1 protein levels and these increase 
appeared to be cumulative. There are two possible explanations for the increase in 
SOD1 protein levels in B50 cells in response to CLN; firstly it could be that in this 
cell line CLN is inducing oxidative stress and the related damage which is leading to 
the induction of antioxidant defence or secondly CLN may be protective and directly 
induce the expression of the antioxidant enzyme in this cell line without the need for 
stress induction in a similar manner to that where oestrogens have been shown to 
induce the expression of SOD2 in MCF-7 cells (Borras et al. 2005). The latter
hypothesis is supported by the fact that CLN was not found to increase ROS in the 
B50 cells using the ROS marker DCF and experimental evidence so far indicates that 
CLN is an antioxidant in its effect (Boldogh et al. 2003; Bacsi et al. 2006). However, 
the concentration of CLN used in the ROS production experiment was different to 
that used in the present experiment and previous work has been done using different 
cells. These results coupled with the finding that CLN was able to reduce a 
menadione-induced increase in ROS in the B50 cell line strongly suggest that CLN 
may have a protective effect against menadione and AP1-42 by reducing oxidative 
stress. The finding that bovine CLN is able to affect the protein levels of SOD1 in 
both primary hippocampal cells and B50 cells is in keeping with work by Szaniszlo 
et al. (2009) which showed that CLN is able to alter the expression of SOD in a 
microarray analysis of the buccal mucosal cell line.
5.5.2. The effect of bovine CLN and beta-amyloid on the protein levels of Cdk5
The second part of the work discussed in this Chapter analysed the protein 
levels of Cdk5 in hippocampal and B50 cell cultures in response to bovine CLN and 
APi_42* Experiments on B50 cells showed that CLN alone or pre-incubated and 
co-administered with AP1-42 did not cause a decrease in Cdk5 levels. In primary 
hippocampal cultures CLN treatment alone led to an increase in CDK5 protein levels 
which was significant. This result apparently argues against the hypothesis that CLN 
may have a protective effect against APi-42-induced toxicity by causing the release of 
TNFa which would decrease the protein levels of Cdk5 and therefore prevent AP1-42 
mediated Tau phosphorylation. This apparent lack of effect of CLN on Cdk5 may be 
due to the fact that only protein levels were examined. There may have been a 
change Cdk5 activity that could not be detected in these experiments but would be 
observed if a Cdk5 activity assay was employed. There was also a significant
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increase seen in Cdk5 protein levels in primary hippocampal cells upon treatment 
with Api-42 which was reversed with the higher concentration of CLN (5pg/ml) and 
there may therefore be a small effect of CLN on Api-42-induced Cdk5 possibly via 
TNFa.
5.5.3. The effect of bovine CLN on the number of cells expressing activated
caspase 3
The results of FACS analysis used to determine the effects of bovine CLN on 
activation of the apoptotic initiator, caspase 3, showed that CLN alone had no 
consistent effect on caspase 3 activation compared to controls in either primary 
hippocampal cells or B50 cells. The variation encountered in the expression of active 
caspase 3 may be due to natural background variation in the levels of apoptosis 
within the cultures. Microarray analysis work carried out by Szaniszlo et a l (2009), 
on TR146 buccal mucosal cells showed that lOOng/ml bovine CLN down-regulated 
gene expression of caspase 3. However this study used a different cell type and the 
longest time point studied in the previous work was 18 hours compared to the 24 
hour treatment prior to FACS analysis. FACS analysis also showed active caspase 3 
expression to be relatively unchanged compared to controls in primary hippocampal 
cells and decreased in B50 cell line upon treatment with 1 pM menadione for 24 
hours. These conditions for menadione treatment have previously been demonstrated 
to lead to the induction of apoptosis and increased expression of active caspase 3 in 
primary hippocamapal cells (Adamec et al. 2000). However Ibuki et al. (2006), 
found that menadione could prevent the apoptosis induced by serum depletion and 
cell detachment in the NIH-3T3 cell line which may explain this decrease in active 
caspase 3 expression observed in the cell line. One possible explanation for the lack 
of a menadione-induced increase in active caspase 3 in the hippocampal cultures is
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that Adamec et al. (2000), used hippocampal cultures at three weeks in culture and 
for these present experiments 3 day old cultures were used for consistency with the 
immunocytochemistry, the toxicity experiments described in Chapter 4 and the 
Western blot experiments detailed in this Chapter, Sections, 5.4.1 and 5.4.2.
5.5.4. Summary
These results show that bovine CLN can prevent ROS production and alter 
the protein levels of the antioxidant enzyme SOD1. CLN does not however have 
significant effects on reducing the protein levels of the kinase Cdk5 or activation of 
caspase 3. The effects of CLN on SOD1 protein levels differed between the two 
culture systems used in this study which may partially explain the lack of protective 
effects of CLN against menadione-induced toxicity seen in the B50 cultures. The 
small changes in the number of MAP-2 positive neurons seen in hippocampal 
cultures when CLN was co-adminsitered with on menadione or Api-42 comapred to 
treatment with either of these compounds alone therefore appear to be largely due to 
antioxidant properties of CLN.
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Chapter 6
General discussion
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6.1. Summary of findings
AD is the most common form of dementia and there is, at present, no cure for 
the disease although treatment can be given to slow its progression and make patients 
more comfortable. The major cause of the neuronal loss and subsequent cognitive 
decline in AD patients is the accumulation of extracellular plaques of A(3 which is 
produced from cleavage of APP, and intracellular NFT containing Tau. It is now 
widely accepted that the amyloid plaques are the initiating factor in 
neurodegeneration, causing toxicity in vivo and in vitro, and leading to the formation 
of NFT which will in turn cause further neurodegeneration. Therefore compounds 
which can prevent the accumulation, aggregation or toxicity of Ap at any level of 
this process may potentially lead to the development of therapies to improve the 
prognosis for AD patients and slow disease progression.
CLN has been found to stabilise symptoms of disease in patients with AD in 
clinical trials lasting up to 16 months. It has also been demonstrated to improve 
spatial memory in aged rats (Popik et al. 2001) and passive avoidance learning in the 
day old chick (Stewart and Banks 2006). In vitro CLN has been shown to have an 
antioxidant effect (Boldogh et al. 2003) and to prevent the aggregation of Ap 
(Schuster et al. 2005). However, the mechanism of action of CLN that allows the 
beneficial effects that have been found in vivo is still unknown and only one study 
has been carried out to look directly at the effects of CLN on Ap-mediated toxicity in 
culture (Schuster et al. 2005). Another study has investigated gene expression 
changes relating to Ap (Szaniszlo et al. 2009) but neither of these studies were 
carried out in primary cells and they did not examine cell type specific changes.
The aim of this project was therefore to investigate the mechanism of action 
of CLN. Previous research has involved only ovine CLN so here the effects of
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bovine CLN on primary hippocampal cells in culture have been examined for the 
first time. The ability of bovine CLN to prevent A P i/2-induced and menadione- 
induced effects on these cells and on B50 cells were also analysed.
The first part of the research analysed the effects of bovine CLN on 
hippocampal cells in culture when given alone, and also possible protective effects 
against menadione-induced, oxidative stress mediated, or Api ^ -induced toxicity. 
This work demonstrated that bovine CLN at lOOng/ml has a small trophic effect on 
neurons and astrocytes in low density cultures of primary hippocampal cells from 
El 8  hippocampus (see Figure 4-12). Furthermore, this concentration of CLN was 
found to cause a trend towards a small reduction in the effects of menadione-induced 
toxicity in primary hippocampal cells in culture (see Figures 4-6 and 4-12) and it did 
not protect B50 cells against menadione-induced toxicity (see Figures 4-19 to 4-23). 
A higher concentration (5pg/ml) of bovine CLN appeared to slightly reduce AP1/ 2- 
induced toxicity although these effects seen in hippocampal cells did not reach 
significance (see Figure 4-28). However, a study carried out as part of this work 
using 5ng/ml bovine CLN demonstrated a significant protective effect against AP1/ 2- 
induced toxicity. This result is in keeping with the findings of Schuster et al. (2005), 
who found that there was a negative correlation between the protective effect on cell 
survival that they observed and the concentration of CLN that was used. These 
authors found that in SH-SY5Y cells there was significant protection against Ap 1^0- 
induced toxicity when CLN was pre-incubated and co-administered with the AP1 /0  
(Schuster et al. 2005). 0.25pM CLN was seen to give about 30% cell survival but 
this protective effect increased to over 40% cell survival at 0.0025pM CLN 
(Schuster et al. 2005). This preliminary experiment using CLN at 5ng/ml described 
here therefore needs to be repeated but was beyond the means of the present research 
due to finance and time constraints.
The next area of analysis was to investigate the specific mechanism of action 
of CLN. On studying the antioxidant effects of bovine CLN it was found that bovine 
CLN could prevent a menadione-induced increase in ROS in B50 cells (see Figure 5-
2). Furthermore bovine CLN at either 5ng/ml or 5pg/ml was able to prevent Api-42- 
induced increase in SOD1 protein levels in primary hippocampal cells demonstrating 
an antioxidant effect (see Figures 5-3 and 5-4). This corroborates previous work 
discussed in Chapter 1, Section 1.6.3, demonstrating antioxidant effects of CLN in 
several cell types and shows for the first time that the effect is present in primary 
hippocampal cells. In B50 cells CLN at 5ng/ml caused an increase in SOD1 (see 
Figures 5-5 and 5-6) implying that CLN increases the antioxidant defence in these 
cells; however, the full details of the mechanism of this effect would require further 
investigation.
It has been reported in the literature that TNFa-mediated cell protection 
against A P i/2-induced toxicity coincides with decreased protein levels of Cdk5 
(Orellana et al. 2006) and CLN has been found in vitro and in vivo to cause the 
release of TNFa (Inglot et al. 1996; Blach-Olszewska and Janusz 1997). The 
experiments carried out here to analyse the effect of CLN on Cdk5 protein levels 
showed that bovine CLN at 5pg/ml did prevent an A p i/2-induced increase in Cdk5 
levels (see Figures 5-9 and 5-10). However, bovine CLN alone also caused an 
increase in Cdk5 protein levels implying that CLN does not mediate cellular 
protection via the release of TNFa inducing a decrease in Cdk5 (see Figures 5-9 and 
5-10).
FACS analysis of the percentage of cells expressing activated caspase 3 in 
primary hippocampal cultures and B50 cells showed that CLN did not have a 
consistent effect on the level of expression of activated caspase 3 in either cell type 
compared to control cultures (see Figures 5-13 to 5-16). However, CLN may affect
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the activation of a different apoptosis initiator and the effect of CLN on Ap-induced 
changes in activated caspase 3 expression was not analysed.
6.2. CLN as a protective agent against beta-amyloid induced 
toxicity
As detailed in Chapter 1 and summarised in Chapter 5, Section 5.2.2 there are 
many mechanisms by which a compound may exert a protective effect against 
Ap-induced toxicity in vivo or in vitro.
The findings of the work presented here are summarised in Figure 6-1 which 
illustrates the points in the mechanism of AP-induced toxicity that CLN affects. The 
results imply that the protective effects of CLN in vitro and benefits in vivo are 
mediated largely by antioxidant effects of CLN and possibly by decreasing an 
APi-42-induced increase in Cdk5 but are unlikely to be mediated by preventing the 
initiation of apoptosis, at least at the level of caspase 3 activation, or by decreasing 
basal Cdk5 levels.
This work along with previous studies showing CLN to have anti-oxidant 
effects (reviewed in Stewart 2008), to be able to reduce the aggregation of Api-40 
(Schuster et al. 2005) and to decrease c-JUN activation (Szaniszlo et al. 2009) 
demonstrates that CLN has effects on several of the mechanisms of Ap-induced 
toxicity. Several other compounds have also been shown to mediate a protective 
effect against Ap via effects on SOD levels or activity, such as Neurokinin B 
(Mantha et al. 2006), oestrogen (Borras et al. 2005; Dong et al. 2007) and hyperzine 
A (Xiao et al. 2000).
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Figure 6-1: Diagrammatic illustration of the points in the mechanism of Ap-induced toxicity that 
CLN has been found to affect and those on which it may not have any effect. The major effects were 
found to be on ROS production and SOD1 with a small effect on Cdk5.
6.3. Potential limitations
6.3.1. The effect of culture on cells
This study has used primary rat hippocampal cultures and B50 neuronal cells 
as model systems for investigating the mechanism of action of CLN and has added to 
the knowledge of the mechanism of action of CLN and, in particular, has illuminated 
its anti-oxidant effects. There are very valid reasons for using culture systems as 
models and the rationale for using hippocampal cultures in this study is discussed in 
detail in Chapter 3, Section 3.2.1.
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However, a 2D culture can never be perfect due to the lack of a natural 3D 
environment without the trophic factors and cellular interactions which occur in vivo 
as well as the additional stress on the cells from dissociation and culturing. Halliwell 
discussed the possible extent of this ‘culture shock’ and the influence of oxidative 
stress on this phenomenon in detail (Halliwell 2003).
Culturing cells can also alter their development compared to that which 
occurs during in vivo development. For example, in long-term culture of embryonic 
stem cells, changes in proliferation and differentiation have been found to occur 
using the cell proliferation marker 5-bromo2’-deoxyuridine (BrdU) (Park et al.
2008). Although Banker and Cowen (1979) saw that some neurons in culture 
appeared to resemble normal pyramidal cells when they compared hippocampal 
neurons from E l9 rats that had been in culture for 7 days to hippocampal neurons 
from P4 rats, they showed that those neurons which had been kept in vitro had 
shorter dendrites and were less advanced than those that had the same developmental 
time but had developed in vivo (Banker and Cowan 1979). Moreover, these authors 
found that the axons which were seen after longer periods in vitro differed from the 
axons of neurons which were developed in vivo (Banker and Cowan 1979).
The specific conditions, growth substrate, culture media and cell density, 
chosen for the culture will affect the survival (Okuda et al. 1994; Xie et al. 2000) as 
well as the growth and development of the cells in culture (Banker and Cowan 1979). 
The conditions may even alter the characteristics of the cells being cultured as has 
been demonstrated with bone marrow stromal cells in culture (Neuhuber et al. 2008) 
and with the SH-SY5Y cell line (Buttiglione et al. 2007).
These negative effects have been reduced in this study by quick, efficient 
culture preparation to minimise cell stress, using optimal media for these cells and a
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short culture time to avoid the effect of changing cell characteristics over long 
periods in culture.
6.3.2. Other potential limitations
In the same way that a 2D culture cannot completely mimic a 3D 
environment it is also not possible to accurately reproduce a disease condition. For 
example, the problems associated with some models of oxidative stress are detailed 
in Chapter 4, Section 4.2.1. Moreover, while the treatment of cultures with AP1-42 
allows the investigation of effects on APi-42-induced toxicity and much information 
may be gained from these studies these cultures are missing the elements of the 
inflammation and NFT that occur in AD.
However, the very fact that these models only encompass one element of the 
disease at a time means that one can study individual factors without complications 
from interference and in this way these models do allow the further understanding of 
effects and interactions of compounds on cells or effects between compounds.
Another potential limitation of this study is that Western blot experiments are 
only semi-quantitative. Despite this limitation, this type of experiment appears in this 
study at least to be the simplest and clearest way to examine changes in protein 
levels.
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6.4. Future work
There are some additional points that could not be included in this work but 
should be investigated to directly follow up the results of the experiments that were 
carried out in this study. These are detailed below.
1) CLN was seen to have a trophic effect at lOOng/ml in low density cultures and 
investigation into the mechanism of this trophic effect is necessary. Microarray 
analysis on TR146 cells showed that CLN can up-regulate the expression of 
PDGF (Szaniszlo et al. 2009) so it would be reasonable to hypothesise that this 
may translate into increased protein levels in vitro and CLN may increase the 
levels of PDGF or other growth factors in culture media. This may be studied by 
analysis of the release of soluble factors into the cell culture media in the 
presence of CLN.
2) Analyses of whether the changes seen in SOD1 protein levels correspond with 
changes in enzyme activity and also if these in vitro effects are also seen in vivo.
I would hypothesise that there would not be changes in SOD1 activity upon 
treatment with Ap as the activity levels of this enzyme have been shown not to 
increase in AD patients but there is some disagreement in the literature on this 
point as discussed in Chapter 1, Section 1.4.3. Moreover oestrogen has been 
found to directly cause an increase in the expression of SOD2 (Borras et al.
2005) and CLN was found to increase protein levels of SOD1 in B50 cells and in 
previous work was shown to increase the expression of antioxidant enzymes in 
TR146 cells (Szaniszlo et al. 2009). Therefore another suggestion for further 
work is an investigation into the effects of CLN on protein levels and activity of 
SOD2 in primary cells or in vivo.
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3) Investigation of changes in Cdk5 activity in response to bovine CLN and Api-42. 
APi-42 has been demonstrated to cause an increase in the activity of Cdk5 that 
relates to toxicity (Orellana et al. 2006) and therefore CLN may be hypothesised 
to prevent this increase in activity despite having no effect on protein levels in 
primary hippocampal cells or B50 cells. Further to this, analysis should be done 
on the effect of CLN on cytokine release in primary hippocampal cells to 
establish whether the hypothesised mode of action of CLN via TNFa release to 
decrease Cdk5 protein levels or activity is correct.
4) CLN did not significantly affect the expression of activated caspase 3 in either 
the primary hippocampal cells or B50 cells but there are other points in apoptotic 
initiation and signalling that CLN may affect. Therefore studying the effects of 
CLN on other apoptotic markers such as caspase 8, annexin V or TUNEL 
labelling would be worthwhile follow up work. Moreover CLN may prevent the 
Ap mediated affects on the levels of apoptotic control molecules, pro-apoptotic 
Bcl-w, or anti-apoptotic Bcl-2, in the same way that oestrogen has been found to 
(Yao et al. 2007).
CLN has been well studied and its effects are now becoming more fully 
understood. There is however much more that can be done in our detailed analysis of 
these effects which does not directly follow on from the experiments carried out in 
this study. There are many other potential mechanisms of action for the beneficial 
effects of CLN that should be investigated in future work in vitro or in vivo. Some of 
these are outlined below.
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1) CLN has been shown using microarrays on TR146, buccal mucosal cells to 
decrease the expression of PKA which regulates Tau phosphorylation (Szaniszlo 
et al. 2009) and the levels of PKA protein and phosphorylated Tau should be 
analysed to assess whether the gene expression change observed translates to 
protein levels changes and ultimately a prevention of Tau phosphorylation.
There has not however been any study to directly investigate the effects of CLN 
on Tau phosphorylation and aggregation. Western blotting may be used to 
examine changes in the levels of phosphorlyated Tau in cell lysate upon 
treatment with CLN and Ap and one would hypothesise that there would be a 
reduction in Tau phosphorylation with CLN treatment.
2) As discussed in Chapter 1, Section 1.1.2 the role of GSK3 P in mediating the 
toxicity of Ap has been well documented (Hooper et al. 2008). Furthermore 
compounds that can prevent the activation of GSK3P have been found to prevent 
the toxicity of Ap as detailed in Chapter 1, Section 1.1.3.2. From this work and 
the work discussed in Section 1, Section 1.6.4 showing that CLN can alter the 
expression of kinases (Szaniszlo et al. 2009) it could be hypothesised that CLN 
would also be able to prevent the Ap induced increase in GSK3P activity and in 
this way dramatically decrease Ap induced toxicity.
3) The immune system is affected in AD as discussed in Chapter 1, Section 1.1.2 
and this may contribute to the initiation and progression of the disease. The 
effects of CLN on the status of the immune system and immune system cells 
have been very well documented as described in Chapter 1, Section 1.6.2. These 
two factors have not yet been tested together and no study has been done to 
investigate the effects of CLN on immune system activity in AD patients.
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4) The long term, 16 month, clinical trials gave CLN orally to the patients (Leszek 
et al. 1999) yet there has not been a study to investigate the mechanism by 
which CLN exerts effects in the CNS. It appears from this study and previous 
work by others that the effects of CLN may be at least partially mediated by 
antioxidant effects and therefore is indirect and we now know many of the 
effects that CLN may have on cells in vitro. However, an important part of our 
understanding of CLN involves knowledge of what tissues it has it has access to 
and may therefore act upon in vivo. CLN as a whole is too large to cross the 
blood-brain barrier although there may be a small active component, such as the 
nonapeptide, which is able to cross in the brain. Moreover, analysis of how well 
CLN is absorbed in the gut and into adipose tissue would greatly add to the work 
that has already been carried out using CLN.
5) It has been shown that CLN is able to prevent and even reverse the aggregation 
of ApMo in vitro (Schuster et al. 2005). However, the action of CLN on the 
production of Ap has not been investigated. A transgenic APP cell line would 
allow this to be studied. Furthermore, the effect of CLN on the production and 
aggregation of Ap in vivo has not yet been examined. Transgenic animals would 
allow the opportunity for these effects to be studied.
6 ) The ultrastructural changes in the brain upon treatment with Ap are now well 
established (Watt et al. 1994; Richardson et al. 2003; Kelly and Ferreira 2007) 
and we have shown that CLN alone does not cause any significant ultrastructural 
changes in hippocampal cells in culture. Further studies should now be carried 
out using electron microscopy to investigate the ability of CLN to prevent the
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Ap-induced ultrastructural changes in synapses in the rat brain or on primary 
cells in culture.
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Appendix
8.1. Materials
Company or source Reagent/Consumable
Gibco/Invitrogen FCS, N2 supplement, EBSS, B27 
supplement, HS and BME.
Sigma-Aldritch DMEM, glutamine, Trypsin-EDTA, 
Penicillin-streptomycin, Papain, 
Cysteine, chicken egg white Trypsin 
inhibitor, Glucose, Sodium pyruvate and 
RIPA lysis buffer.
Coming Culture flasks
Greiner Culture plates as well as other plastics
VWR Glass coverslips
Agar Scientific Citifluor mountant
Regen Therapeutics Bovine CLN, AP1-42
Biosource A p i-4 2
Promega The MTS cytotoxicity assay kit
Kindly donated by Kathleen Wright and 
James Phillips
DCFH-DA from Sigma-Aldritch
Biorad DC protein assay
National diagnostics Protogel and Tris/glycine, 
Tris/glycine/SDS buffers
Perkin-Elma ECL developing reagents
GE healthcare Full range rainbow protein marker
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8.2. Antibodies
8.2.1. Primary antibodies
Cell type/epitope Antibody Company
Neurons Mouse monoclonal anti-MAP-2 raised against 
rat brain MAPs
Abeam 
(ab11267)
Astrocytes Rabbit polyclonal anti-GFAP antibody raised 
against GFAP from cow spinal cord
Dako-
Cytomation
(20334)
Oligodendrocytes Mouse monoclonal antibodies against 
CNPase raised against the full length human 
protein
Abeam
(ab6319)
Microglia Mouse monoclonal antibody against CD1 lb 
raised against rat macrophages
Abeam
(abl211)
SOD1 Rabbit anti-SODl antibody raised against 
residues on synthetic human SOD1
Abeam
(ab51254)
Cdk5 Rabbit polyclonal antibody against Cdk5 
raised against the C-terminus of human Cdk5
Santa Cruz 
(SC-173)
Activated caspase 3 Rabbit polyclonal antibody against activated 
caspase 3 raised against a synthetic peptide 
conjugated to KLH derived from within 
residues 150 - 250 of human active caspase 3
Abeam
(abl3847)
Actin Rabbit monoclonal antibody against modified 
P-cytoplasmic actin N-terminal peptide, Ac- 
Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp- 
Asn-Gly-Ser-Gly-Lys.
Sigma-
aldritch
(A1978)
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8.2.2. Secondary antibodies
Antibody Company
anti-rabbit biotinylated GE Healthcare (RPN1004V1)
strepavidin fluorescein GE Healthcare (RPN123V1)
Goat anti-mouse AMCA conjugated Millipore (AP13 0M)
Goat anti-mouse Rhodamine conjugated Millipore (AP124R)
Anti-rabbit Horseraddish peroxidise 
conjugated
Thermo Scientific -Pierce (31460)
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